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Summary  
Microcephaly describes a reduced brain size in patients that manifests in an evidently 
reduced head circumference compared to healthy individuals of same age, sex and 
ethnicity. Even though microcephaly is still considered a rare clinical feature in 
Europe, hundreds of syndromes manifest with microcephaly indicating that the 
identification and characterization of microcephaly-associated genes can help to 
shed light on cellular processes important for brain development, but also beyond.  
Since a substantial number of microcephaly patients remain without a genetic 
diagnosis, I investigated in the first part of my thesis whole-exome sequencing (WES) 
data of three patients from non-consanguineous families. In the first family of 
Pakistani descent, different family members were presenting with varying severities 
of syndromic microcephaly pointing towards an autosomal dominant or X-linked 
mode of inheritance. Using a combination of WES and deep amplicon sequencing, I 
identified the c.848delA mutation in the novel and highly convincing microcephaly-
associated candidate gene DLG3 and confirmed a low-level somatic mosaicism in 
one affected family member. In the second family, I applied WES and identified two 
novel nonsense mutations (c.442C>T; p.Gln148* and c.2557C>T; p.Arg879*) in the 
DDX11 gene, associated with Warsaw breakage syndrome. With this, I expanded the 
spectrum of mutations and phenotypes associated with the DDX11 gene. In the last 
family, I identified two novel mutations affecting splicing in the FANCI gene (c.2890-
2A>G and c.2108A>G; p.Asp703Gly), associated with Fanconi anemia.  
In the second part of my thesis, I characterized the novel microcephaly-associated 
gene KMT2B and the previously identified de novo c.5462insC (p.Leu1822Thrfs*12) 
mutation in more detail. KMT2B encodes a H3K4 methyltransferase and exerts 
essential functions especially during early embryonic developmental stages. Ectopic 
overexpression of wild-type and p.Leu1822Thrfs*12 KMT2B in COS-7 cells 
confirmed stability of the mutant protein, albeit the nuclear import was impaired. 
Further characterization of endogenous RNA and protein levels in patient-derived 
cells demonstrated a reduction of KMT2B RNA and protein. I applied deep amplicon 
sequencing and verified stability of the c.5462insC transcript. However, I did not 
detect the p.Leu1822Thrfs*12 protein, neither by using Western Blot nor by using 
mass spectrometry, pointing towards protein instability and favoring 
haploinsufficiency as disease underlying effect. The bulk levels of H3K4me3 were not 
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affected in patient-derived fibroblasts, and cells showed no increased apoptosis 
activation. Patient-derived fibroblasts were successfully reprogrammed into induced 
pluripotent stem cells (iPSC), and subsequent RNA sequencing (RNAseq) uncovered 
differential expression of several WNT-signaling-associated genes. Differentiation of 
iPSC into early neural progenitor cells (NPC) confirmed a normal course in the 
expression of pluripotency marker OCT4 and the NPC markers SOX1 as well as 
PAX6 indicating successful initiation of differentiation. In order to investigate the 
pathomechanism in vivo, I used a CRISPR/Cas9-based strategy and generated a 
knock out (KO) model of KMT2B in the zebrafish Danio rerio. Targeting the KMT2B 
homologs kmt2ba and kmt2bb, I showed that homozygous kmt2ba as well as kmt2bb 
KO animals were viable. KO of kmt2bb, but not kmt2ba, resulted in growth 
retardation and microcephaly at 14 days post fertilization (dpf), thereby mimicking the 
phenotype of our patient. Whole-mount immunostainings for activated Caspase 3 
illustrated increased activation of apoptosis in affected embryos at 32 hours post 
fertilization (hpf). In order to characterize early corticogenesis prior to the onset of 
apoptosis, I investigated a murine conditional heterozygous Kmt2b KO model 
(heterozygous Kmt2b cKO) at embryonic day 13.5 (E13.5). Immunohistochemistry 
did not reveal any differences between control and heterozygous Kmt2b cKO 
embryos. Based on this, only a very mild phenotype was to be expected and the 
sensitive next-generation sequencing (NGS)-based approach of single-cell RNA 
sequencing (scRNAseq) was applied for gene expression analysis. Subsequently, 
analysis of scRNAseq data pointed towards a mild imbalance in the number of 
proliferating vs. non-proliferating radial glial cells (RGCs) in developing forebrains of 
heterozygous Kmt2b cKO embryos.  
In summary, via WES analysis, the data of my PhD thesis end the long odyssey of an 
unknown diagnosis for three families and provide important information about the 
underlying genetic cause and open perspectives in the field of therapeutic 
approaches. The characterization of KMT2B and the c.5462insC mutation provides 
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Zusammenfassung 
Mikrozephalie beschreibt eine verminderte Gehirngröße bei Patienten, welche sich in 
einem signifikant verringertem Kopfumfang im Vergleich zu gesunden Menschen 
gleichen Alters, Geschlechts und Ethnizität wiederspiegelt. Auch wenn Mikrozephalie 
in Europa ein seltenes klinisches Merkmal ist, findet man es als Teil des Phänotyps 
in mehreren Hundert Syndromen. Dies bedeutet, dass die Identifizierung und 
Charakterisierung Mikrozephalie-assoziierter Gene neue Einblicke in zelluläre 
Prozesse der Gehirnentwicklung und weiterer Organe liefern kann. 
Da eine genetische Diagnose bei einer beträchtlichen Anzahl an Patienten mit 
Mikrozephalie immer noch nicht bekannt ist, habe ich im ersten Teil meiner 
Doktorarbeit whole-exome Sequenzierungsdaten (WES) von drei Patienten aus 
nicht-konsanguinen Familien untersucht. In der ersten Familie pakistanischen 
Ursprungs zeigten mehrere Familienmitglieder eine unterschiedlich starke 
Ausprägung an Mikrozephalie, was auf einen autosomal dominanten oder X-
Chromosomal gekoppelten Erbgang hindeutete. Mit einer Kombination von WES und 
Deep Amplicon Sequencing konnte ich die c.848delA Mutation in dem neuen 
Mikrozephalie-Kandidatengen DLG3 identifizieren und in einem betroffenen 
Familienmitglied einen somatischen Mosaizismus nachweisen. In der zweiten Familie 
konnte ich mit WES zwei neue nonsene Mutationen (c.442C>T; p.Gln148* und 
c.2557C>T; p.Arg879*) in dem Gen DDX11 nachweisen, welches bereits mit dem 
Warsaw breakage Syndrom assoziiert ist. In der dritten Familie habe ich schließlich 
zwei neue Mutationen in dem FANCI Gen identifiziert (c.2890-2A>G und c.2108A>G; 
p.Asp703Gly), die den Prozess des Spleißens beeinflussen.  
Im zweiten Teil meiner Arbeit habe ich das neue Mikrozephalie-assoziierte Gen 
KMT2B und die identifizierte de novo c.5462insC (p.Leu1822Thrfs*12) Mutation 
charakterisiert. KMT2B kodiert eine H3K4 Methyltransferase und übt essentielle 
Funktionen vor allem in frühen Phasen der Embryonalentwicklung aus. Eine 
ektopische Überexpremierung von Wild-Typ und p.Leu1822Thrfs*12 KMT2B in COS-
7 Zellen bestätigte, dass das mutierte Protein zwar stabil ist, seine Fähigkeit in den 
Zellkern transportiert zu werden allerdings beeinträchtigt ist. Eine weitere 
Charakterisierung zeigte, dass die Menge an endogener RNA sowie an endogenem 
Protein in den Patientenzellen reduziert war. Ich konnte mithilfe von Deep Amplicon 
Sequencing aufzeigen, dass das c.5462insC Transkript zwar stabil war, das Protein 
aber wahrscheinlich nicht, da es weder mit Western Blot noch mit der 
 Zusammenfassung  
 
   X 
Massenspektrometrie nachgewiesen wurde und somit auf eine zugrundeliegende 
Haploinsuffizienz hindeutete. Die Gesamtmenge an H3K4me3 war in Patienten-
Fibroblasten nicht verändert und diese Zellen zeigten keine erhöhte Apoptose-
Aktivierung. Patienten-Fibroblasten wurden im Verlauf der Arbeit erfolgreich in 
induzierte pluripotente Stammzellen (iPSC) umprogrammiert und eine anschließende 
RNA Sequenzierung (RNAseq) zeigte, dass einige Gene, die mit dem WNT-
Signalweg assoziiert sind, unterschiedlich exprimiert waren. Eine Differenzierung der 
iPSC in frühe neuronale Vorläuferzellen (NPC) war mit einem normalen 
Expressionsverlauf des Pluripotenz-Markers OCT4 sowie der NPC Marker SOX1 und 
PAX6 verbunden. Diese Daten deuteten daher auf eine erfolgreiche Initiation der 
Differenzierung hin. Um den Pathomechanismus in vivo genauer zu untersuchen, 
habe ich mit der CRISPR/Cas9-Methode ein Knock Out (KO) Modell für KMT2B in 
dem Zebrafisch Danio rerio hergestellt. Die beiden KMT2B Homologe kmt2ba und 
kmt2bb wurden ähnlich der Position der humanen Mutationsstelle modifiziert. Ich 
konnte zeigen, dass homozygote kmt2ba KO Tiere sowie homozygote kmt2bb KO 
Tiere lebensfähig waren. KO von kmt2bb, aber nicht von kmt2ba, führte zu 
Wachstumsverzögerungen und Mikrozephalie. Dies wurde in den Tieren 14 Tage 
nach der Befruchtung (dpf) sichtbar und ähnelte den Merkmalen unseres Patienten. 
Whole-mount Immunfärbungen für aktiviertes Caspase 3 zeigte eine erhöhte 
Apoptose-Aktivierung bei 32 Stunden nach der Befruchtung (hpf). Um die frühe 
Phase der kortikalen Entwicklung vor dem Auftreten der Apoptose genauer zu 
charakterisieren, habe ich weitere Analysen in einem Mausmodell durchgeführt. 
Dafür habe ich ein konditionales heterozygotes Kmt2b KO Modell (heterozygoter 
Kmt2b KO) an Embryonalstadium 13.5 (E13.5) untersucht. Immunohistochemische 
Analysen zeigten keine Unterschiede zwischen Kontrollen und heterozygoten Kmt2b 
KO Embryonen was auf einen schwachen Phänotyp hindeutete. Aus diesem Grund 
wurde die sensitive Next-Generation sequencing (NGS) basierte Methode single-cell 
RNA sequencing (scRNAseq) für die Analyse der Genexpression angewendet. Die 
Auswertung der scRNAseq Daten wies auf ein leichtes Missverhältnis von teilenden 
und nicht-teilenden Radial Gliazellen (RGC) in dem sich entwickelnden Vorderhirn 
der heterozygoten Kmt2b KO hin. 
Zusammenfassend lässt sich sagen, dass ich mit Hilfe von WES in drei Familien die 
zugrundeliegende genetische Diagnose der Mikrozephalie identifiziert habe. Meine 
Ergebnisse liefern den Familien nicht nur die genetische Ursache, sondern eröffnen 
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ihnen auch Perspektiven hinsichtlich Therapiemöglichkeiten. Die Charakterisierung 
von KMT2B und der c.5462insC Mutation ermöglicht neue Einblicke in den 
Pathomechanismus der Mikrozephalie und auch neue Einblicke in zelluläre Prozesse 
darüber hinaus. 
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1 Introduction 
1.1 The mammalian neocortex 
The mammalian cerebral cortex consists of the allocortex and the neocortex. The 
neocortex accounts for the largest part and is responsible for higher cognitive 
functions in humans (Figure 1A) [1]. Its size expanded tremendously during 
mammalian evolution, which is reflected mainly via an expansion of the surface area, 
while cortical thickness did not change significantly (Figure 1D/E) [1]. As a result, the 
cerebral cortex is arranged in folds (cortical gyrification) in some species including 
humans, while it appears smooth in other species like mice (Figure 1A/B). Even 
though neocortical tissues of human and mice possess some differences, 
investigations of physiological and pathological processes have been studied in detail 




Figure 1 The cerebral cortex in different species. The cerebral cortex (blue) in human (A), mouse (B) and zebrafish (C) is 
part of the forebrain (F). The cerebral cortex faces the outside in human and mouse forebrains, while the dorsal pallium in 
zebrafish faces the inside (dashed colour). Images do not represent size differences. Midbrain (M), Hindbrain (H). Cerebellum in 
red. (D) and (E) Size comparison of human and mouse brain. (E) illustrates frontal view of the section plane from (D) (dashed 
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1.1.1 Developmental stages and characteristics of murine neocortex 
The neocortex consists mainly of neurons and glial cells, which are generated in a 
tightly controlled spatial and temporal manner during embryogenesis. Neurons are 
generated first, followed by the generation of glial cells [7]. The two main classes of 
neurons in the neocortex are excitatory projection neurons (glutamatergic) and 
inhibitory neurons (GABAergic), which both can be further subdivided into a wide 
range of subclasses and subtypes [8-10]. Projection neurons form long axons even 
to other brain regions, while interneurons build contacts within the neocortex itself 
[11]. Beside neurons, different oligodendrocytes and astrocytes are components of 
the neocortex as well.  
The source for the majority of cells in the developing neocortex is formed by different 
types of neural progenitor cells (NPCs), which are already important prior to the 
onset of neurogenesis that starts at embryonic day 10.5 (E10.5) in the mouse. 
Neuroepithelial cells (NECs) are the first stem cells in the central nervous system. 
NECs divide rapidly and perform mainly symmetric proliferative cell divisions thereby 
generating two daughter cells with identical cellular fate and expanding the pool of 
progenitors cells in the ventricular zone (VZ) [12]. Between E9 and E10, these NECs 
transform into radial glial cells (RGCs), which perform mainly asymmetric cell 
divisions [13,14]. One daughter cell remains as RGC in the VZ (Figure 2). The other 
daughter cell can either differentiate into an intermediate progenitor cell (IPC) and 
form the subventricular zone (SVZ), or it can leave the proliferative zones, and finally 
differentiate into a post-mitotic neuronal cell [15-18]. IPCs in turn, mainly perform 
symmetric cell divisions yielding either two post-mitotic neuronal daughter cells or 
two IPCs [16,19,20]. In addition, more progenitors including short neural precursors 
(SNPs) have been described making the process of cortical neurogenesis even more 
complex [21].  
From E10.5, increasing numbers of post-mitotic neuronal cells leave the VZ and SVZ 
and migrate along the intermediate zone (IZ) to build up the characteristic layering of 
the neocortex (Figure 2) [22]. The preplate (PP) can be detected first and it is 
separated by E13 into the subplate (SP) and marginal zone (MZ). Subsequently, the 
cortical plate (CP) is formed in an “inside-out” manner indicating that deeper layers 
are generated prior to upper layers. With progressive corticogenesis, the 
characteristic six-layered neocortex emerges and remains throughout lifetime [23].  
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Figure 2: Steps of murine cortical neurogenesis from E11 to adulthood. Neural progenitor cells (green) residing in the 
ventricular zone (VZ) and in the subventricular zone (SVZ). At the beginning of neurogenesis, post-mitotic cells leave these 
regions and form initially the preplate (PP), and thereafter, the subplate (SP) and marginal zone (MZ). In the course of 
neurogenesis, migrating neurons form the cortical plate (CP), which can be found in adult mice as six-layered cerebral cortex 
(layer I-VI). Intermediate Zone (IZ). Figure modified after Gupta et al. 2002; Dehay & Kennedy 2007 [23,24]. 
 
 
1.1.2 Signaling pathways involved in cortical neurogenesis 
It is still not completely understood how the fate of a differentiating cell is determined 
during cortical neurogenesis. One challenging question for example is, why 
progenitors during early embryonic stages produce a broader range of neurons than 
progenitors during later embryonic stages. Furthermore, it is currently unclear how 
the cellular switch from neurogenesis to gliogenesis is regulated. However, a wide 
range of intrinsic and extrinsic factors have been identified that play an important role 
in these processes. These include different signaling pathways including WNT, 
Notch, BMP and Hedghog signaling that have been shown to be involved in the 
regulation of cortical neurogenesis, and are described in the following.  
The Wingless-related integration site (WNT) protein family consists of secreted 
glycoproteins, which induce an intracellular signaling cascade via binding of Frizzled 
(Fz) receptor complexes on the outer cellular membrane [25]. This binding stabilizes 
cytosolic β-Catenin, which translocates to the nucleus and subsequently regulates 
expression of downstream target genes via interaction with the transcription factor 
family TCF/LEF (canonical WNT-signaling) [26]. In addition, WNT proteins can also 
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activate WNT/Ca2+ and planar cell polarity pathway independent of β-Catenin (non-
canonical WNT-signaling) (Figure 12) [25].  
Several Wnt and Fz genes are expressed during different stages of cortical 
neurogenesis and some genes already as early as E9.5 [27]. Activated WNT-
signaling is detectable in the VZ around E14, but is reduced when differentiating 
post-mitotic neurons leave the VZ and migrate along IZ to form the CP [28]. In 
addition, canonical WNT-signaling activates expression of Pax6 and Ngn1, two key 
transcription factors of cortical neurogenesis [29,30]. It seems that WNT-signaling 
can have different effects on cortical neurogenesis. In RGCs, WNT-signaling 
promotes symmetric proliferative cell divisions thereby increasing the number of 
RGCs and inhibiting their differentiation [28,31]. In line with this, overexpression of β-
catenin results in a delayed generation of IPCs and these mice are characterized by 
an enlarged cortical surface area with cortical gyrification similar to human brain 
morphology [32,33]. In contrast, during later developmental stages, WNT-signaling 
promotes differentiation of IPCs as well, indicating that effects of WNT-signaling for 
cortical neurogenesis vary and are dependent on the cellular background [31,34].  
Notch-signaling is another pathway and especially important for short range signals 
since Notch receptors face the extracellular space and can be bound by membrane 
coupled ligands (Delta-like and Jagged) of neighboring cells [35]. Binding of Notch 
receptors subsequently results in proteolytic cleavages of the intracellular receptor 
domain and finally activates expression of downstream target genes including Hes 
genes, a family encoding transcriptional repressors [35]. Notch-signaling has been 
reported to inhibit cortical neurogenesis via affecting NECs and differentiation of 
RGCs [14,36]. As a result, an overexpression of activated Notch from E9.5 maintains 
RGCs and reduces their differentiation into neurons [37]. Similarly, Notch-signaling 
critically determines the cell fate after asymmetric cell divisions also in zebrafish [38].  
BMP (Bone morphogenetic protein) and Hedgehog-signaling are two additional 
pathways, that have been suggested to take part in diverse functions during cortical 
neurogenesis. The BMP pathway regulates migration of neurons during 
corticogenesis [39]. In addition, in vitro data point towards an involvement of BMP-
signaling in cell fate determination and in the transition from neurogenesis to 
gliogenesis [40]. The importance of Hedgehog-signaling is reflected by a conditional 
knock out (cKO) of Shh, which alters the cell cycle length of progenitor cells and 
finally decreases the number of generated neurons [41].  
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Taken together, these data indicate that the involvement of signaling pathways in 
cortical neurogenesis is a complex process and far more complicated than illustrated 
here. One signaling pathway can not only affect different cells and stages of cortical 
neurogenesis, but also affect the signaling of other pathways thereby forming a 
complex network required to build up the six-layered neocortex during 
embryogenesis [42]. 
1.2 Isolated and syndromic forms of human microcephaly  
Microcephaly describes a reduced head circumference in patients of at least 3 SD 
below the mean compared to healthy individuals of same sex, age and ethnicity [43]. 
The reduction of the head circumference derives from a reduction of the brain size 
and mainly from a reduction of the cerebral cortex, which can additionally manifest in 
simplified cortical gyrification and cognitive impairments. The overall structure of the 
brain is usually not affected [44,45]. Microcephaly is described as isolated when no 
other malformations are present. In contrast, microcephaly can also develop as 
clinical feature in a wide range of inherited syndromes with additional severe brain 
malformations and other affected organs. To date, hundreds of microcephaly-
associated syndromes have been described with microcephaly either manifesting 
during embryogenesis (primary microcephaly) or after birth (secondary microcephaly) 
(www.omim.org). Between 2011 and 2017, microcephaly occurred with a prevalence 
of 1.89 per 10,000 individuals in the European population and thus, it is still a rare 
clinical feature in Europe (www.eurocat-network.eu).  
1.2.1 Autosomal recessive and autosomal dominant inheritance 
Cortical neurogenesis involves different cellular processes including cell proliferation, 
DNA damage response, apoptosis, cell migration, and cell differentiation, which 
together refine the number of generated cells and cortical layering. Isolated and 
syndromic forms of primary microcephaly can therefore manifest from mutations in 
genes, which are associated with any of these cellular processes [46,47]. The 
microcephaly panel at the Institute of Human Genetics (Göttingen), as an example, 
consists of 75 microcephaly-associated genes and is used for routine diagnostic 
testing to date (www.humangenetik-umg.de). Most microcephaly-associated genes, 
including the following examples, show an autosomal recessive mode of inheritance 
and are thought to cause loss of protein function. MCPH1 (MIM 251200) was the first 
identified gene associated with autosomal recessive primary microcephaly (MCPH) 
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[48]. Depletion of Mcph1 results in hypersensitivity to γ-irradiation and premature 
switch from symmetric to asymmetric cell divisions, which is accompanied by a 
depletion of NPCs [49,50]. Mutations in ASPM (MIM 605481) account for most cases 
of MCPH [44,51]. Similar to Mcph1, Aspm is important for maintaining symmetric 
proliferative cell divisions in NPCs [52]. Overexpression of stabilized β-catenin can 
partially rescue these defects indicating that ASPM is linked to canonical WNT-
signaling [53]. Genes associated with DNA damage response like XRCC2 (MIM 
600375), XRCC4 (MIM 94363) and LIG4 (MIM 601837) underlie syndromic forms of 
microcephaly, namely Fanconi anemia, “Seckel-like” and LIG4 syndromes, 
respectively [54-56]. Depletion of any of these genes results in defective cortical 
neurogenesis in mice, which is accompanied by excessive apoptosis [57-59]. 
To date, a few genes underlying autosomal dominant forms of isolated and 
syndromic microcephaly have been described as well. Missense mutations in the 
microtubule-associated genes like KIF5C (MIM 604593), KIF2A (MIM 602591) and 
TUBB2B (MIM 612850) have been identified in patients with complex cortical 
dysplasia [60,61]. Tubb2b was shown to regulate neuronal migration, while a 
knockdown of Kif2a causes impaired proliferation of RGCs followed by premature 
neuronal differentiation [60,62]. Kadir et al identified a missense mutation in the 
autophagy related gene WDFY3 (MIM 617485) in a patient presenting with primary 
microcephaly [63]. Using different in vitro and in vivo approaches the authors 
identified a link between primary microcephaly and canonical WNT-signaling. Their 
model proposes that WDFY3 attenuates canonical WNT-signaling through 
degradation of β-Catenin. This reduction is required for the physiological transition of 
RGCs to IPCs, which is accompanied by a switch from symmetric to asymmetric cell 
divisions.  
1.2.2 Model systems for functional analysis of microcephaly 
Several model systems are used to study the pathogenesis of microcephaly and 
other neurodevelopmental diseases in vivo. Zebrafish (Danio rerio) and mouse (Mus 
musculus) are among the most frequently used model systems for this achievement.  
The nervous system of zebrafish is simple, but, similar to mammals, the brain can be 
subdivided into forebrain, midbrain and hindbrain (Figure 1A-C). The cerebral cortex, 
as found in mammals, is not detectable in zebrafish. However, the dorsal pallium has 
been proposed as the corresponding homolog, which faces the inside of the forebrain 
and not, as in mammals, the surface [64]. The use of zebrafish as a model system 
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possesses several advantages over other species. The embryos are transparent and 
enable whole-mount embryo immunofluorescence stainings during the first days of 
development [65]. The embryogenesis takes in total three days and has been 
described in detail [66]. After embryogenesis, animals are considered larvae until 
they reach the juvenile stage and finally become fertile adults [67]. Adult zebrafish 
can lay batches of 200 – 300 eggs. Fertilization and embryonic development are 
external, thereby facilitating genetic manipulations. For this, two approaches are 
mainly used in zebrafish, namely injection of morpholinos in order to knock down 
(KD) the gene of interest and CRISPR/Cas9 for knock out (KO) studies [68,69]. Due 
to gene duplications, several human genes have two or even more homologs in 
zebrafish [70]. These homologs frequently show different expression patterns as well 
as functions and it is possible that clinical features of the human phenotype are 
spread over these homologs, when they are depleted separately [68,71-73]. 
The murine cortical neurogenesis has been extensively studied (see 1.1.1.). It peaks 
around E13.5 and takes in total eight days (E11 – E19) [24]. Mostly, microcephaly-
associated genes are either knocked out or knocked down in order to study their in 
vivo functions, whereas the generation of a knock in is still difficult [59,62]. Since KO 
of several genes results in early embryonic lethality and hence, prevents proper 
cortical analysis, the Cre/loxP system is frequently used in order to generate a cKO 
[74,75]. In these transgenic animals, a KO is only achieved in cerebral cortices when 
Cre recombinase is expressed under the control of cortex specific promoters like the 
Emx1-promoter [76]. Emx1 is expressed from E9.5 initially in VZ and with 
progressing neurogenesis also in IZ, PP, and CP [77]. Cre subsequently excises a 
targeted exon (flanked by floxP sites) of the gene of interest in developing cortices, 
while the gene remains intact in other tissues where Cre is not expressed. Depletion 
of several microcephaly-associated genes recapitulated the severity of the human 
phenotypes in mice [78-80]. However, for some genes, only a milder or missing 
phenotype has been reported, which might be explained either by differences 
between murine and human cortices, or by a higher robustness of mice for genetic 
changes [24,50,81,82]. Therefore, other in vivo models came more and more into the 
focus of scientists including ferrets, which have gyrified cortices and enable 
investigations for genes, which do not recapitulate murine phenotypes [83]. 
To date, in vitro cultures also gained more attention based on the introduction of 
induced pluripotent stem cells (iPSC) and their differentiation into NPCs and cerebral 
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organoids [84,85]. So far, functional studies using patient-derived material were 
mainly limited to the use of dermal fibroblasts and even if a molecular phenotype was 
detectable, the question of the significance for neurogenesis remained unclear [86]. 
Cerebral organoids might solve this problem. These in vitro systems are small three 
dimensional cultures, which are characterized by several brain-like regions including 
detectable layers of the cerebral cortex. To date, cerebral organoids have been 
already used as a model system to study the pathogenesis of microcephaly 
especially for genes with only mild or missing murine phenotypes [85,87]. In addition, 
iPSC derived NPCs can be cultured in vitro in order to investigate proliferation 
defects, apoptosis and differentiation ability towards cortical neurons underlying 
microcephaly [88]. In contrast to the above described in vivo animal models, iPSC 
cultures and differentiated progenies have the strong advantage that the genetic 
background, including epigenetic effects, of the patient remains unchanged, which 
might influence the disease severity.  
1.3 Epigenetic modifications in stem cells and during cortigogenesis 
Epigenetics describes modifications, which are not encoded in the genome itself, but 
distributed as patterns of DNA methylations and histone modifications all along the 
genome. Importantly, these modifications influence each other, and thus, they can 
not be seen as isolated processes [89-91]. Proteins, which are involved in 
epigenetics can be sub-divided into writers, readers and erasers [92]. Writers modify 
DNA or histones, readers detect these modifications, and erasers finally remove 
these modifications.  
DNA methylations are accomplished at cytosines by different DNA 
methyltransferases (DNMTs) in mammals [93]. Depending on the cell type, 
methylations occur either at CpG dinucleotides or at non-CpG dinucleotides and this 
modification is mainly associated with gene silencing [94]. Histone modifications, on 
the other hand, consist of a wide range of modifications like acetylations and 
methylations that affect the chromatin state and hence, the accessibility for gene 
expression [95]. Histone modifications are accomplished mainly via two groups of 
modifiers that act as antagonists in mammals, namely the Polycomb group (PcG) 
and Trithorax group (TrxG) [96]. The relevance of PcG and TrxG for stem cells and 
their neuronal differentiation has already been shown [97]. H3K27me3 is considered 
to mainly repress gene expression and this modification is accomplished by PcG. 
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TrxG, on the other hand, accomplishes H3K4me3, which is mainly associated with 
active gene expression [98,99].  
The chromatin at developmental genes, including the NPC marker Pax6, is bivalently 
marked in embryonic stem cells (ESCs) via trimethylation of lysine 27 on histone 3 
(H3K27me3) and trimethylation of lysine 4 on histone 3 (H3K4me3) [100]. Together, 
these modifications keep genes in a poised state with no or only very low gene 
expression (bivalent state) [100-102]. With initiation of differentiation, the promoters 
of genes important for the neural lineage are de-methylated at H3K27 and these 
genes are subsequently expressed [103]. Thus, if H3K27me3 is not properly 
removed in ESCs, these cells have an impaired ability to differentiate towards the 
neuronal lineage [104]. Pluripotency-associated genes, on the other hand, which are 
highly expressed in ESCs, loose the activating H3K4me3 modification in the course 
of neural differentiation and are silenced via H3K9me3 [105].  
PcG and TrxG have also been shown to be important during cortical neurogenesis in 
vivo. The PcG members Ring1b and Ezh2, for instance, are reported to regulate 
termination of neurogenesis and initiate gliogenesis [106]. Furthermore, Nguyen et al. 
showed that the TrxG members BAF155 and BAF170 are important for the promotion 
of neuronal differentiation and repression of cell proliferation during late cortical 
neurogenesis [74,107]. The authors propose that this regulation is accomplished via 
interactions of BAF155/BAF170 with demethylases Kdm1a and Kdm6a/b, which 
results in the removal of H3K27me3 and H3K4me2, respectively. Finally, genes 
related to neural differentiation are expressed, while genes related to cell 
proliferation, including WNT-signaling-associated genes, are repressed.  
1.4 The KMT2 family – The TrxG histone modifier for H3K4me1/me2/me3 
As already described, histone modifications are accomplished by different enzymes 
including members of the heterogeneous groups PcG and TrxG. TrxG can be further 
divided into different subclasses including the lysine methyltransferase subclass 2 
(KMT2) [108]. Members of KMT2 are related to Set1, the only H3K4 
methyltransferase found in yeast [109]. The fruit fly Drosophila melanogaster 
contains already three different H3K4 methyltransferases, which evolved after gene 
duplication events, namely, drosophila Set1 (dSet1), Thritorax (Trx) and Trithorax-
related (Trr) [110]. In mammals, each Drosophila gene duplicated once more, giving 
a total number of six KMT2s (Figure 3A) [111,112]. KMT2A (MIM 159555) and 
KMT2B (MIM 606834) evolved from Trx, KMT2C (MIM 606833) and KMT2D (MIM 
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602113) from Trr, and KMT2F (MIM 611052) as well as KMT2G (MIM 611055) from 
dSet1. All encoded KMT2 proteins are characterized by high molecular weights 
ranging from 186 kDa (KMT2F) up to 593 kDa (KMT2D) and by an intrinsic 
methyltransferase activity in form of the highly conserved SET domain (Figure 3B). 
KMT2E, on the other hand, has no intrinsic methyltransferase activity and shows 
more homologues features to a different histone modifier family than the KMT2 family 
[113]. The intrinsic methyltransferase activity of the SET domain, however, is not 
solely sufficient for proper H3K4me1/me2/me3. Instead, all KMT2 members are 
found in large multi-protein complexes being called Complex of proteins associated 
with Set1 (COMPASS) (with KMT2F/G proteins) or COMPASS-like (with 
KMT2A/B/C/D proteins) (Figure 3A) [114-119]. Importantly, COMPASS(-like) 
complexes share some common cofactors, but they also have additional unique 
cofactors. The cofactors MENIN, PTIP and WDR82 are specific for KMT2A/KMT2B, 
KMT2C/KMT2D and KMT2F/KMT2G COMPASS-(like) complexes, respectively 
[112,114,117]. On the other hand, the proteins WDR5, RBBP5, ASH2L and DPY30 
form the WRAD complex, which binds to the SET domain of all COMPASS(-like) 
complexes (Figure 3A) [120,121]. These cofactors have been shown to be important 
to increase the enzymatic activity of the SET domain and to guide KMT2s to specific 
target sites [122-126].  
1.4.1 The KMT2 family – Importance for embryonic development and diseases 
The fact that mammals need more than one H3K4 methyltransferase immediately 
raises the question about the reason. A reduction of Kmt2a, Kmt2b and Kmt2c does 
not affect bulk levels of either H3K4me1, H3K4me2 or H3K4me3 in murine ESCs 
indicating that these enzymes indeed have some redundant functions [127,128]. 
KMT2s, however, also acquired unique essential functions, which is highlighted by 
different propensities for H3K4me modifications and target sites. As an example, the 
proteins KMT2A and KMT2B, as well as KMT2F and KMT2G, show mainly different 
locations in nuclei, and hence have different target sites [118,129]. Most KMT2s are 
capable of accomplishing H3K4me1, H3K4me2 and H3K4me3 [130-135]. KMT2A 
and KMT2B show high rates of H3K4me1 and H3K4me2, and bind to promoter as 
well as enhancer regions [133,134,136,137]. Even though their H3K4me3 rates are 
low, Kmt2b is the major modifier for H3K4me3 at promoter regions in murine ESC 
and importantly, Kmt2a seems to be its backup [127,128]. KMT2C and KMT2D  
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Figure 3: The KMT2 family in mammals. (A) Three pairs of proteins evolved in mammals after gene duplication events. 
KMT2F and KMT2G evolved from dSet1, KMT2A and KMT2B from Trx and KMT2C and KMT2D from Trr. KMT2s are found in 
large COMPASS(-like) complexes characterized by unique and overlapping cofactors. (B) Comparison of KMT2A and KMT2B 
protein with similar domain structure and Taspase 1 cleavage sites (purple flash). Figure modified after Hu et al. 2013; 
Bögershausen et al. 2013; Rao & Dou 2015 [128,143,144]. 
 
accomplish H3K4me1 at enhancer regions, whereas KMT2F and KMT2G are linked 
to H3K4me3 modifications and bind mainly to promoters [117,138-142]. 
How these complexes are recruited to their target sites is still not entirely understood. 
However, long non-coding RNAs (lncRNAs), a wide range of cofactors, different 
patterns of DNA methylations and transcription factors seem to be involved [108].  
The different patterns of H3K4me1/me2/me3 regulate essential processes during 
embryogenesis. KMT2A as well as KMT2B are considered crucial regulators for a 
different subset of HOX genes, which are important to regulate segment identities 
during embryonic development [145-147]. KO of any Kmt2 member results in lethality 
during different stages of embryogenesis and is characterized by different congenital 
phenotypes. KO of Kmt2f results in lethality as early as E7.5, whereas KO of the 
A 
B 
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other Kmt2s ranges from E10.5 (Kmt2a) over E11.5 (Kmt2b, Kmt2d and Kmt2g) up to 
time of birth (Kmt2c) [130,141,146,147]. Similarly in humans, no homozygous 
mutations have been reported in genetic diseases yet, indicating that a complete loss 
of any KMT2 member is also in humans not compatible with life. In contrast, 
heterozygous mutations have been reported in almost all KMT2 genes, which most 
probably result in loss of protein function. These genetic developmental diseases 
include Wiedemann-Steiner syndrome (KMT2A), childhood-onset dystonia (KMT2B), 
Kleefstra syndrome 2 (KMT2C), Kabuki syndrome (KMT2D), and schizophrenia 
(KMT2F) [148-152]. Microcephaly has been reported as a clinical feature in patients 
with mutations in KMT2B, KMT2C and KMT2D, accounting for up to 58 % of affected 
individuals [150,153,154].  
Finally, somatic mutations have frequently been reported in all KMT2 genes 
underlying different types of cancer in tissues like lung, brain and bladder 
(https://cancer.sanger.ac.uk/cosmic). KMT2C is considered an important tumor 
suppressor gene [155]. The proto-oncogene KMT2A, on the other hand, is known 
especially for its involvement in the development of acute leukemia. Loss of Kmt2a 
causes hematopoietic abnormalities, but does not result in the onset of leukemia 
[147]. Different chromosomal abnormalities, however, cause leukemia via the 
formation of KMT2A fusion proteins with a wide range of fusion partners, that operate 
as gain-of-function mutants and cause expression of different target genes [156,157]. 
Even though the pathomechanism is still under investigation, it is already known that 
the wt KMT2A protein plays an essential role in leukemia development, although wt 
KMT2A and KMT2A fusion proteins have different target sites [158]. Beside this, 
KMT2A fusion proteins can act as dominant-negative mutants as well. In this 
scenario, KMT2A fusion proteins impair the S phase checkpoint after DNA damage, 
which prevents stabilization of wt KMT2A protein [159].  
These data highlight that all KMT2s have essential unique functions during 
embryonic development and diseases. Since KMT2B is of great interest for the 
present PhD thesis, the current knowledge about KMT2B is summarized in the 
following paragraph.   
1.4.2 KMT2B - The unique KMT2 family member 
KMT2B is widely expressed throughout human tissues [160]. The gene consists of 
roughly 8.2 kilobases (kb), which are packed in 37 coding exons. In addition to one 
protein coding transcript (ENST00000420124.2), the KMT2B gene encodes for an 
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additional non-coding lncRNA (ENST00000606995.2), which can be found in 
different cell types, including dermal fibroblasts and iPSC (Figure S1).  
Full-length KMT2B has a molecular weight of 298 kDa and possesses several 
important domains and motifs, however, their functions are not completely 
characterized (Figure 3B). AT hook and CXXC domains are DNA binding domains at 
the N-terminus of KMT2B and the latter has been shown to be essential for guidance 
of Kmt2b to correct target sites [129,137]. KMT2B has four PHD fingers that seem to 
recognize histone modifications and might be involved in the guidance of KMT2B to 
correct target sites as well. The second PHD finger (PHD2) has an intrinsic E3 
ubiquitin ligase activity and can modify H3 and H4, which raises the possibility that 
the remaining PHD fingers might also perform other so far unknown tasks [161]. A 
BROMO domain is located between PHD3 and PHD4, however, its function in 
KMT2B has not been characterized yet. Subsequently, KMT2B has a FYRN domain, 
a FYRC domain and finally the SET domain at its C-terminus (Figure 3B).  
Full length KMT2B is cleaved by the endopeptidase Taspase 1 [162]. The conserved 
DGVDD cleavage site is located between the FYRN and FYRC domains of KMT2B 
and these two domains associate after cleavage [163,164]. Even though the 
relevance of protein cleavage for protein function is still not completely understood, it 
might be involved in guidance to target sites [164,165]. 
Beside its function in murine ESCs, the function of KMT2B has been studied in 
human ESCs as well. It has been shown that bivalent modifications of developmental 
genes in human ESCs are not fixed, but are dynamically regulated in the course of 
the cell cycle via KMT2B [166]. These modifications are accomplished in G1 phase 
and are regulated via phosphorylation of KMT2B by Cyclin-dependent kinase-2 
(CDK2). As a result, developmental genes are shortly transcribed during G1 phase 
and differentiation is initiated [166,167]. KMT2B has been linked to the cell cycle by 
different previous studies as well. Takeda et al. reported that the C-terminus of 
KMT2B can bind to the transcription factors E2Fs in vitro, a protein family of key 
regulators for cell cycle progression [162]. In addition, KMT2B regulates the 
expression of other cell cycle associated proteins like Cyclin B, Cyclin D, p27, 
HOXA5 and HOXB7 [168]. Reduced proliferation rates after KMT2B depletion, 
however, were only shown in cancer cell lines like human osteosarcoma U2OS cells, 
while most other publications reported not a reduced proliferation rate, but an 
increase in apoptosis as cause for observed proliferation defects [168,169].  
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Kmt2b KO in murine ESCs results in increased apoptosis rates and significantly 
impaired differentiation in vitro mainly towards the ectodermal and mesodermal 
lineage [170]. This is in line with the phenotype of the Kmt2b KO mouse, which is 
characterized by increased apoptosis rates and embryonic lethality before E11.5 
[146]. Kmt2b seems to be essential mostly during early embryonic development 
since Cre/loxP induced KO after E11.5 does not result in embryonic lethality and 
instead, results in viable mice characterized by sterility [133,171]. The sterility in male 
mice derives from an impaired differentiation ability of spermatogonial stem cells, 
which is accompanied again by increased rates of apoptosis [171,172]. Similarly, 
investigation of oocytes in female mice points towards an increased expression of 
several apoptosis-associated genes [133]. 
Cre/loxP induced KO of Kmt2b in adult mice results only in mild phenotypic 
abnormalities [171]. Glaser et al. however failed to induce Cre recombination in 
brains and as a result, effects of Kmt2b KO on whole brains in adults can not be 
excluded. In line with this, Kerimoglu et al. conditionally knocked out Kmt2b only in 
excitatory forebrain neurons of adult mice and indeed, observed a phenotype [173]. 
Depletion of Kmt2b resulted in reductions of H3K4me2 and H3K4me3 at promoter 
regions and impaired memory formation [173]. A cKO of Kmt2a resulted in impaired 
memory formation as well, albeit most deregulated target genes differed from Kmt2b 
cKO mice [174].  
In contrast, severe phenotypic abnormalities have not been reported in heterozygous 
Kmt2b KO mice. Investigations at molecular level, however, revealed that 
haploinsufficiency of Kmt2b results in the development of diabetes [175]. In humans, 
heterozygous KMT2B mutations cause childhood-onset dystonia. The first patients 
have been reported in 2016 with suggested haploinsufficiency as the disease 
underlying effect [148,176]. The mutation spectrum ranges from missense, over 
nonsense and frameshift to splice site mutations, which are distributed all along the 
KMT2B gene. The phenotypic spectrum varies also extensively. Microcephaly is 
reported in 21 % of patients and occurs only in association with mutations predicted 
to have a severe effect on protein function [154]. Recently, Barbagiovanni et al. 
aimed to investigate the pathomechanism underlying dystonia in more detail [177]. 
They differentiated Kmt2b KO murine embryonic fibroblasts (MEFs) into induced 
neuronal cells (iNs) and observed that Kmt2b is essential for differentiation as well as 
maturation of iNs and for suppression of myocyte fate genes. 
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2 Study aims 
Thanks to next-generation sequencing (NGS)-based approaches like whole-exome 
sequencing (WES), the number of microcephaly-associated genes has increased 
drastically during the past years. However, the associated molecular changes 
causing microcephaly are frequently not known and await investigation. In addition, 
the underlying genetic cause for a large number of patients has not been identified 
resulting in patients and families that still have to live without a clear genetic 
diagnosis. This indicates that even though progress has been made in the 
identification of microcephaly-associated genes and associated molecular changes 
during the past years, many scientific questions still await investigation.  
Facing this, the aim of my PhD thesis can be divided into two separate parts. In the 
first part of my PhD thesis, I aimed to identify the genetic causes in three patients 
with different forms of syndromic microcephaly and yet unknown genetic diagnosis. 
For this, WES data should be analyzed in order to identify novel microcephaly-
associated candidate genes or mutations in already known microcephaly-associated 
genes.  
In the second part of my PhD thesis, I aimed to characterize a recently identified 
mutation in the novel microcephaly-associated gene KMT2B in a patient with 
syndromic microcephaly and no signs of any movement disorder. The KMT2B gene 
is ubiquitously expressed and encodes for a methyltransferase that is important for 
the regulation of wide range of target genes, especially during embryonic 
development. In order to understand the underlying pathomechanism in the affected 
patient, functional analyses should be performed using different in vitro as well as in 
vivo models.  
In summary, the data of my PhD thesis should help to expand our current knowledge 
about genetic causes and associated molecular changes that underlie syndromic 
forms of microcephaly. In addition, a deeper characterization of the widely expressed 
KMT2B gene should help to better understand physiological as well as pathological 
epigenetic processes even beyond microcephaly development.  
 
 Material & Methods  
 
   16 
3 Material & Methods 
3.1 Material 
3.1.1 Subjects 
The present PhD thesis adheres to the Declaration of Helsinki protocols. Patients and family 
members gave written approval prior to blood or skin biopsy donation. DNA and RNA were 
extracted using standard protocols by the laboratory diagnostics of the Institute of Human 
Genetics (Cologne, Germany) and of the Institute of Human Genetics (Göttingen, Germany). 
Index patient K3627 was clinically investigated at the Institute of Human Genetics 
(Düsseldorf, Germany). Index patients K3923, K3929 and K3027 were all clinically 
investigated at the Marmara University Hospital (Istanbul, Turkey). A skin biopsy of index 
patient K3027 was collected, which was subsequently used to culture primary dermal 
fibroblasts. WT fibroblasts were either purchased from PromoCell GmbH (Heidelberg, 
Germany) or received from a female patient who had a breast reduction at the University 
Medical Center Göttingen (UMG).  
3.1.2 Enzymes 
Table 1 lists all enzymes, which were applied in the course of my PhD thesis. 
 




 Nuclease Novagen, Merck Chemicals GmbH, Schwalbach, 
Germany 
Calf intestine alkaline phosphatase Fermentas, Thermo Fisher Scientific, Bonn, 
Germany 
Exonuclease I New England Biolabs, Frankfurt, Germany 
(Fast Digest) restriction enzymes Thermo Fisher Scientific, Bonn, Germany 
Pfu Polymerase Promega GmbH, Mannheim, Germany 




 Protease Inhibitor Cocktail Thermo Fisher Scientific, Bonn, Germany 
Proteinase K AppliChem, Darmstadt, Germany 
Shrimp Alkaline Phosphatase Promega GmbH, Mannheim, Germany 
Taq Polymerases  Thermo Fisher Scientific, Bonn, Germany 
T4 DNA Ligase Thermo Fisher Scientific, Bonn, Germany 
Trypsin/EDTA Gibco
®
, Life Technologies GmbH, Darmstadt, 
Germany  
 
3.1.3 Synthetic oligonucleotides 
All synthetic oligonucleotides were either purchased from Integrated DNA Technologies 
(Leuven, Belgium) or from Eurofins Genomics (Ebersberg, Germany). List of used synthetic 
oligonucleotides can be found in the supplementary.  
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3.1.4 Bacteria and plasmids 
Tables 2 and 3 summarize bacteria and plasmids, which were applied in the course of my 
PhD thesis. 
Table 2: Bacteria used during PhD project. 
Bacteria Company 
E.coli Top10F’ Life Technologies GmbH, Darmstadt, Germany 
XL10-Gold
® 
Ultracompetent cells Agilent Technologies MfG GmbH & Co. KG, 
Wagenhäusel-Wiesental, Germany 
 
Table 3: Plasmids used during PhD project. 
Plasmid Company 
FLAG-HA_KMT2B_pcDNA5/FRT/TO Kind gift of Prof. Dr. Robert Roeder, Laboratory 
of Biochemistry and Molecular Biology, 
Rockefeller University, New York, USA 
pCasx hCas9 Kind gift of PD Dr. Roland Dosch, Institute of 
Human Genetics, Göttingen, Germany 
pCR™Blunt II-TOPO
®
 Life Technologies GmbH, Darmstadt, Germany 
pcS2+ Kind gift of PD Dr. Roland Dosch, Institute of 
Human Genetics, Göttingen, Germany 
peGFP-N1 Clontech, Becton Dickinson, Heidelberg, 
Germany 
pJet1.2blunt Thermo Fisher Scientific, Bonn, Germany 
 
3.1.5 Antibodies 
Table 4 lists all antibodies, which were applied in the course of my PhD thesis. 
 
Table 4: Antibodies used during PhD project. 
Type Antibody Dilution Company 
Primary 
Antibodies 
α-Tubulin 1:10,000 (WB) unknown 
β-Actin 1:20,000 (WB) Sigma-Aldrich Chemie GmbH, 
Schnelldorf, Germany 
Caspase-3 (14220) 1:1,000 (WB) Cell Signaling Technology 
Europe, Frankfurt, Germany 
Cleaved Caspase-3 (9664) 1:500 (WMI) Cell Signaling Technology 
Europe, Frankfurt, Germany 
Cytochrome C (sc-13156) 1:100 (ICC) Santa Cruz Biotechnology Inc., 
Dallas, Texas, USA 
GFP (11814460001) 1:4,000 (WB) Roche Diagnostics, 
Indianapolis, USA 
Histone 3 (9715) 1:1,000 (WB) Cell Signaling Technology 
Europe, Frankfurt, Germany 
H3K4me3 (ab8580) 1:1,000 (WB) Abcam, Cambridge, UK 
HSC70 (sc-7298) 1:1,000 (WB) Santa Cruz Biotechnology Inc., 
Dallas, Texas, USA 
HuC/HuD (A-21271) 1:20 (IHC) Thermo Fisher Scientific, Bonn, 
Germany 
Ki-67 (PA5-19462) 1:100 (ICC) Thermo Fisher Scientific, Bonn, 
Germany 
KMT2B/MLL4 (ab56770) 1:500 (WB) Abcam, Cambridge, UK 
Kmt2b 1:1,000 (WB) Kind gift of Francis Stewart, 
BioInnovationsZentrum, 
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Dresden, Germany 
Lamin A+C (ab108922) 1:1,000 (WB) Abcam, Cambridge, UK 
LIN-28A (AF3757) 1:1,000 (WB) R&D Systems, Inc., 
Minneapolis, USA 
Nestin (4D11) 1:100 (ICC) Novus Biologicals, Cambridge, 
UK 
NeuN (MAB377) 1:200 (IHC) Merck Chemicals GmbH, 
Darmstadt, Germany 
Oct-3/4 (AF1759) 1:1,000 (WB) R&D Systems, Inc., 
Minneapolis, USA 
Pax6 (PRB-278P) 1:100 (IHC) Developmental Studies 
Hybridoma Bank, Iowa, USA 
Sox2 (MA1-014) 1:1,000 (WB) 
 
Thermo Fisher Scientific, 
Carlsbad, USA 
Sox2 (14-9811-82) 1:200 (IHC) eBioscience, San Diego,USA 
TBR2 / Eomes (14-4875-
82) 










Thermo Fisher Scientific, 
Carlsbad, USA 
Goat-anti-mouse IgG-HRP 1:10,000 (WB) Santa Cruz Biotechnology Inc., 
Dallas, Texas, USA 
Goat-anti-rabbit IgG-HRP 1:10,000 (WB) Santa Cruz Biotechnology Inc., 
Dallas, Texas, USA 
Goat-anti-rat IgG-HRP 1:10,000 (WB) Santa Cruz Biotechnology Inc., 
Dallas, Texas, USA 
 
3.1.6 Solutions and buffers 
Exo-Sap-Mix (400 μl)       Agarose gel (1,0 % gel) 
Shrimp Alkaline Phosphatase  10 μl     Agarose 1.5 g 
Exonuclease I    15 μl     1x TBE-Buffer 150 ml 
dH2O 375 μl          
Mix was stored at -20°C and thawed before usage. 
 
LB medium (0.5 l)        Agar (0.3 l) 
Peptone 5 g         Peptone 3 g 
Yeast extract 2.5 g        Yeast extract 1.5 g 
NaCl 2.5 g         NaCl 1.5 g 
Add dH2O to 500 ml        Agar 4.5 g 
Add dH2O to 300 ml 
LB medium and agar were autoclaved and stored at 4°C. 
 
Antibiotic stocks 
Ampicillin (100 mg/ml):  Ampicillin 1000 mg 
dH2O/EtOH (1:1) 10 ml 
Kanamycin (30 mg/ml):  Kanamycin 300 mg 
dH2O 10 ml 
 
Stocks were stored at -20°C and diluted 1:1000 with Agar/LB medium for use. 
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Cell culture medium (Fibroblasts, COS-7, HEK293, HeLa) 
DMEM (1x)        500 ml 
FCS         50 ml 
Pen/Strep (10,000 U Pen/ml; 10,000 μg Strep/ml)   5 ml 
Amphotericin B       1.4 ml 
 
10x TBS Buffer (1 l)        TBST Buffer (1 l) 
Tris   24.2 g        Tween 20  1 ml 
NaCl   87.6 g        10x TBST  100 ml 
Add dH2O to 1 l        dH2O   899 ml 
The pH value was adjusted with HCl 
to 7.4 and stored at room temperature (RT). 
 
Total cell lysis buffer (10 ml) 
TRIS/HCl (1 M, pH 7.5) 0.2 ml 
NaCl (1 M)   1.5 ml 
EDTA (10 mM)   1 ml 
NP 40 (10 %)    1 ml 
SDS (10 %)    0.25 ml 
Protease inhibitors   0.25 ml (added immediately before use) 
dH20     5.8 ml 
Total cell lysis buffer was kept on ice. 
 
Cell fractionation buffer  
Nuclear fraction buffer (10 ml)    Cytosolic fraction buffer (1 ml) 
1 M Tris (pH 7.5)   200 µl    1 M Tris (pH 7.5)  50 µl 
0.5 M KCl   200 µl    1 M NaCl  400 µl 
10 mM EDTA   100 µl    10 mM EDTA  100 µl 
10 % NP40   500 µl    10 % NP40  100 µl 
Protease Inhibitor  250 µl    10 % SDS  50 µl 
Add dH2O to 10 ml      Protease Inhibitor 25 µl 
        Add dH2O to 1 ml 
 
Transfer Buffer KMT2B (10x)  Transfer Buffer KMT2B (1x) 
Glycine  144.1 g  Transfer Buffer KMT2B (10x)  100 ml 
Tris   30.3 g   100 % Methanol    100 ml 
Add dH2O to 1 l    10 % SDS    2.5 ml  
Adjust pH 8.3     Add dH2O to 1 l 
 
Nuclei buffer (NB)      
10 mM Tris-HCl (pH 7.4)   
10 mM NaCl 
3 mM MgCl2 
stored at 4°C 
 
Nuclei suspension buffer (NSB) (fresh prepared) 
NB  
1 % SUPERase in RNase Inhibitor (20 U/µl, Ambion) 
2 % BSA (20 mg/ml, New England Biolabs GmbH) 
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Cell lysis buffer (CLB) 
NB 
0.1 % IGEPAL® CA-630 
1 % SUPERase in RNase Inhibitor (20 U/µl, Ambion) 
2 % BSA (20 mg/ml, New England Biolabs GmbH) 
 
Glyoxal solution 
100 % EtOH   1.6 ml 
40 % Glyoxal   0.6 ml 
Acetic acid  60 µl 
dH20   5.74 ml 
pH was adjusted with 1 N NaOH to 6.5 and solution was always prepared fresh.  
3.1.7 Kits 
Table 5 summarizes kits, which were applied in the course of my PhD thesis. 
 
Table 5: Kits used during PhD project. 
Kits Company 
Big Dye Terminator V1.1 and V3.1 Cycle 
Sequencing Kit 
Life Technologies GmbH, Darmstadt, Germany 
CloneJET PCR Cloning Kit Thermo Fisher Scientific, Carlsbad, USA 
DNase I, Amplification Grade Thermo Fisher Scientific, Carlsbad, USA 
DNeasy Blood & Tissue Kit Qiagen GmbH, Hilden, Germany 
First Strand cDNA Synthesis Kit Thermo Fisher Scientific, Carlsbad, USA 
Gibson Assembly Cloning Kit New England Biolabs GmbH, Frankfurt, Germany 
Invisorb
®
 Spin DNA extraction Kit  Stratec Molecular GmbH, Berlin, Germany 
MEGAscript
®
 T7 Kit Thermo Fisher Scientific, Carlsbad, USA 
MicroSpin™ G-50 columns Merck Chemicals GmbH, Darmstadt, Germany 
mMESSAGE mMACHINE® kit Thermo Fisher Scientific, Carlsbad, USA 
NucleoBond
®








 BCA Protein Assay Kit Thermo Fisher Scientific, Carlsbad, USA 
Qiagen Multiplex PCR Kit Qiagen GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
QuantiNova SYBR
® 
Green RT-PCR Kit Qiagen GmbH, Hilden, Germany 
QuantiFast SYBR
®
 Green RT-PCR Kit Qiagen GmbH, Hilden, Germany 










 PCR Cloning Kit Thermo Fisher Scientific, Carlsbad, USA 
 
3.1.8 Reference sequences 
The following reference sequences were used: 
 
KMT2B RefSeq NM_014727; NP_055542 
DLG3 RefSeq NM_021120; NP_066943 
DDX11 RefSeq NM_001257144; NP_152438 
FANCI RefSeq NM_001113378; NP_NP001106849 
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3.1.9 Chemicals and expendable items 
Chemicals were purchased from the following manufacturers:  
Applied Biosystems, Invitrogen, Gibco®, Life Technologies GmbH (Darmstadt, Germany), 
AppliChem GmbH (Darmstadt, Germany), Biochrom AG (Berlin, Germany), Carl Roth GmbH 
+ Co. KG (Karlsruhe, Germany), Fermentas, Thermo Fisher Scientific (Carlsbad, USA), 
Merck Chemicals GmbH (Schwalbach, Germany), Promega GmbH (Mannheim, Germany), 
Qiagen GmbH (Hilden, Germany), Roche Diagnostics (Indianapolis, USA), Sigma-Aldrich 
Chemie GmbH (Schnelldorf, Germany), 4titude Ltd (Wotton, UK). 
 
Expendable equipment was purchased from the following manufacturers:  
Becton Dickinson (Heidelberg, Germany), Bio-Rad Laboratories Inc. (Hercules, USA), 
Corning Incorporated (Corning, USA), Eppendorf (Hamburg, Germany), Carl Roth GmbH + 
Co. KG (Karlsruhe, Germany), GE Healthcare Europe GmbH (Freiburg, Germany), Greiner 
Bio-One GmbH (Frickenhausen, Germany), Labomedic (Bonn, Germany), Merck Chemicals 
GmbH (Schwalbach, Germany), Sarstedt AG & Co. KG (Nümbrecht, Germany), Starlab 
GmbH (Hamburg, Germany), Stem Cell Technologies (Vancouver, Canada), Stratec 
Molecular GmbH (Berlin, Germany), Thermo Fisher Scientific (Carlsbad, USA), VWR 
International GmbH (Darmstadt, Germany). 
 
3.1.10 Non-expandable equipment 
Table 6 lists non-expandable equipment, which was applied in the course of my PhD thesis. 
 















Thermo Fisher Scientific, Carlsbad, USA 
Thermo Fisher Scientific, Carlsbad, USA 
VWR International GmbH, Langenfeld, Germany 
FACSCanto II flow cytometer Becton Dickinson, Heidelberg, Germany 
Gel Electrophoresis Chambers Thermo Fisher Scientific, Carlsbad, USA 
Heracell 240 CO2 Incubator Heraeus Med GmbH, Meerbusch, Germany 
IKA
®
 RCT basic IKAMAG™ Safety Control 
Magnetic Stirrer 
IKA-Werke GmbH & Co. KG, Staufen, Germany 
Julabo
TM
 shaking water bath SW22 JULABO GmbH, Seelbach,Germany 
Lab water system arium
®
 pro Sartorius AG, Göttingen, Germany 
Leica CM3050 S cryostat Leica Biosystems Nussloch GmbH, Wetzlar, 
Germany 
Microscopy Inverted AE2000 Trinocular 
cell microscope 
Olympus FLUOVIEW FV1000 
confocal laser scanning 
microscope 
Olympus BX60 Fluorescence 
microscope 
ZEISS Axio Imager 2 
 
Zeiss Axio Imager Z1 
 
Motic Europe, Barcelona, Spain   
 
Olympus Europa SE & Co. KG, Hamburg, 
Germany 
 
Olympus Europa SE & Co. KG, Hamburg, 
Germany 
Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
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Zeiss SteREO Lumar.V12 Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Microwave NN-E201WM Panasonic Corporation, Oaza Kadoma, Japan 
Mr. Frosty
TM
 Cryo Freezing Container Thermo Fisher Scientific, Carlsbad, USA 
NanoDrop
TM
 One Thermo Fisher Scientific, Carlsbad, USA 






 40 Eppendorf AG, Hamburg, Germany 
pH meter Hanna Instruments™ HI2211-02 Hanna Instruments Deutschland GmbH, 
Vöhringen, Germany 
QuantStudio 5 Real-Time PCR System Thermo Fisher Scientific, Carlsbad, USA 
Scale MC-1 Sartorius AG, Göttingen, Germany 
S1000 ThermalCycler Bio-Rad Laboratories, Inc., Hercules, USA 
ThermoMixer
TM
 F1.5 Eppendorf AG, Hamburg, Germany 
ThermoScientificTM Safe 2020 Class II 
Biological Safety Cabinet 
Thermo Fisher Scientific, Carlsbad, USA 














Bio-Rad Laboratories, Inc., Hercules, USA 
 
3.1.11 Online resources and software 
Tables 7 and 8 list all online resources and software, which were applied in the course of my 
PhD thesis. 
 
Table 7: Online resources used during PhD project. 
Online Resource Domain 
BLAST https://blast.ncbi.nlm.nih.gov/Blast.cgi 










Exac Browser http://exac.broadinstitute.org 
Fugene HD Protocol database https://www.promega.com/techserv/tools/FugeneHdTool/ 
GENECODE https://www.gencodegenes.org 
Human Gene Mutation Database 
(HGMD) 
http://www.hgmd.org/ 
Human splicing finder (HSF) http://www.umd.be/HSF/ 
Institute of Human Genetics 
(Göttingen) 
https://www.humangenetik-umg.de 
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Mouse organogenesis cell atlas https://brotmanbaty.org/mouse-organogenesis-cell-atlas-moca/ 























 CS3 and CS6 Data processing and image design 
BD FACSDiva  6.1.3 FACS data analysis 
DNASTAR
®





 5.0a Scientific graphing and statistics 















 Mac 2011 14.7.2 Text writing 
PyMOL v1.7.0.5 3D visualization of proteins and mutagenesis 
R version 3.4.4 Analysis of RNAseq and scRNAseq data 
Sequence Pilot Deep amplicon sequencing analyses 
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3.2.1 Analysis of nucleic acids 
3.2.1.1 Polymerase Chain Reaction (PCR) 
Target sequences were amplified via Polymerase chain reaction (PCR). Standard PCR 
conditions were the following: 
 
Standard PCR reaction  (25 µl)   Touchdown-like 58 PCR program  
             (TOUCH58) 
10x Taq Buffer  2.5 µl    94°C  3 min 
MgCl2 (25 mM)  1.5 µl    94°C  30 sec 
dNTPs (2.5 mM each) 2 µl    62°C  30 sec 
Forward primer (10 µM) 1 µl    72°C   variable 
Reverse primer (10 µM) 1 µl    94°C  30 sec 
Taq Polymerase (5 U/µl) 0.15 µl    60°C  30 sec 
DNA (20 ng/µl)  2 µl    72°C  variable 
dH2O    14.85 µl   94°C  30 sec 
        58°C  30 sec 
72°C  variable 
72°C   10 min 
10°C  10 min 
 
The duration of the extension step varied depending on the length of the amplified sequence. 
For Taq Polymerase reactions, 1 min was used per 1 kb of fragment size. If target 
sequences could not be amplified using the standard PCR reaction, the following PCR 
reaction was applied. 
 
HotStar PCR reaction (20 µl)   Multiplex cycler program 
Multiplex PCR Master Mix  10 µl   94°C  15 min 
Forward primer (10 µM)  1 µl   94°C  30 sec 
Reverse primer (10 µM)  1 µl   62°C  30 sec 
DNA (20 ng/µl)/cDNA   2 µl   72°C  variable 
dH2O     6 µl   94°C  30 sec 
        60°C  30 sec 
72°C  variable 
        94°C   30 sec 
58°C  30 sec 
72°C  variable  
72°C   10 min 
10°C  10 min 
3.2.1.2 Quantitative PCR (qPCR) 
cDNA samples were diluted 1:10 with dH2O. PCR were performed in 10 µl reaction volumes 
on 384 well plates using QuantStudio5 (Thermo Fisher Scientific). Either QuantiNovaTM 
SYBR® Green PCR Kit (Qiagen GmbH) or QuantiFast SYBR Green PCR Kit (Qiagen GmbH) 
were used following manufacturer’s instructions. Three technical replicates were always 
analyzed per run and sample. Data were analyzed using the ΔΔ CT-method and normalised 
to human or murine GAPDH. 
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3.2.1.3 Reverse Transcription PCR (RT-PCR) 
After RNA isolation and cDNA synthesis, a standard PCR reaction was applied using 2 µl of 
synthesized cDNA as template.  
3.2.1.4 Gel electrophoresis 
To examine DNA fragments, 5 µl of each PCR product was mixed with 6x Loading Dye and 
separated on a 1.0 % agarose gel. 5 µl of a DNA ladder was used as size standard. If 
fragments had to be extracted, the QIAquick Gel Extraction Kit was used following 
manufacturer’s instructions.  
3.2.1.5 Purification and Sanger sequencing 
In order to prepare PCR products for DNA sequencing, 8 µl of each PCR product was mixed 
with 2 µl Exo-Sap-Mix and incubated 30 min at 37°C followed by 5 min at 95°C. Samples 
were diluted with dH2O if necessary and used for Sequencing reaction. 
 
Sequencing reaction (10 µl)    Sequencing cycler program 
5x Buffer    2.25 µl   95°C   30sec 
BigDye Terminator v1.1 or v3.1 0.25 µl   95°C  10sec 
Primer (10 µM)   0.25 µl   55°C  5sec        35 cycles 
purified PCR product   0.5 µl   60°C  4min 
dH2O     6.75 µl   4°C  10min  
 
To confirm sequences for cloning approaches, 100-150 ng of purified plasmids were used 
per sequencing reaction. Sanger sequencing was performed either by the CCG, the 
laboratory diagnostic of the Institute of Human Genetics (Göttingen) or Microsynth Seqlab 
(Göttingen) [178]. Sequences were analyzed with DNASTAR® FinchTV.  
3.2.1.6 DNA extraction 
In order to perform the Array-CGH analysis in iPSC, DNA was extracted using the DNeasy 
Blood & Tissue Kit (Qiagen GmbH) and following manufacturer’s instructions. 
3.2.1.7 RNA extraction and cDNA synthesis 
RNA isolation was either performed using the RNeasy Mini Kit (Qiagen GmbH) and following 
manufacturer’s instructions or after the protocol of the Transcriptome Analysis Labor (TAL) 
(Göttingen). Briefly, the medium was aspirated from cells and washed once with PBS. 
Depending on number of cells, cells were lyzed with 0.5 – 1.0 ml TRIzol per dish. Lysates 
were collected in 1.5 ml reaction tubes on ice and stored at -80 °C until all samples have 
been collected.  
Samples were thawed and incubated 5 min at room temperature (RT) while shaking. 0.2 ml 
Cloroform was added per 1 ml TRIzol, samples were shaken for 30 seconds, subsequently 
incubated for 5 min at RT and centrifuged at 12.000 x g for 15 min at 4 °C. In the meantime 1 
µl GlycoBlue and 0.5 ml ice-cold isopropyl alcohol per 1 ml TRIzol were added to a new tube 
on ice. After centrifugation, the upper phase was transferred to the fresh prepared tubes, 
vortexed and incubated overnight at -20 °C. The following day, samples were centrifuged at 
12,000 x g for 30 min. at 4 °C. The supernatant was removed and the pellet was washed 
once with ice-cold 75 % Ethanol (1 ml per 1 ml TRIzol). Samples were centrifuged again (see 
above) and washing was repeated once. Finally, the supernatant was removed, pellets were 
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dried at 37 °C, resuspended in 20 µl H20 and measured with the NanoDrop (Thermo Fisher 
Scientific).  
1 µg RNA was used for DNase treatment using DNase I, Amplification Grade (Thermo Fisher 
Scientific) and following manufacturer’s instructions. Subsequently, RNA was used to 
reversely transcribe cDNA with the First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific) following manufacturer’s instructions. Samples were stored at -80°C and kept on 
ice during usage. 
3.2.1.8 NGS-based methods 
3.2.1.8.1 Whole exome sequencing (WES) 
WES was performed as already previously described [179]. Briefly, sequences were 
enriched using the Agilent sureselect V6 enrichment kit and were run on an Illumina 
HiSeq2000 or on an Illumina HiSeq4000 sequencer by the Cologne Center for Genomics 
(CCG). Data were analyzed with the ‘Varbank’ exome and genome analysis pipeline v.2.1. 
3.2.1.8.2 Deep amplicon sequencing 
In order to generate PCR products for deep amplicon sequencing analysis, primers were 
designed for PCR products of approximately 150 bp and flanking the site of interest. A 
standard PCR reaction was performed and quality of products was checked on 1 % agarose 
gels. Deep amplicon sequencing was performed by the CCG. Data were analysed using the 
Sequence Pilot Software (jsi medical systems GmbH). 
3.2.1.8.3 RNA sequencing (RNAseq) by Poly(A) selection 
Extracted RNA from iPSC were used for RNAseq performed by the TAL. Data pre-
processing was accomplished by the TAL using log2foldchange ≥1 or ≥-1 and p-value <0.05. 
Analyses of candidate gene lists were performed via Gene set enrichment analysis with 
‘topGO’ version 2.30.1 in R version 3.4.4 [180].  
3.2.1.8.4 Single cell RNA sequencing (scRNAseq) 
E13.5 embryos were extracted from maternal uteri. Embryos were decapitated, forebrains 
dissected and snap-frozen in liquid nitrogen. Tissues were stored at -150 °C. Four forebrains 
of each genotype were pooled for further analysis. Tissues were collected in 2 ml low binding 
Eppendorf tubes using 1.5 ml Cell lysis buffer (CLB) and pipetted up and down 20 times 
using a 1000 µl pipette. Suspensions were filtered using a 40 µm cell strainer and thereafter, 
the cell strainer was washed once with 200 µl CLB. Samples were centrifuged at 4 °C, 500 x 
g for 10 min and supernatant was discarded. Subsequently, nuclei were re-suspended in 
1000 µl Nuclear Suspension Buffer (NSB), centrifuged (see above), pellets were re-
suspended in 300 µl NSB and filtered with 40 µm cell strainer. Finally, nuclei were counted 
using a Neubauer counting chamber and diluted with NSB to 1,000 nuclei per µl. 20 µl were 
used for further processing. Library preparation was performed by the Max Planck Institute 
for Molecular Genetics Berlin using the Chromium Single Cell 3ʹ Library & Gel Bead Kit v3 
(10x Genomics). 
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3.2.1.9 Cloning of KMT2B 
3.2.1.9.1 Cloning of mutant KMT2B harboring a C-terminal GFP-tag in peGFP-N1 
Full length KMT2B cDNA with a C-terminal GFP-tag was already generated during my 
Master’s thesis. To mimic the mutation of patient K3027 in KMT2B (c.5462insC; 
p.L1822Tfs*12), a fragment of KMT2B was amplified with the Pfu Polymerase Mastermix and 
TOUCH58 using the primers KMT2Bcl_F3_F and KMT2B_K3027cl_R and cDNA of patient 
K3027 as PCR template.  
 
Standard Pfu PCR reaction (50 µl)   
10x Pfu Buffer with MgSO4  5 µl 
dNTP (2.5 mM each)   4 µl 
Forward Primer (10 µM)  1 µl 
Reverse Primer (10 µM)  1 µl 
Pfu Polymerase (2.5 U/µl)  1.25 µl 
DNA (20 ng/µl)/cDNA   2 µl 
dH2O     35.75 µl 
 
The amplified fragment was cloned into pCR®2.1-TOPO® and used for another round of PCR 
to introduce the restriction site BamHI at the 3 prime region with the reverse primer 
KMT2B_K3027_rev_BamHI_GFP_N1. PCR products were subsequently purified. Full length 
KMT2B cDNA in peGFP-N1 with GFP-tag were digested with EcoRV and BamHI. Mutant 
KMT2B fragments were cloned into digested KMT2B peGFP-N1 using the Gibson 
Assembly® Cloning Kit (New England Biolabs) and XL10-Gold® Ultracompetent cells 
following manufacturer’s instructions.  
3.2.1.9.2 TOPO® cloning and pJET1.2 cloning 
If fragments had to be cloned into pCR®2.1-TOPO® as an intermediate step, an Adenine 
overhang was added to the PCR product, which was not amplified using Taq polymerase.  
  
Adenine Overhang (50 µl) 
10x Taq Buffer    5 µl 
dNTPs (2.5 mM each)  4 µl 
MgCl2 (25 mM)   3 µl 
Taq Polymerase (5 U/µl)  1 µl 
purified PCR product   37 µl 
 
Samples were incubated for 30 min at 72°C and afterwards purified using the QIAquick Gel 
Extraction Kit following manufacturer’s instructions. Ligation of inserts with pCR®2.1-TOPO®, 
pCR®4Blunt-TOPO® or pJET1.2/blunt were performed according to manufacturer’s 
instructions and subsequently used for transformation of E. coli Top10F’.  
3.2.1.9.3 Different KMT2B constructs with N terminal Flag-HA tag in pCS2+ 
Full length KMT2B cDNA with a N-terminal FLAG-HA tag was kindly provided by the lab of 
Prof. Dr. Robert Roeder from the Rockefeller University, New York, USA. The cDNA was 
inserted into the pcDNA5/FRT/TO plasmid. Full length KMT2B cDNA was cut off from 
plasmid by using the restriction enzyme PmeI (Thermo Fisher Scientific) and cloned into StuI 
(Eco147I) digested pCS2+ plasmid.  
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To mimic the mutation of patient K3027 in KMT2B (c.5462insC; p.L1822Tfs*12), a fragment 
of KMT2B was amplified with Pfu Polymerase using the primers KMT2Bcl_Fr.3_F and 
KMT2B_K3027_Stopp_XbaI_R and mutant KMT2B-peGFP-N1 (c.5462insC; p.L1822Tfs*12) 
as PCR template. PCR product was purified, cloned into pJET1.2./blunt plasmid and 
subsequently digested with EcoRV and XbaI to remove the fragment. Finally, the fragment 
was ligated into EcoRV/XbaI digested KMT2B-pCS2+. 
In order to generate full length KMT2B harbouring a catalytic inactive SET domain (c. 
7810_7811delTAinsGC; p.2604Y>A) or mimicking the c.7852G>A mutation (p.Glu2618Lys), 
the following cloning strategy was applied. A KMT2B fragment was amplified using the 
primers KMT2B_7364_F and KMT2BwtNtagR and full length KMT2B-peGFP-N1 as 
template. The amplified fragment was purified and cloned into pJET1.2./blunt plasmid. 
Subsequently, a mutagenesis PCR was performed using the primers KMT2B_Y-A_2604_F 
and KMT2B_Y-A_2604_R or KMT2B_2618_3_F and KMT2B_2618_3_R. In order to 
exchange the mutant fragment in wild-type KMT2B, the mutant fragment in pJET1.2./blunt 
plasmid and full length KMT2B-pCS2+ were digested using AflII and XbaI (Thermo Fisher 
Scientific). Since AflII cuts the full length KMT2B at position c.7705 and additionally at the 5 
prime region, a two step ligation procedure was performed. In a first step, the AflII/XbaI 
digested fragment was ligated in AflII/XbaI digested pcs2+. In a second step, the re-ligated 
plasmid was cut with AflII and the KMT2B sequence 5 prime of cDNA position 7705 was 
inserted.  
Finally, a KMT2B construct was generated with a premature stop codon 5 prime of the PHD 
fingers (c.3522insGA; p.F1175*). A KMT2B fragment was amplified using the primers 
KMT2B_Fr.3_F and KMT2B_noPHD_rev and full length KMT2B-peGFP-N1 as template. 
PCR product was purified, cloned into pJET1.2./blunt plasmid and subsequently digested 
with EcoRV and XbaI to remove the insert. Finally, the insert was ligated into EcoRV/XbaI 
digested KMT2B-pCS2+. 
For long-term storage of transformed bacteria, 800 µl of individual bacterial colonies were 
mixed with 200 µl 100 % Glycerol in a cryo vial and stored at -80°C.  
3.2.1.9.4 Colony PCR 
In order to identify colonies carrying the correct sequences, single bacteria colonies were 
picked and diluted in 20 µl dH2O. Primers were chosen that either bind to the appropriate 
vector or to the inserted sequence. Amplification occurred with the Colony PCR reaction and 
TOUCH58 program. 
 
Colony PCR reaction (25 µl) 
10x Taq buffer   2.5 µl 
MgCl2 (25 mM)   1.5 µl 
dNTPs  (2.5 mM each)  2 µl 
Forward Primer (10 µM)  1 µl 
Reverse Primer (10 µM)  1 µl 
Taq Polymerase (5 U/µl)  0.15 µl 
Colony diluted in dH2O   5 µl  
dH2O     11.85 µl 
  
PCR products were separated on 1.0 % agarose gels. Positive colonies were inoculated in 4 
ml LB medium containing the appropriate antibiotic and incubated overnight at 37°C while 
shaking at 225 rpm. Plasmids were isolated with the NucleoSpin® Plasmid Kit, digested with 
appropriate restriction enzymes and finally prepared for Sanger sequencing. 
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3.2.1.9.5 Digestion with restriction enzymes 
For the following sub-cloning of inserts into expression vectors, inserts and target vectors 
had to be digested with appropriate restriction enzymes. The amount of used enzymes and 
choice of most suitable buffers based on information from the Thermo Scientific 
DoubleDigest online tool, and were performed in a 30 µl reaction volume. 500-1500 ng of 
vectors were used per reaction and incubated for at least 2 h at 37°C. If FastDigest enzymes 
(Thermo Fisher Scientific) were used, samples were incubated 15-30 min at different 
temperatures according to manufacturer’s instructions. Digested products were separated on 
1 % agarose gels, purified with the QIAquick Gel Extraction Kit and stored at -20°C. To 
prevent re-ligation of single digestion reactions, 1 µl of CIAP was added to the vector-
enzyme digestion reaction after 3 h and additionally incubated for 1 h at 37°C. 
3.2.1.9.6 Ligation and Transformation 
The following ligation reaction was prepared and incubated for 2 h at RT.  
 
Ligation reaction (10 µl) 
digested vector   1 µl 
10x T4 DNA Ligase buffer  1 µl 
T4 DNA Ligase    1 µl 
digested insert   7 µl 
 
A negative control (no insert) was always performed to determine the amount of successfully 
digested vectors. Thereafter, the ligated constructs were used for transformation of E. coli 
bacteria using the heat shock method. For that purpose, 50 µl of competent E. coli Top10F’ 
bacteria were thawed, mixed with the ligation reaction and incubated on ice for 30 min. 
Samples were heat shocked for 20 sec in a 42°C water bath and immediately filled up with 
300 µl LB medium. Depending on the positive selection markers Ampicillin and Kanamycin, 
bacterial cultures were shaken at 225 rpm in the 37°C shaker for 30 min or 60 min, 
respectively. Finally, cultures were spread on antibiotic containing agar plates and incubated 
overnight at 37°C. 
3.2.2 Cell culture 
Cells were kept in an incubator in a humidified atmosphere at 37 °C and 5 % CO2, unless 
otherwise stated. 
3.2.2.1 Cultivation of fibroblasts from a skin biopsy of index patient K3027 
A skin biopsy of index patient K3027 was cut using a sterile scalpel, transferred to 10 cm cell 
culture dish and incubated in cell culture medium which was exchanged if necessary. After a 
few weeks, fibroblasts became apparent and had to be detached for the first time. For this, 
the cell culture medium was removed and cells were washed once with 6 ml PBS. 2 ml of 
0.02 % EDTA/PBS was subsequently added and dishes were incubated in the incubator for 
several minutes until cells became bent. The EDTA/PBS solution was discarded and 2 ml 
Trypsin was added. Upon cell detachment, 8 ml cell culture medium was added per dish. 
Fibroblasts were transferred to new 10 cm cell culture dishes and designated as passage 1 
(P1). 
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3.2.2.2 Reprogramming dermal fibroblasts to human induced pluripotent stem 
cells (iPSC) 
Passages 3 of control and patient-derived human primary fibroblasts were used for 
generation of iPSC following the TeSR™-E7™ episomal protocol of Stem Cell Technologies. 
Briefly, primary fibroblasts were detached, 1 x 106 cells re-suspended in 120 µl Buffer R and 
transferred to a mixture of episomal vectors containing 3 µg each (OCT4, SHP53, SOX2, 
KLF4, LIN28 and L-MYC) and 1 µg of GFP encoding control plasmid. Cells were 
electroporated using the Neon® Transfection System (Invitrogen) and each vial was 
subsequently distributed onto two matrigel (Corning) pre-coated 10 cm dishes. Cells were 
cultured in cell culture medium for at least two days and afterwards in TeSRTM-E7TM until 
iPSC colonies emerged. iPSC colonies were passaged manually and each colony was 
transferred to a separate matrigel  pre-coated well of a 6-well plate containing mTeSRTM1 
medium including 10 µM Y-27632. Henceforth, cells were cultured either in mTeSRTM1 
medium or in StemMACS™ iPS-Brew XF.  
3.2.2.3 Differentiation of iPSC into neural progenitor cells (NPCs) 
iPSC were cultured in StemMACS™ iPS-Brew XF medium (Miltenyi Biotec) for several 
passages prior to the differentiation start at passage 19. Cells were cultured for 4 passages 
after being thawed before initiation of differentiation. Two days prior to the start of 
differentiation, iPSC were counted using the CASY® Cell Counter and 1.4x105, 1.6x105 and 
1.8x105 cells were seeded on matrigel coated 6 well-plates. Differentiation was accomplished 
following the Monolayer Culture Protocol of STEMdiffTM Neural System (Stem Cell 
Technologies). Only iPSC wells with confluencies < 85 % were considered for differentiation. 
After washing cells once with 1 ml of Versene solution (Gibco), 2 ml of Gentle Cell 
Dissociation Reagent (Stem Cell Technologies) was added per well and plates were 
incubated for 10 min at 37 °C. Each well was rinsed several times with a 1000 µl pipette and 
cells of corresponding iPSC clones were pooled in one 50 ml Falcon tube. To ensure 
breakage of cell clusters and generation of single cells, cell suspensions were re-suspended 
for at least 200 times using the 1000 µl pipette. Formation of single cells was always 
confirmed with a microscope. 10 ml of DMEM/F-12 was added to each tube and cells were 
centrifuged for 7 min at 300 x g. The supernatant was discarded and cells were re-
suspended in 1-4 ml STEMdiffTM Neural Induction Medium (+SMADi and 10 µM Y-27632). 
Subsequently, cells were counted using the CASY® Cell Counter and 1.5 x 106 cells were 
seeded on matrigel coated 6-well plates (3x105 for 24-well plates and 6x105 cells for 12-well 
plates). A medium change was performed daily (without Y-27632). On day 5, cells were 
passaged for the first time to obtain P1 of NPCs. Briefly, the medium was removed and 1 ml 
Accutase was added per 6-well. Cells were incubated for 8 min at 37 °C. Each well was 
rinsed several times by using a 1000 µl pipette and cells of corresponding clones were 
pooled in one 50 ml Greiner tube. 5 ml DMEM/F-12 (Gibco) was added to each tube and 
cells were centrifuged for 5 min at 300 x g. The supernatant was discarded and cells were re-
suspended in 1-3 ml STEMdiffTM Neural Induction Medium (+SMADi and 10 µM Y-27632). 
Subsequently, cells were counted using the CASY® Cell Counter and 1.23x106 cells were 
seeded on matrigel coated 6-well plates (2.5x105 for 24-well plates and 5x105 cells for 12-
well plates). A medium change was performed daily (without Y-27632) until cells were either 
harvested or passaged for the next time.  
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3.2.2.4 Passaging cells 
3.2.2.4.1 iPSC  
Detachment of iPSC was performed either with ReLeSRTM (Stem Cell Technologies) or 
Versene (Gibco) following manufacturer’s instructions. Size of iPSC colonies was reduced by 
re-suspending cell suspensions carefully with a 1000 µl pipette. Matrigel coated dishes were 
prepared at least 3 h prior to usage and stored in the cell incubator, at room temperature or 
in the fridge up to one week. Cell suspensions were transferred to freshly coated matrigel 
dishes in different dilutions.  
3.2.2.4.2 Primary fibroblasts, HEK293T and COS-7 cells 
Cells were washed once with PBS. After removal of PBS, 2 ml Trypsin was added and 
dishes were incubated at 37°C until cells detached. 8 ml cell culture medium was added and 
cell suspensions were distributed to new dishes at desired dilutions. 
3.2.2.5 Freezing and thawing cells 
3.2.2.5.1 iPSC  
After detachment of cells (see above), cell suspensions were collected in 15 ml Falcons and 
mixed with FBS (ES, heat-inactivated) and DMSO. Each cryo vial contained a mixture of 400 
µl FBS, 100 µl DMSO and 500 µl cell suspension. Cryo vials were transferred to -80 °C in Mr. 
FrostyTM Freezing Container. For long-term storage cells were transferred to -150 °C. 
For revival, cryo vials were thawed in 37 °C water bath. Cell suspensions were transferred to 
15 ml Falcon tubes containing 5 ml iPSC culture medium and centrifuged for 5 min at 300 x 
g. The supernatant was discarded and the cell pellet carefully re-suspended in iPSC culture 
medium (+10 µM Y-27632). Finally, cells were transferred to matrigel coated dishes and 
incubated at 37 °C.  
3.2.2.5.2 Primary fibroblasts, HEK293T and COS-7 cells 
Cells were detached and after addition of fresh cell culture medium, the cell suspensions 
were transferred to 15 ml tubes and centrifuged for 5 min at 1500 rpm. After centrifugation, 
supernatants were carefully removed and cells were re-suspended in 2 ml freezing medium 
(90 % FCS and 10 % DMSO) and distributed to cryo vials. Cryo vials were transferred to Mr. 
FrostyTM Freezing Container and placed into the -80°C freezer. For long-term storage, cells 
were placed in the liquid nitrogen tank or in the -150 °C freezer. 
For revival, cryo vials were immersed in a 37°C water bath until the suspension was almost 
thawed. The content was pipetted into a 10 cm cell culture dish containing 10 ml cell culture 
medium. The medium was always exchanged the following day.  
3.2.2.6 Cell transfection 
Transfections were performed using FuGENE® HD Transfection reagent (Promega) and 
following manufacturer’s instructions. Cells were analysed 24 - 48 h post transfection. 
3.2.2.7 Protein extraction 
3.2.2.7.1 Total cell lysate  
Cells were washed once with PBS while keeping the dishes on ice. 200-1000 µl ice cold total 
cell lysis buffer was added per dish. Cells were scraped off using a cell scraper and collected 
 Material & Methods  
 
   32 
in 1.5 ml reaction tubes. If pellets were supposed to be stored, cells were detached, collected 
in 15 ml Falcon tubes and centrifuged for 5 min at 300 x g. The supernatant was removed 
and pellets were washed once with PBS. After centrifugation for 5 min at 300 x g, the 
supernatant was removed and pellets were stored at -80 °C. In order to continue with the 
protocol, cell pellets were re-suspended in cold lysis buffer. Lysates were incubated on ice 
for 5 min. 1.0 µl Benzonase was added to each tube and incubated on ice for additional 30 
min while vortexing the sample every few minutes. Lysates were stored at -20 °C or -80 °C. 
3.2.2.7.2 Cell fractionation 
Cells were washed once with PBS while keeping dishes on ice. 200-1000 µl ice cold buffer 1 
was added per dish. Cells were scraped off using a cell scraper, collected in 1.5 ml reaction 
tubes and incubated on ice for 20 min while vortexing every few minutes. Cells were 
centrifuged for 10 min at 12.000 x g and 4 °C. The supernatant containing the cytoplasmic 
fraction was frozen at -20 °C or -80 °C. The pellet was re-suspended in 50-100 µl buffer 2. 1 
µl Benzonase was added per sample and incubated on ice for 30 min while vortexing every 
few minutes. Samples were centrifuged for 5 min at 13.000 rpm and 4 °C. The supernatant 
containing the nuclear fraction was stored at -20 °C or -80 °C. 
3.2.2.7.3 Measurement of protein concentration 
The total protein concentration of cell lysates was estimated after the Bicinchoninic acid 
assay (BCA) [181]. The BCA Protein Assay Kit was used following manufacturer’s 
instructions. The light absorbance was measured with a spectrophotometer at 562 nm and 
concentrations were estimated using a calibration curve. 
3.2.2.8 Mass spectrometry 
Different cell lysates were separated on 4-20 % Mini-PROTEAN® TGXTM precast protein gels 
(Bio-Rad Laboratories) following manufacturer’s instructions. Subsequently, gels were 
incubated overnight in Roti®-Blue (Carl Roth GmbH + Co. KG) while shaking at 4°C. Gels 
were washed several times in dH2O and forwarded to the Proteomics Service Facility 
(Göttingen) who performed targeted mass spectrometry using the parallel reaction 
monitoring technique (PRM). Data were analyzed using scaffold and skyline software. 
3.2.2.9 Fluorescence activated cell sorting (FACS) 
Cells were detached, collected in 15 ml Falcons and centrifuged at 300 x g for 5 min. The 
supernatant was discarded, samples were washed once with 2 ml PBS and centrifuged. The 
supernatant was discarded again and pellets were dissolved in 300 µl cold PBS. 
Subsequently, 700 µl ice-cold 100 % Ethanol was added drop-wise while vortexing samples 
carefully. Samples were stored at -20 °C overnight or up to one week. Subsequently, 
samples were centrifuged at 300 x g for 5 min, the supernatant discarded and pellets re-
suspended in 500 µl PBS. 5 µl PureLinkTMRNase A (Thermo Fisher Scientific) and 5 µl 
propidium iodide (Merck Chemicals GmbH) were added. Samples were incubated for 30 min 
at 37 °C, protected from light while shaking at 190 rpm and afterwards kept on ice. Data were 
measured using the FACSCanto II flow cytometer and BD FACSDiva Version 6.1.3.  
3.2.3 Immunological approaches 
3.2.3.1 Western Blot 
To prepare samples for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
Page), 15 - 100 µg of protein lysates were mixed with 4x NuPAGE® LDS Sample Buffer 
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(Thermo Fisher Scientific) and 10x NuPAGE® Reducing Agent (Thermo Fisher Scientific), 
followed by incubation at 95°C for 5 min. Either the Precision Plus Protein All Blue Standards 
(Bio-Rad Laboratories) or the SeeBlue Plus2 Pre-Stained Standard (Thermo Fisher 
Scientific) were used as reference. For the Thermo Fisher Scientific system, different gels 
were used including NuPAGE® 4-12 % Bis-Tris Mini Gels with running buffers NuPAGE® 
MOPS SDS and NuPAGE® MES SDS or NuPAGE® 7% Tris-Acetat Mini Gels with the Tris-
Acetate SDS running buffer. The gel electrophoresis was performed with 130-150 V for 1.5 h 
in the XCell SureLock Electrophoresis Cell (Thermo Fisher Scientific). To transfer proteins to 
nitrocellulose or polyvinylidene difluoride (PDVF) membranes, a blotting sandwich was 
prepared in a XCell Blot Module. PVDF membranes were initially activated in 100 % 
methanol (30 seconds) and subsequently washed in dH2O. Several blotting pads, two filter 
papers and one membrane were completely soaked 1x Transfer Buffer (wet blotting). The 
chamber was filled up with 1x Transfer Buffer. 25-30 V was applied for 2.5 h to enable 
blotting. 
For the Bio-Rad Laboratories system, 4-20 % Mini-PROTEAN® TGXTM precast protein gels 
were used with 1x TGS Buffer following manufacture’s instructions. Electrophoresis was 
performed with 80-110 V for 1.5 h in Mini-PROTEAN Tetra cells. Semi dry blotting was 
performed with the Trans-Blot Turbo Transfer System following manufacturer’s instructions.  
For blocking, membranes were incubated in 5 % powdered milk/TBST for 1 h at RT. 
Subsequently, membranes were incubated at 4°C overnight in 2 % powdered milk/TBST 
including the primary antibody at different dilutions. Membranes were washed three times for 
20 min with 2 % powdered milk/TBST followed by incubation in 2 % powdered milk/TBST 
containing the secondary antibody for 1 h at RT. Thereafter, membranes were washed three 
times with 2 % powdered milk/TBST for 20 min and three times in PBS for 10 min. Either the 
SuperSignal West Pico Chemoluminescent Substrate (Thermo Fisher Scientific) or the 
Clarity Western ECL Substrate (Bio-Rad Laboratories) were used for protein detection. All 
washing and incubation steps were performed while membranes were gently shaking.  
3.2.3.1.1 Western Blot of the KMT2B protein 
The HiMark Pre-Stained Protein Standard (Thermo Fisher Scientific) was used as reference. 
For separation, lysates were run with NuPAGE® 7% Tris-Acetat Mini Gels and Tris-Acetate 
SDS running buffer (Thermo Fisher Scientific). For blotting of KMT2B protein, the self-made 
“1x Transfer buffer KMT2B” was prepared and a wet blot was used with PVDF membranes. 
The blotting sandwich was prepared in a XCell SureLock Electrophoresis Cell (Thermo 
Fisher Scientific) and immersed in prepared transfer buffer. A magnetic stirrer was inserted 
and the blotting chamber was placed in a box surrounded by ice. Blotting was performed at 
4°C at 30 V overnight while the magnetic stirrer stirred slowly.  
3.2.3.2 Immunocytochemistry (ICC) 
Cells were seeded in 24-well plates on cover slips at least 24 h prior to harvesting. The 
medium was removed and cells were washed once with PBS. iPSC were incubated 20 min in 
4 % Roti® -Histofix (Carl Roth GmbH + Co. KG) and primary fibroblasts 30 min in 4 % 
polymeric formaldehyde (PFA) at RT. Cells were washed with PBS and stored at 4 °C for up 
to one week. Subsequently, cells were washed twice with PBS and blocked with 50 mM 
NH4Cl for 10 min at RT. Cells were washed twice with PBS and permeabilized three times for 
4 min with 0.2 % Triton in PBS. Primary antibodies were diluted in 0.2 % Triton/PBS (1:40 – 
1:300 dilutions) and incubated either 1 h at RT or overnight at 4 °C. Cells were washed three 
times for 4 min with 0.2 % Triton/PBS and subsequently incubated with the secondary 
antibody (1:300 – 1:1000 in 0.2 % Triton/PBS) for 1 h at RT (protected from light). Cells were 
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washed three times for 4 min with 0.2 % Triton/PBS, two times for 5 min with PBS and 
merged in ProLong® Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific) on 
slides. Slides dried overnight at RT (protected from light) and were stored at 4 °C. Pictures 
were taken either with Zeiss Axio Imager Z1 or Olympus FLUOVIEW FV1000 confocal laser 
scanning microscope. If Phalloidin stainings were performed, Phalloidin was diluted 1:2000 
and incubated for 1 h with the secondary antibody solution. To exclude unspecific binding of 
secondary antibodies, one sample without primary antibody was used as control.  
3.2.3.3 Immunohistochemistry (IHC) 
Frozen slides were thawed and washed 10 min with PBS in a staining dish while rocking. 
Sections were surrounded with an ImmEdge Pen (Vector). Thereafter, slides were incubated 
for 1 h at RT in a humidified box with 50 µl blocking solution (5 % Normal goat serum (Biozol) 
in PBT Triton 0.1 %). Slides were washed twice with PBS for 5 min while rocking in a staining 
dish. Primary antibodies were diluted in blocking solution and incubated with samples 
overnight at 4 °C in a humidified box. Samples were washed twice with PBS for 15 min while 
rocking in a staining dish. Secondary antibodies were diluted in blocking solution and 
incubated with samples for 2 h at RT in a humidified box. Samples were washed twice with 
PBS for 30 min while rocking in a staining dish. For staining of multiple antigens, the previous 
described steps were repeated beginning with dilution of primary antibodies. Finally, 
Vectashield with DAPI (Biozol) was added, samples were covered with cover slips and 
stored at 4 °C. Images were taken using ZEISS Axio Imager 2 and processed with Adobe 
Photoshop CS3 or CS6. 
3.2.4 The zebrafish Danio rerio – in vivo analysis 
3.2.4.1 Maintenance of zebrafish 
Maintenance followed the description by Westerfield and was in accordance with regulations 
of the Georg-August-University Göttingen, Germany [182]. 
3.2.4.2 Genotyping zebrafish 
Fishes were anaesthetized in 200 ml water containing 4 ml 0.4 % Tricaine and 200 µl 1 % 
Isoflurane. The exterior part of the fin was cut with a scalpel and transferred to a PCR tube. 
Embryos and tail fins were lysed under the following conditions. After removal of E3 medium, 
25 µl 25 mM NaOH, 0.25 mM EDTA was added per sample and incubated for 30 min at 95 
°C. Subsequently, 25 µl 40 mM Tris (pH 7.5) was added and samples were stored at -20 °C. 
1 µl was used as template for PCR reactions using the primers of Table 9, and genotyping 
was performed via subsequent Sanger sequencing: 
 
Table 9: Primers used for genotyping of zebrafish. 
Gene Forward primer Reverse primer 
tyr AGCTCTTCAGCTCGTCTCTC TGAGTGAGGATACTGCGG 
kmt2ba CACACAATTGTGCACAGTCC GAGACAGATGAGCACAAGAC 
kmt2bb GAAGCCCTTGAATTGGGGTT TGAACAACGTTCAAATCGGTATC 
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3.2.4.3 CRISPR/Cas9-based gene editing in zebrafish 
3.2.4.3.1 Establishment of positive control tyrosinase 
To establish the CRISPR/Cas9-based knock out strategy in zebrafish, a knock out of the 
tyrosinase gene was chosen as positive control following the protocol of Varshney et al. 
[183]. Briefly, tyrosinase sgRNA was amplified in a primer based PCR reaction using the 
following primers and Mastermix: 
 
    Phusion    0.5 µl 
    Phusion Buffer   10 µl 
    dNTPs    2 µl 
    CRISPR_F primer   2.5 µl 
    tyr_gRNA_4_R primer 2.5 µl 
    dH2O     32.5 µl 
 
PCR product was purified using the Invisorb® Spin DNA extraction Kit (Stratec Molecular 
GmbH) and quality was evaluated on a 1 % agarose gel. 250 ng of purified PCR product was 
used as template to reversely transcribe RNA using the Ambion Megascript Kit T7 (Thermo 
Fisher Scientific) and purified with the Microspin™ G-50 Columns (Merck Chemicals GmbH). 
Quality of RNA was analyzed with a 1 % agarose gel (appearance of double band) and 
concentration was measured with NanoDrop. Aliquots were stored at -80 °C until usage. 
For preparation of Cas9 enzyme, 5 µg of hCas9 encoding plasmid pCasX was linearized with 
Asp718I restriction enzyme and checked on a 1 % agarose gel. For purification, digestion 
solution was filled with RNase free dH2O to 100 µl. 100 µl Phenol/Chloroform/Isoamylalcohol 
(50:49:1) was added and mixed. Solution was centrifuged 5 min at maximal speed. The 
aqueous phase was transferred to a fresh tube. 10 µl 3 M NaAC (pH 5.2) and 250 µl 100 % 
EtOH were added and centrifuged 15 min at maximum speed. Pellet was washed with 250 µl 
70 % EtOH, dried and re-suspended in 20 µl RNase free dH2O. RNA was reversely 
transcribed using the mMESSAGE mMACHINE™ T7 Transcription Kit (Thermo Fisher 
Scientific) and purified with the Microspin™ G-50 Columns (Merck Chemicals GmbH). 
Quality of RNA was checked on a 1 % agarose gel and concentration measured with 
NanoDrop. Aliquots were stored at -80 °C until use. 
3.2.4.3.2 Injection of CRISPR/Cas9 solutions 
Prior to injections, micro needles were calibrated in order to inject 2 nl per pulse. The 
following injection solution was prepared on ice and injected into one or two cell stages of 
wild-type zebrafish embryos (hybrid of ABxTLF) to ensure delivery of 300 pg Cas9 and 50 pg 
sgRNA:  
 
Cas 9 RNA  x µl (150 ng/µl)  
tyr sgRNA  x µl (25 ng/µl) 
1 M KCl  1 µl 
0.5 % Phenolred 1 µl 
RNase free water x µl 
      10 µl 
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In addition, a solution without sgRNA was always injected to confirm intactness of Cas9 
enzyme and un-injected embryos were kept as references. Embryos were incubated in E3 
medium for 48 h at 28.5 °C and finally checked for pigmentation alterations with a binocular.  
3.2.4.3.3 Generation of stable kmt2ba and kmt2bb knock out lines 
Target sites for kmt2ba and kmt2bb were selected with the designing tool CRISPRSCAN 
[184]. Exon 28 of each homolog was used as regions of interest to find protospacer adjacent 
motif (PAM) candidates in order to generate knock outs reflecting the truncating mutation of 
index patient K3027 (KMT2B c.5462insC; p.L1822Tfs*12) in close proximity. Additionally, 
exons 28 of kmt2ba and kmt2bb were sequenced in ABxTLF to exclude impairments at 
target sites. sgRNAs were amplified as already described above using the reverse primers 
kmt2ba_ex28_CRSC_R and kmt2bb_ex28_CRSC_R for kmt2ba and kmt2bb, respectively. 
Cas9 synthesis and injections were performed as already described above. Approximately 
100 injected embryos per homolog were raised to adulthood, 20 candidates were genotyped 
via Sanger sequencing to confirm mosaics and positive fish were crossed with ABxTLF. 
Approximately 100 embryos of the F1 generation were raised to adulthood and genotyping 
was performed via Sanger sequencing in order to identify candidates for further breeding.  
3.2.4.4 Measurement of head area 
After crossing kmt2ba+/- x kmt2ba+/- and kmt2bb+/- x kmt2bb+/-, F1 generation was 
investigated from 1 dpf. Embryos and larvae were fixed in Glyoxal solution. For this, embryos 
were anaesthetized in 0.4 % Tricaine/1 % Isoflurane, incubated in Glyoxal solution for 30 min 
on ice and subsequently for 30 min at RT. Animals were either imaged immediately or stored 
at 4°C for up to 7 days. Subsequently, embryos and larvae were positioned on petri dishes 
filled with 1 % agarose. Pictures were taken from dorsal view using the Zeiss SteREO 
Lumar.V12 microscope. Animals were collected in single PCR tubes, labelled according to 
the order of pictures and genotyped. The head area was determined as illustrated in figure 
18B with ImageJ.  
3.2.4.5 Hematoxylin and eosin (HE) stain 
At 12 dpf larvae were anaesthetized, fixed in Glyoxal solution (see 3.2.4.4) and tail biopsies 
were used for genotyping. Larvae were incubated for 24 h in 4 % PFA at RT, embedded in 
paraffin and subsequently cut with technical support of Anke Frommhold, Institute of Human 
Genetics (Göttingen). Slides were incubated for 20 min in Xylol, followed by a declining EtOH 
series (100 %, 96 % and 70 %) for 1 min each. Slides were washed with dH2O and incubated 
for 15 min in a hematoxylin solution. Thereafter, slides were washed in warm tap water (5 
min) and incubated for 20 sec in a 1 % eosin solution. Subsequently, slides were quickly 
washed in dH2O and incubated in ascending EtOH series (70 %, 96 %, 100 %) and in Xylol. 
Coverslips were attached with one drop of PERTEX® (VWR International) and slides were 
dried for 15 min at 55°C. Pictures were taken using the Olympus BX60 fluorescence 
microscope. 
3.2.4.6 Whole-mount immunofluorescence (WMI) for activated Caspase 3 
Whole-mount immunofluorescence for activated Caspase 3 was performed at 32 hpf 
following the protocol of Sorrells et al. [65]. Embryos were embedded in 4% methylcellulose 
and imaged using the Olympus BX60 fluorescence microscope. 
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3.2.5 Mus musculus – in vivo analysis 
3.2.5.1 Mouse strains 
C57BL/6N mice were provided from the animal facility of the Institute of Human Genetics 
(Göttingen). Srg3-Emx1-Cre and Mll2CamK-Cre mice were kindly provided by Dr. Tran Tuoc 
(Institute of Neuroanatomy, Göttingen, Germany) and Prof. Andre Fischer (German Centre 
for Neurodegenerative Diseases (DZNE), Göttingen, Germany), respectively. All experiments 
were performed according to the European and German protection of animal acts. Animals 
were kept at a 12 h light/dark cycle at 22 °C and 55 ± 5 % relative humidity. Srg3-Emx1-Cre 
were crossed with C57BL/6N mice in order to outcross the floxed Srg3 allele in animals 
which were subsequently applied for experiments (Emx1-Cre).  
3.2.5.2 Genotyping mice 
Ear or tail biopsies were incubated overnight at 55 °C in 100 µl DirectPCR-Tail lysis reagent 
(VWR International) and 5 µl Proteinase K while shaking at 350 rpm. Samples were 
incubated for 5 min at 95 °C, followed by centrifugation for 5 min at 4 °C and 13.500 rpm. 1 
µl was used for PCR reactions using the primers in Table 10. 
 
Table 10: Primers used for genotyping of mice. 
Gene Forward primer Reverse primer 
Srg3 TGTCATCCATGAGGAGTGGTC GGTAGCTCACAAATGCCTGT 
Emx1-Cre ATGCTTCTGTCCGTTTGCCG CCTGTTTTGCACGTTCACCG 
Kmt2b CGGAGGAAGAGAGCAGTGACG GGACAGGAGTCACATCTGCTAGG 
 
3.2.5.3 Cryosections 
Embryos were extracted from maternal uteri and collected in petri dishes containing cold 1x 
PBS-DEPC on ice. For E13.5, embryos were decapitated and entire heads were used for 
further investigation. Tissues were transferred to 12-well plates and washed twice for 15 min 
in cold 1x PBS-DEPC on ice while rocking. Subsequently tissues were fixed in 4 % PFA. 
E13.5 heads were incubated 4 h while rocking on ice. Tissues were washed three times for 
15 min in cold 1x PBS-DEPC on ice and subsequently incubated in 25 % Sucrose/1xPBS-
DEPC at 4 °C overnight while rocking. Tissues were transferred to soft papers to remove 
residual sucrose, transferred into boxes with Tissue freezing medium (Leica Instruments) 
and incubated at 4 °C for 1 h. Finally, tissues were positioned in embedding medium, fixed 
on dry ice and stored at -20 °C. Tissues were sliced using the Leica CM3050 S cryostat in 10 
µm thickness. Sections were transferred to slides, dried on a 37 °C heating plate and stored 
at -20 °C. 
3.2.6 Statistics 
Data were analyzed using Microsoft Excel and Prism 5 software. The two-tailed student’s t-
test was applied to evaluate differences between patient and wt samples. Significance is 
indicated with: *p<0.05, **p<0.01, ***p<0.001. 
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4 Results 
4.1 Analyses of whole-exome sequencing (WES) data 
4.1.1 DLG3 - A novel microcephaly-associated candidate gene 
4.1.1.1 Clinical characterization of index patient K3627 
A non-consanguineous family of Pakistani descent was clinically investigated at the 
Institute of Human Genetics in Düsseldorf. Both parents and daughters were 
introduced as healthy, while the male index patient K3627 presented with a 
syndromic form of microcephaly (Figure 4A). He was the second child and born after 
an uneventful pregnancy at 37 weeks’ of gestation with normal length (48 cm), weight 
(2.65 kg) and head circumference (34 cm). The motoric development was already 
impaired in infancy with postural and tonus abnormalities. Physiotherapeutic 
treatment improved symptoms, so that the patient presented only with a slight form of 
general muscle hypotonia at the age of 12 7/12 years. His speech development was 
delayed. Hearing was not impaired. The index patient K3627 had intellectual 
disability and visited a school for children with learning difficulties. His facial features 
included longitudinal-oval face, upslanting palpebral fissures, narrow nasal bridge, 
hyperpigmentation of the oral mucosa, and high-arched palate. At the age of 12 7/12 
years his body length (-2 SD), weight (-3 SD) and head circumference (-5 SD) were 
reduced.  
Chromosomal analysis was normal (46, XY) and FISH analysis excluded DiGeorge 
syndrome. Sanger Sequencing of MCPH-associated genes including ASPM, CASC5, 
CDK5RAP2, CENPJ, CEP135, CEP152, MCPH1, STIL, WDR62, and ZNF33 did not 
identify any disease causing mutations.  
A clinical re-evaluation of the family showed that the mother (K3629) and the two 
sisters (K3626 and K3628) were presenting with microcephaly (K3629 -4.2 SD, 
K3626 -3.3 SD, K3628 -4.3 SD) as well (Figure 4A). In addition, the older sister 
(K3626) presented with learning difficulties and growth retardation pointing towards 
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Figure 4: Identification of a variant in HUWE1. (A) Pedigree of a non-consanguineous family of Pakistani descent. The male 
index patient K3627 was severely affected (filled symbol), while his sisters (K3626 and K3628) and his mother (K3629) were 
only mildly affected. DNA samples of K3627, K3628 and K3629 were subjected to WES (hash). The father (K3630) was healthy, 
while some family members of his lineage were presenting with developmental delay (asterisk). (B) Electropherograms 
depicting the position of the identified c.3949G>A variant in HUWE1 after Sanger sequencing. (C) Position of the identified 
p.Val1317Ile variant (red) in HUWE1 protein characterized by DUF908, DUF913, WWE DUF4414 and HECT domains. 
 
 
4.1.1.2 Somatic mosaicism of DLG3 in a family with a syndromic form of 
microcephaly 
In order to identify the underlying genetic cause for the syndromic form of 
microcephaly in the family, DNA from index patient K3627, his younger sister 
(K3628) and mother (K3629) were subjected to WES, performed by the Cologne 
Center for Genomics (CCG). Analysis and filtering was conducted with the analysis 
pipeline ‘Varbank’ of the CCG. In total, a mean coverage of 74 reads was achieved 
for index patient K3627, as well as 79 and 78 reads for his sister and mother, 
respectively. Furthermore, 96.4 % of targets were covered more than 10 x in index 
patient K3627 and his sister, and 96.3 % in the mother. Based on the family history, I 
applied filter criteria to search for autosomal dominant and X-linked variants present 
in all three family members with a severe effect on protein function. However, with 
this filtering strategy, no convincing candidate gene was identified. Therefore, WES 
data were re-analyzed with focus on heterozygous missense variants having a milder 
A 
B C 
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effect on protein function. This strategy resulted in a candidate list containing 38 
heterozygous and hemizygous variants (Table S1). By the use of different analyses 
tools (see 3.1.11) and published literature, only one promising variant remained, 
namely the c.3949G>A variant (p.Val1317Ile) in the HUWE1 gene (MIM 300697). 
Subsequent Sanger sequencing confirmed that the identified variant was hemizygous 
in index patient K3627 and heterozygous in his mother and sisters (Figure 4B). The 
identified missense variant in HUWE1 was promising because firstly, missense 
variants in HUWE1 have already been identified in microcephalic patients with 
overlapping phenotypic features and affected females have been reported as well 
[185,186]; secondly, the p.Val1317Ile variant was not listed in the ExAC Browser, 
which contains 60,706 WES datasets of unrelated individuals (in 2019). Thirdly, 
HUWE1 is located on the X Chromosome, explaining a more severe phenotype in 
index patient K3627 compared to his female family members; and finally, HUWE1 
encodes for an E3 ubiquitin ligase important for the regulation of apoptosis, a 
common mechanism underlying the pathogenesis of microcephaly [187]. On the 
other hand, the p.Val1317Ile variant is not located in a known HUWE1 protein 
domain (Figure 4C), and in silico prediction tools differ massively and assign the 
variant either as benign (PolyPhen-2) or disease causing (MutationTaster).  
Therefore, I re-analyzed WES-data to ensure that no other variant was overlooked. 
This time, filter criteria were applied to search for variants with a severe effect on 
protein function, detectable in index patient K3627 and his sister, but not in the 
mother. Using this filter strategy, one severe frameshift mutation was identified in the 
DLG3 gene (MIM 300189, RefSeq NM_021120) predicted to generate a stop codon, 
namely a deletion of adenine at cDNA position 848 (c.848delA; p.Asn283Thrfs*7) 
(Figure 5A). This mutation was highly convincing because firstly, the deletion was not 
annotated in the ExAC Browser, secondly, the identified mutation introduces a stop 
codon and hence exerts a severe effect on protein function via truncating the protein. 
Thirdly, the DLG3 gene is located on the X Chromosome, explaining a more severe 
phenotype in index patient K3627 compared to the milder affected sisters. Fourthly, 
similar mutations in DLG3 have already been identified in patients with a non-
syndromic form of X-linked mental retardation, with overlapping phenotypic features 
and affected females have been reported as well [188]. Finally, Dlg3 is expressed 
during early brain development and involved in signal transduction [189]. A Dlg3 
knock out results in reduced brain weight and reduction of the neocortex area in mice  
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Figure 5: Low-level DLG3 mosaicism. (A) Varbank pictures illustrating that the identified c.848delA mutation in DLG3, which 
was identified in index patient K3627 and K3628 but not in the mother K3629. (B) Electropherograms highlighting that the 
identified c.848delA mutation was not detectable in different tissues of the mother K3629 with Sanger sequencing 
 
 
[189]. Based on these data, I decided to continue with this mutation and Sanger 
sequenced all family members. As expected, the hemizygous state of the DLG3 
mutation was verified in index patient K3627, while both milder affected sisters were 
heterozygous. However, the mutation was not detectable in the mother K3629 
(Figure 5B). As a result, a gonosomal mosaicism for the identified DLG3 mutation 
was hypothesized in the mother. This type of mosaicism describes mutations that are 
detectable only in a subset of germ and somatic cells, perfectly matching the 
segregation of the disease in the present family [190]. DNA derived from blood, from 
dermal fibroblasts, from mucosa of left cheek and from mucosa of right cheek of the 
mother were Sanger sequenced; but again, neither tissue was positive for the 
c.848delA variant (Figure 5B).  
The reported variant allele frequencies (VAF) of mosaics ranges enormously in 
published literature and variants with frequencies of 6 % can not be detected with 
Sanger sequencing anymore [191,192]. Giving that the c.848delA mutation was not 
detectable in the mother via Sanger sequencing, the VAF was hypothesized of being 
less or equal 6 %. Therefore, DNA samples derived from different tissues of the 
mother and DNA of two control samples (Father K3630 and K3923) were subjected 
A B 
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to closer examination using NGS-based deep amplicon sequencing, performed by 
the CCG. For this NGS-based approach, a PCR product surrounding the c.848delA 
mutation is subjected to parallel sequencing. This strategy increased the coverage at 
cDNA position 848 from 103 reads (in WES), up to at least 1,805,656 reads (in deep 
amplicon sequencing) (Table 11). The c.848delA mutation was not detectable in both 
control samples (0 %), while its frequency ranged from 0.3 % up to 0.9 % in different 
tissues derived from the mother (Table 11).  
 
Table 11: Results of deep amplicon sequencing using different DNA samples. Table specifies total number of reads 
covering the cDNA position 848 in DLG3. Frequency of c.848delA in different DNA samples in percentage. Numbers in brackets 
indicate amount of c.848delA positive reads. 
Sample total number of reads c.848delA frequency 
Blood K3923 1,805,656 0 % (3) 
Blood K3630 3,583,971 0 % (10) 
Blood K3629 3,461,401 0.4 % (13651) 
Primary Fibroblasts K3629 2,067,722 0.3 % (5175) 
Left cheek K3629 2,383,373 0.9 % (21615) 
Right cheek K3629 1,843,730 0.3 % (6313) 
 
 
Taken together, the presented data indicate that DLG3 is a novel candidate gene 
underlying microcephaly and the predicted severe effect of the c.848delA variant on 
protein function makes DLG3 a more convincing candidate compared to the identified 
HUWE1 variant. Further functional analyses will be essential to finally proof, which of 
the identified variants is the underlying cause for the genetic disease in the presented 
family. 
4.1.2 Identification of novel microcephaly causing mutations 
4.1.2.1 DDX11 - Novel nonsense mutations underlying syndromic 
microcephaly 
Index patient K3923 was clinically examined in the Department of Pediatrics at the 
Marmara University Hospital in Istanbul, Turkey. His parents were not related. The 
mother had a previous miscarriage and index patient K3923 was the only child 
(Figure 6A). At the age of 18 months he was presenting with deafness, reduced body 
weight (-2 SD), reduced body length (-2 SD), and reduced head circumference  
(-6 SD).  
In order to identify the underlying genetic cause, DNA of index patient K3923 was 
subjected to WES, performed by the CCG. WES data were analyzed for variants in  
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Figure 6: Identification of two novel nonsense mutations in DDX11. (A) Pedigree of index patient K3923 illustrating a non-
consanguineous family. (B) Electropherograms confirming compound heterozygousity in index patient K3923 for the identified 
nonsense mutations in exon 4 and 26 of DDX11. 
 
 
known microcephaly-associated genes. Based on the pedigree of the family, filter 
criteria were applied in order to search for compound heterozygous variants and two 
variants in the known microcephaly-associated gene DDX11 (MIM 601150, RefSeq 
NM_001257144) were identified, affecting exon 4 and exon 26 of the gene [193]. 
Both identified mutations are predicted to introduce stop codons in DDX11 and were 
not annotated in the ExAC Browser. The c.442C>T mutation in exon 4 is inherited by 
the father and predicted to terminate translation of DDX11 protein early at amino acid 
position 148 (p.Gln148*) (Figure 6B). The c.2557C>T mutation in exon 26 is inherited 
by the mother and predicted to introduce a stop codon at amino acid position 879 
(p.Arg879*). 
DDX11 is a DNA helicase important for the proper cohesion of sister chromatids 
during mitosis [194]. Recessive mutations in DDX11 underlie Warsaw breakage 
syndrome and to date only 12 patients have been reported [195]. Patients with 
Warsaw breakage syndrome present with diverse clinical features, however, almost 
all reported patients are characterized by severe microcephaly, intrauterine growth 
retardation, and deafness [195]. The type of DDX11 mutations reported so far range 
from missense to nonsense mutations, which are distributed along the DDX11 gene.  
A B 
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Based on the severe effect of both identified nonsense mutations and the matching 
phenotypic overlap with Warsaw breakage syndrome, the presented DDX11 variants 
were considered as disease causing.  
4.1.2.2 FANCI – Novel mutations affecting splicing in a patient with Fanconi 
anemia 
A 2 year old boy (index patient K3929) was examined in the Department of Pediatrics 
at the Marmara University Hospital in Istanbul, Turkey (Figure 7A). He was the only 
child of unrelated parents and presented with a severe form of microcephaly (-6 SD), 
craniosynostosis, mild trigonocephaly, metopic sutur synostosis, reduced body 
weight (-2 SD), and reduced body length (-2 SD). He had bilateral clinodactyly and 
semian creases on both hands. His dysmorphic features included bilateral 
epicanthus and hyperthelorism. Blood count was normal.  
DNA of index patient K3929 was subjected to WES, performed by the CCG. Based 
on the family pedigree, WES data were analyzed for variants with a severe effect on 
protein function and either a dominant or compound heterozygous mode of 
inheritance. Using this strategy, I identified two heterozygous mutations in the known 
microcephaly-associated gene FANCI (MIM 611360, RefSeq NM_001113378), which 
were not annotated in the ExAC Browser. One mutation affects the acceptor splice 
site at the 3’ end of intron 26 and changes AG to GG (c.2890-2A>G). The Human 
Splicing Finder predicts this mutation to most probably affecting the splicing of FANCI 
pre-mRNA. The second mutation is a missense mutation (c.2108A>G; p.Asp703Gly) 
in exon 21. The prediction tools MutationTaster and Human Splicing Finder propose 
that the mutation is not only a missense mutation but also a mutation that alters 
splicing via the activation of an exonic cryptic donor site in exon 21. Sanger 
sequencing confirmed the compound heterozygous mode of inheritance in the family 
since the c.2890-2A>G mutation was inherited by the father and the c.2108A>G 
mutation by the mother (Figure 7B).  
Mutations in the FANCI gene underlie a phenotypic heterogeneous group of patients 
with Fanconi anemia and hematological abnormalities as the striking hallmark 
appearing at different time points during childhood [196]. Since index patient K3929 
was only 2 years of age during his clinical examination and no abnormal blood count 
was detectable, I contacted the responsible clinician and requested a clinical update. 
Indeed, it was confirmed that index patient K3929 was positively tested for cytopenia  
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Figure 7: Detection of defective splicing of FANCI pre-mRNA. (A) Pedigree of index patient K3929. (B) Sanger sequencing 
confirmed identified mutations in the FANCI gene in exon 21 and intron 26. (C) Reverse transcribed cDNA derived from the 
mother K3930 was investigated for a hypothesized splicing defect. Sanger sequencing confirmed formation of an aberrant splice 
site in exon 21 resulting in the deletion (del.) of 62 bp (red). Cartoon illustrates the position of the c.2108A>G mutation in exon 
21, and position of primers used for reverse transcription PCR (RT-PCR). 
 
 
by the age of 5 years. A Diepoxybutane (DEB) test was positive as well, which further 
emphasized that FANCI was the disease-associated gene.  
In order to confirm that the identified c.2108A>G mutation is not only a missense 
mutation but also a mutation affecting splicing of FANCI pre-mRNA, patient-derived 
RNA was intended to be analyzed in more detail. However, since index patient 
K3929 received already two bone marrow transplantations, which prevented analysis 
of blood derived RNA, RNA of his mother (K3930), who carried the mutation, was 
analyzed instead. In fact, the analysis confirmed that not only the c.2890-2A>G 
mutation but also the c.2108A>G mutation affects splicing of FANCI pre-mRNA. The 
mutation creates an aberrant exonic splice site in exon 21, which results in the 
deletion of 62 bp predicted to cause a frameshift and premature deletion of FANCI 
translation (p.Asp703Glyfs*2) (Figure 7C).  
Taken together, compound heterozygous mutations were identified in the FANCI 
gene in index patient K3929 with a predicted severe effect on splicing. The presented 
A C 
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analysis underscores the important teamwork between clinicians and scientists, 
which is required in order to identify underlying causes of genetic diseases. 
 
 
4.2 Functional characterization of KMT2B, a novel gene associated with 
syndromic microcephaly 
4.2.1 Clinical characterization of index patient K3027  
Index patient K3027 (hereinafter referred to as “patient”) was clinically examined in 
the Department of Pediatrics at the Marmara University Hospital in Istanbul, Turkey. 
The patient is the third daughter of healthy, non-consanguineous Turkish parents 
(Figure 8A). She was born after an uneventful pregnancy at 39 weeks’ of gestation. 
Both siblings were healthy. She presented with microcephaly and dysmorphic facial 
features including a long nose and bilateral epicanthic folds. At the age of 6 years 
and 6 months, body weight (-5 SD), body length (-3 SD), and head circumference (-9 
SD) were reduced. Hematological and biochemical tests were normal. At a follow-up 
examination at the age of 8 years and 3 months, her body weight was 14.3 kg (-5 
SD), body length 108 cm (-3 SD), and head circumference 44.3 cm (-7 SD). Cranial 
CT was normal. The patient had mild intellectual disability, learning difficulties and 
was hyperactive. She visited a school for children with learning difficulties. At the age 
of 10 years, the patient spoke well, was able to run and cycle and hence, she did not 
present with any movement disorder.  
4.2.2 KMT2B – Identification of a novel candidate gene 
Prior to the start of my PhD thesis, DNA of the patient was subjected to WES. After 
exclusion of variants in known microcephaly-associated genes, a heterozygous 
mutation in exon 27 of the lysine methyltransferase 2B (KMT2B) gene (RefSeq 
NM_014727) was identified, namely c.5462insC predicted to result in a frameshift 
and truncated protein (p.Leu1822Thrfs*12) (Figure 8B). Parenthood was confirmed 
via microsatellite marker analysis and subsequent Sanger sequencing confirmed the 
de novo status of the mutation and verified that neither the mother nor the father 
were carriers (Figure 8C).  
At the time when the mutation was identified, KMT2B was not associated with any 
genetic developmental disease, however, the mutation was highly convincing due to 
the following reasons. Firstly, de novo mutations in other members of the KMT2 
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Figure 8: The novel microcephaly-associated gene KMT2B. (A) Pedigree of the female index patient K3027. (B) Cartoon 
illustrating the KMT2B gene consisting of 37 coding exons and position of the c.5462insC mutation in exon 27. KMT2B protein 
consists of several domains and motifs. The identified p.Leu1822Thrfs*12 mutation is located between the FYRN domain and 
the Taspase 1 cleavage site. Cartoon modified after Bögershausen et al. [144] (C) Sanger sequencing illustrating the de novo 
occurrence of the identified c.5462insC mutation. 
 
 
family have already been associated with developmental diseases and microcephaly 
is a known phenotypic feature among them [149-153]. Secondly, the identified 
c.5462insC mutation was not annotated in the ExAC Browser and in addition, the 
ExAC Browser did not contain any nonsense or frameshift mutation in KMT2B at all.
Finally, the mutation was predicted to introduce a frameshift, which causes loss of 
the highly conserved SET domain pointing towards loss of protein function (Figure 
8B). Based on these data, I decided to functionally investigate KMT2B and the 
identified c.5462insC mutation in the course of my PhD thesis. 
4.2.3 Ectopically expressed KMT2B shows altered cellular localization 
The identified c.5462insC mutation (p.Leu1822Thrfs*12) in KMT2B is predicted to 
cause a frameshift and consequently, loss of the highly conserved SET domain. 
KMT2B is initially proteolytically cleaved before N- and C-terminus dimerize via 
A C 
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Figure 9: Ectopic overexpression of WT and mutant KMT2B protein. (A) WB using an N-terminal binding KMT2B antibody 
and a C-terminal binding GFP antibody in HEK293T cells confirmed stability of mutant protein. WT KMT2B was cleaved, 
however, mutant protein was not cleaved. (B) Representative immunofluorescence image of WT and mutant KMT2B protein in 
COS-7 cells. (C) Quantification of the cellular localization of GFP-tagged WT and mutant KMT2B protein in COS-7 cells. At least 
60 pictures of each expression construct were analyzed per transfection (n=3). 
 
 
association of its FYRN and FYRC domains [163,164]. The cleavage site and the 
FYRC domain are located C-terminally of the identified mutation and 
p.Leu1822Thrfs*12 KMT2B is therefore not cleaved (Figure 8B). However, since the 
FYRN domain is located N-terminally of the identified p.Leu1822Thrfs*12 mutation 
and is intact, it is possible that the FYRN domain of p.Leu1822Thrfs*12 KMT2B 
associates with the FYRC domain of wild-type (wt) KMT2B. In this scenario,
the mutation causes a more severe dominant negative effect and not only loss of 
protein function (haploinsufficiency). In order to get experimental data for the 
responsible mutational effect, I initially cloned wt and mutant KMT2B 
(p.Leu1822Thrfs*12) harboring a C-terminal GFP-tag into a mammalian expression 
construct (see 3.2.1.9). Overexpression of constructs in HEK293T cells and 
subsequent Western Blot (WB) analysis confirmed the integrity of these expression 
constructs and the stability of the mutant protein (Figure 9A). Use of a N-terminally 
binding KMT2B antibody and a C-terminally binding GFP antibody detected un-
A C 
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cleaved (full length) KMT2B (294 kDa plus GFP-tag) as well as cleaved KMT2B 
protein (223 kDa N-terminus and 71 kDa C-terminus plus GFP-tag) in wt lysates. In 
contrast, only one truncated un-cleaved KMT2B protein was detectable after 
expression of mutant KMT2B protein (199 kDa plus GFP-tag). Next, I overexpressed 
both KMT2B constructs in COS-7 cells and quantified the cellular localization of the 
GFP signal. Figure 9B illustrates a representative immunofluorescence image. As 
expected, wt KMT2B was mostly localized to the nucleus (99 % of cells) and only to a 
small extend outside the nucleus (16 % of cells) (Figure 9C). Mutant KMT2B showed 
a reduced nuclear localization (75 % of cells) and an increased localization outside 
the nucleus (84 % of cells) indicating that the truncation of the KMT2B protein 
interferes with nuclear translocation.  
In summary, these data indicate that the ectopically expressed mutant KMT2B 
protein is stable and characterized by an altered cellular localization thereby leaving 
the possibility of a dominant negative effect. To further analyze the mutational effect 
in vitro, I aimed to investigate the cellular effects in patient-derived fibroblasts as a 
next step.  
4.2.4 Investigation of patient-derived primary dermal fibroblasts  
A skin biopsy of the patient was used to culture primary dermal fibroblasts for 
subsequent in vitro experiments. Since KMT2B encodes a methyltransferase, I 
initially aimed to investigate the methylation level of H3K4 in patient-derived 
fibroblasts. It has already been shown that a reduction of KMT2 family members 
does not result in bulk changes of either H3K4me1, H3K4me2 or H3K4me3 
[127,128]. In order to confirm this, whole cell lysates of wt and patient-derived 
primary fibroblasts were analyzed via WB with the focus on H3K4me3. Indeed, in line 
with the previous publications, differences in bulk levels of H3K4me3 were not 
detected (Figure 10A). 
Since KMT2B is involved in the regulation of gene expression and mutations in 
KMT2B can therefore impact different cellular processes, the published literature was 
intensively searched for potential pathomechanisms underlying syndromic 
microcephaly. Interestingly, in vivo as well as in vitro experiments have already 
shown that a reduction of KMT2B, or its murine homolog, results in increased 
activation of apoptosis, a known cellular mechanism underlying the pathogenesis of 
microcephaly [146,170]. Ansari et al., for example, showed in in vitro experiments  
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Figure 10: Characterization of patient-derived fibroblasts. (A) WB for H3K4me3 illustrates that the bulk levels of H3K4me3 
were not affected in patient-derived cells. H3 and HSC70 served as loading controls (n=3). (B) Immunofluorescence stainings 
for Cytochrome C did not detect any increased release to the cytoplasm. Actin filaments were stained with phalloidin (n=3). 
Scale bars=10 µm. (C) Representative image of flow cytometry analysis focusing on the cell cycle distribution of WT and 
patient-derived fibroblasts with percentage of cells in subG0/1 phase. (n=3) (D) WB using a Caspase 3 antibody that recognizes 
full length (35 kDa) as well as activated Caspase 3 (17 and 19 kDa). Only full length Caspase 3 was detected in WT as well as 
patient-derived fibroblasts. α-Tubulin served as loading control (n=3). 
 
 
that a knock down of KMT2B causes release of the mitochondrial protein 
Cytochrome C, which is only detectable in the cytoplasm after initiation of apoptosis.
Furthermore, they observed an increased population of apoptotic cells (sub-G0/1) 
with flow cytometry [168].  
In order to analyze the effect of the identified mutation in patient-derived fibroblasts, I 
performed immunostainings for Cytochrome C and imaged cells with a confocal laser 
scanning microscope (CLSM). However, contrary to Ansari et al., no differences 
between wt and patient-derived cells were detectable (Figure 10B). To investigate 
the cell cycle distribution with flow cytometry, cells were fixed and subsequently 
stained with propidium iodide (PI). Figure 10C depicts one exemplary measurement 
and illustrates that the number of cells in sub-G0/1 phase was similar. On average 
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phase (p=0.5789). Finally, whole cell lysates of wt and patient-derived fibroblasts 
were investigated with WB for activated Caspase 3 (17 and 19 kDa), a key player in 
apoptosis activation. However, similar to the previous results, only the inactive full 
length form of Caspase 3 (35 kDa) was detectable in patient-derived fibroblasts and 
not the activated form (Figure 10D). 
Taken together, the presented data indicate that no activation of apoptosis was 
detectable in patient-derived fibroblasts. Since the identified mutation affects mainly 
cortical development and this at early embryonic stages, I decided to continue with 
the functional analysis in a different in vitro and more similar model and aimed to 
generate iPSC as a next step. 
4.2.5 Reprogramming primary fibroblasts to iPSC  
It has not been investigated whether KMT2B is required for reprogramming of 
somatic cells to iPSC to date. In collaboration with the lab of Prof. Dr. Jay 
Gopalakrishnan, I therefore aimed to reprogram wt and patient-derived fibroblasts to 
iPSC in a next step. Patient-derived cells did not show any obvious differences 
during the reprogramming process and first colonies, resembling iPSC morphologies, 
emerged at a similar time as wt colonies (data not shown). Since reprogramming is 
known to affect the chromosomal integrity of iPSC, an Array-CGH analysis was 
applied, which was performed by the laboratory diagnostic of the Institute of Human 
Genetics (Göttingen) [197]. Three wt and two patient-derived iPSC clones were 
analyzed. The analysis confirmed three chromosomal deletions present in all iPSC 
clones, which were not detectable in original fibroblasts indicating that 
reprogramming was the source for these copy-number variations (CNV) and hence, 
these CNV were iPSC specific (Table S2). Since these deletions did not contain any 
disease-associated genes or genes related to pluripotency and similar CNVs, which 
were related to iPSC reprogramming, have already been published, we decided to 
continue with two wt-derived (WT1 and WT2) and two patient-derived iPSC clones 
(Pat1 and Pat2) [197]. Figure 11A illustrates the typical iPSC colony morphology on 
matrigel coated plates. Both wt and patient-derived iPSC clones were characterized 
by compact cells and high nucleus to cytoplasm ratios. Subsequent quantitative 
PCRs (qPCRs) revealed that all iPSC clones expressed the pluripotency markers 
OCT4, SOX2 and NANOG, while they did not express the fibroblast marker COL1A1 
anymore (Figure 11B) [198]. In addition, WB experiments confirmed that OCT4, 
SOX2 and LIN-28 proteins were detectable to similar extends, which is in line with  
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Figure 11: Characterization of iPSC. (A) Representative image of iPSC colony morphology after reprogramming wt and 
patient-derived fibroblasts. Two iPSC clones (WT1,WT2 and Pat1,Pat2) were investigated. scale bars=50 µm. (B) qPCR results 
for expression of pluripotency markers OCT4, SOX2 and NANOG (n=4), and fibroblast specific marker COL1A1 (n=3). Mean ± 
SD. OCT4 expression: WT1 vs. Pat1 ***p=0.0002; WT1 vs. Pat2 *p=0.0102; WT2 vs. Pat1 ***p=0.0002; WT2 vs. Pat2 
**p=0.0087. unpaired t-test. Expression levels were normalized to GAPDH. (C) WB analysis for the pluripotency marker OCT4, 
LIN-28 and SOX2. HSC70 and α-Tubulin served as loading control (n=5). 
 
 
previous publications confirming that expression of pluripotency markers is not down-
regulated in Kmt2b KO ESCs (Figure 11C) [137,170]. 
Taken together, these data show that patient-derived fibroblasts were successfully 
reprogrammed to iPSC indicating that reduced expression of KMT2B, due to the 
identified mutation, did not result in obvious reprogramming impairments. In a next 
step, patient-derived fibroblasts and patient-derived iPSC were used for a detailed 
characterization of the identified c.5462insC mutation. 
4.2.6 Investigation of endogenous KMT2B in patient-derived fibroblasts and 
iPSC  
Initially, in order to investigate the expression and transcript stability of endogenous 
KMT2B in patient-derived fibroblasts and iPSC, qPCRs were performed with primers 
spanning the site of the c.5462insC mutation in exon 27 (Figure 12A). In patient-
derived fibroblasts, the expression of KMT2B was significantly reduced compared to 
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Figure 12: Investigation of endogenous KMT2B. (A) Position of primers used for qPCR as well as for the PCR. PCR 
products were subsequently subjected to deep amplicon sequencing. (B) qPCR results of KMT2B expression in wt and patient-
derived fibroblasts and iPSC (WT1,WT2 and Pat1,Pat2). Mean ± SD. WTFibro vs. PatFibro **p=0.0012; WT1 vs. Pat1 
p=0.2659; WT1 vs. Pat2 p=0.1855; WT2 vs. Pat1 **p=0.0055; WT2 vs. Pat2 **p=0.0043 (unpaired t-test). WT1 vs. WT2 
p=0.1600; Pat1 vs. Pat2 p=0.7414 (paired t-test) (n=3). (C) WB for KMT2B using nuclear lysates of wt and patient-derived 
fibroblasts. LAMIN A/C served as loading control. (n=3) (D) Representative image of one KMT2B specific peptide identified 
using skyline software in nuclear lysates of WT1 and Pat1, and cytosolic lysates of Pat1. Peak area determines the relative 
amount of the identified peptide and indicates that KMT2B was reduced in the nuclear fraction of Pat1, whereas KMT2B was not 
detectable in the cytoplasmic fraction. (N=3; n=1) 
 
 
KMT2B in patient-derived iPSC clones was only detectable in comparison to WT2 
(WT2 vs. Pat1 **p=0.0055; WT2 vs. Pat2 **p=0.0043). A comparison of both patient-
derived iPSC clones with WT1 revealed only slight reductions of 7 % and 10 % (WT1 
vs. Pat1 p=0.2659; WT1 vs. Pat2 p=0.1855) indicating that the KMT2B expression 
was not consistently reduced in patient-derived iPSC clones and instead, similar to 
wt cells. Since these qPCR data did not reveal any information about the quantity of 
wt and c.5462insC transcripts, one PCR product of each iPSC clone was subjected 
to NGS-based deep amplicon sequencing, performed by the CCG. Using this 
approach, the total number of reads surrounding the mutation site ranged from 4.7 x 
106 to 8.3 x 106 in WT1 and WT2, respectively, and 4.0 x 106 to 4.1 x 106 in Pat1 and 
Pat2, respectively. Both wt samples showed the nucleotide adenine at cDNA position 
5462 with a frequency of 99.5 % (4.65 x 106 reads in WT1 and 8.26 x 106 reads in 
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nucleotides indicating artifact background. In addition, the cytosine insertion was not 
detectable. In contrast, the c.5462insC mutation was detected at a frequency of 26.4 
% and 27.5 % in Pat1 and Pat2 (1.05 x 106 reads in Pat1 and 1.14 x 106 reads in 
Pat2), respectively, indicating that the c.5462insC transcript was stable and enabling 
the possibility for translation of the p.Leu1822Thrfs*12 KMT2B protein. 
Next, I analyzed the stability of wt and c.5462insC KMT2B on protein level. 
Therefore, I used nuclear protein lysates of wt and patient-derived fibroblasts and 
performed WB using a N-terminal binding KMT2B antibody. Figure 12C illustrates the 
reduction of KMT2B in patient-derived fibroblasts compared to wt cells of 
approximately 50 %. Since the p.Leu1822Thrfs*12 KMT2B protein was predicted to 
have roughly the molecular weight of the cleaved N-terminal part of wt KMT2B, it 
should be detectable in the WB, if present. However, no aberrant protein band in the 
patient sample was observable indicating that the p.Leu1822Thrfs*12 protein was not 
able to translocate to the nucleus, which is in line with the previous results in 4.2.3.  
Since overexpression of mutant KMT2B protein showed an increased aberrant 
localization outside the nucleus (see 4.2.3.), I aimed to investigate the cytoplasmic 
fraction of protein cell lysates in more detail. Cytoplasmic as well as nuclear fractions 
of patient-derived iPSC clones were analyzed with mass spectrometry by the 
proteomics service facility of the University Medical Center Göttingen (UMG). For 
this, I separated cell lysates under reducing conditions with gel electrophoresis. Gel 
bands were subsequently excised, purified and spiked with specific amounts of 
Cytochrome C serving as an internal protein reference. Targeted mass spectrometry 
using the parallel reaction monitoring technique (PRM) was used in order to detect 
the specific peptides of the KMT2B protein. Three technical replicates were 
performed. Amounts of detected peptides were subsequently analyzed with skyline 
and scaffold software. With this, different KMT2B peptides located N-terminally of the  
 
Table 12: Mass spectrometry results using scaffold software of three technical replicates (N1-N3). Relative amounts of 
all detected KMT2B peptides in Total Spectrum Count [TSC]. WT1 and Pat1 were analyzed first and subsequently WT2 and 
Pat2 resulting in different relative amounts. Meas.: Measurement 
  cytoplasmic fraction  nuclear fraction [TSC] 
Meas. Sample N1 N2 N3 N1 N2 N3 
1 WT1 n.a. n.a. n.a. 163 279 186 
 Pat1 n.d. n.d. n.d. 78 115 94 
2 WT2 n.a. n.a. n.a. 6 5 1 
 Pat2 n.d. n.d n.d. 4 1 0 
n.a.: not applied, n.d.: not detected 
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p.Leu1822Thrfs*12 mutation were identified. Analysis with skyline and scaffold 
revealed that KMT2B was not detectable in the cytoplasmic fraction of patient 
samples and only with reduced amounts in the nuclear fraction, namely 45,7 % in the 
first and 42 % in the second measurement compared to wt samples (Table 12 and 
Figure 12D). 
In summary, the presented data reveal that even though the c.5462insC transcript 
was detectable, the corresponding p.Leu1822Thrfs*12 KMT2B protein was not, 
which indicates that the p.Leu1822Thrfs*12 protein is likely unstable and hence, 
favor loss of KMT2B function as disease underlying effect. 
4.2.7 Analyses of RNAseq data in iPSC  
Since KMT2B is a methyltransferase and therefore important for the regulation of 
gene expression during embryonic developmental stages, gene expression was 
investigated in patient-derived iPSC in more detail. RNA samples of each wt and 
patient-derived iPSC clone were extracted at passage 19 and subjected to RNA-
sequencing (RNAseq) by Poly(A) selection. RNAseq as well as pre-processing of 
data (log2foldchange ≥1 or ≥-1; p-value <0.05) was performed by the transcriptome 
and genome analysis laboratory (TAL) in Göttingen. Table 13 summarizes the 
number of differentially expressed (DE) genes and the amount of up- and down-
regulated genes after single comparison of each wt-derived iPSC clone with each 
patient-derived iPSC clone.  
 
Table 13: Number of DE genes after RNAseq in iPSC and comparison of each wt-derived clone with each patient-
derived clone. 






WT1vs.Pat1 288 189 99 
WT1vs.Pat2 788 214 574 
WT2vs.Pat1 330 155 175 
WT2vs.Pat2 1197 271 926 
Shared by all 
comparisons 
84 56 28 
 
 
In three out of four comparisons, more genes were down- than up-regulated, which is 
in line with Kmt2b as the main H3K4me3 modifier at promoter regions in stem cells 
and H3K4me3 being mainly associated with active gene expression [128,199]. The 
number of DE genes was drastically reduced when candidate lists were screened for  
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Figure 13: RNAseq in iPSC. (A) Venn diagram depicting the number of differentially expressed genes after single comparison 
of each wt-derived iPSC clone with each patient-derived iPSC clone. Red circles highlight genes, which were analyzed with 
gene set enrichment analysis. (B) Log2foldChanges of identified differentially expressed genes. (C) qPCRs in order to confirm 
differentially expression of identified genes. WIF1: WT1 vs. Pat1 ***p=0.0003; WT1 vs. Pat2 ***p<0.0001; WT2 vs. Pat1 
**p=0.0013; WT2 vs. Pat2 ***p=0.0001. FZD2: WT1 vs. Pat1 **p=0.0015; WT1 vs. Pat2 ***p=0.0006; WT2 vs. Pat1 **p=0.0048; 
WT2 vs. Pat2 **p=0.0017. NPTX1: WT1 vs. Pat1 **p=0.0069; WT1 vs. Pat2 *p=0.0235; WT2 vs. Pat1 *p=0.0104; WT2 vs. Pat2 
p=0.1027. TMEM88: WT1 vs. Pat1 ***p<0.0001; WT1 vs. Pat2 **p=0.0036; WT2 vs. Pat1 ***p<0.0001; WT2 vs. Pat2 
**p=0.0094. (n=3; Mean ± SD; unpaired t-test) 
 
 
genes shared by all four comparisons. Then, only 84 genes remained consisting of 
56 up- and 28 down-regulated ones (Table 13, Figure 13A). To get a better insight 
into the function of these shared DE genes, I performed a gene set enrichment 
analysis using top gene ontology (GO) in R [180]. Different GO pathways were
enriched in GO categories “molecular function” and “biological process” (Table S3). 
Among involved genes were two genes particularly interesting, namely NPTX1 and 
APC2 (Figure 13B). NPTX1 is an important player for the differentiation of human 
pluripotent stem cells into the neural lineage [200] and similarly, APC2 is involved in 
WNT-signaling, a well known pathway also important for differentiation of stem cells 
[201-203]. Re-investigation of data showed that beside APC2 also CTNNB1 
encoding β-Catenin and the WNT-signaling regulator TMEM88 were increased in 
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pathomechanism in the present patient is in line with the data of Singh et al., who 
showed that KMT2B is important for the initiation of differentiation in human 
pluripotent stem cells [166]. 
In a next step, I also included DE genes, which were shared by three out of the four 
comparisons for the gene set enrichment analysis (Figure 13A and Table S4). Using 
this strategy, more WNT-signaling-associated genes were identified, namely WIF1 
and FZD2 as well (Figure 13B) [205]. qPCR confirmed that FZD2 and TMEM88 were 
both up- and WIF1 down-regulated in patient-derived iPSC clones (Figure 13C). 
Contrary, the significant up-regulation of NPTX1 in patient samples was not 
consistent among iPSC clones, even though the trend was apparent (WT1 vs. Pat1 
**p=0.0069; WT1 vs. Pat2 *p=0.0235; WT2 vs. Pat1 *p=0.0104; WT2 vs. Pat2 
p=0.1027). Similarly, an up-regulation of CTNNB1 and APC2 was not consistent 
among iPSC clones (Figure S2). 
Since the RNAseq data of patient-derived iPSC clones showed a high variance, 
which prevented further analyses, I aimed to investigate the RNAseq data of one 
comparison in more detail (Figure S3). For this, I re-analyzed, with bioinformatician 
Dr. Alexander Wolff, the data of “WT2 vs. Pat1”. This comparison was chosen 
because firstly, the biological variance between these samples was low and 
secondly, RNAseq data of three biological replicates from each iPSC clone enabled a 
more robust data analysis than analysis of clones with only two biological replicates 
(Figure S3). An over-representation analysis (ORA) for Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways was performed with a false discovery rate (FDR) of 
less than 5 % [206]. This analysis revealed that 1,172 genes were differentially 
expressed in Pat1 compared to WT2. The top 30 of called KEGG pathways listed the  
 
 
Table 14: KEGG pathway enrichment of comparison “WT2 vs. Pat1”: DE genes in apoptosis and WNT-signaling pathway. 
bold letters indicate an up-regulation of genes and thinner letters indicate a down-regulation. 
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Figure 14: Immunocytochemistry for Cytochrome C. No increased release of Cytochrome C to the cytoplasm was 
detectable in wild-type (WT) and patient-derived iPSC. Actin filaments were stained with phalloidin (n=3). Scale bars=10 µm. 
 
 
apoptosis and WNT-signaling pathway (Table S5). The apoptosis pathway consisted 
of in total 116 genes. Of these 116 genes were 36 differentially expressed in Pat1 
and more precisely, 19 genes were up- and 17 down-regulated (Table 14). 
Amongst these DE genes, the pro-apoptic gene TRP53 was down- and the anti-
apoptic gene BCL2L1 up-regulated [207]. p53 is a master regulator for several 
cellular processes, including the induction of apoptosis, and has been shown to be 
involved in the release of Cytochrome C [208]. In line with a down-regulation of 
TRP53 in Pat1, immunostainings for Cytochrome C in patient-derived iPSC clones 
did not show any aberrant apoptosis activation, which is illustrated in Figure 14. 
The WNT-signaling pathway in the KEGG analysis consists of 134 genes, which are 
either associated with canonical or non-canonical WNT-signaling. 40 genes were 
differentially expressed in Pat1 compared to WT2, namely, 27 genes were up- and  
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Figure 15: KEGG pathway analysis. Several identified differentially expressed genes in “WT2 vs. Pat1” were associated with 
WNT-signaling pathway. Green=down-regulation. Red=up-regulation. 
 
 
13 genes were down-regulated (Figure 15 and Table 14). WNT8A, CTNNB1 as well 
as different Frizzled class receptor genes (FZD2, FZD3, FZD5, FZD7 and FZD8) 
were consistently up-regulated, while WNT-signaling inhibitors, like WIF1 and NKD2, 
were down-regulated. In addition, effectors of WNT-signaling including CCND1, 
encoding Cyclin D1 and the transcription factors NFATC1 as well as FOSL1 (FRA1) 
were down-regulated, which further strengthens a putative involvement of WNT-
signaling in the underlying pathomechanism of our patient.  
Taken together, the presented RNAseq data give first hints for an impaired 
differentiation ability of patient-derived iPSC. In order to investigate the differentiation 
ability of patient-derived iPSC into the neural lineage in more detail, I differentiated 
iPSC to neural progenitor cells (NPCs) in a next step. 
4.2.8 Differentiation of iPSC into neural progenitor cells (NPCs) 
In order to investigate the differentiation ability of patient-derived iPSC, I 
differentiated all iPSC clones to early passages of NPCs, in collaboration with the 
stem cell unit (SCU) at the UMG. Figure 16A summarizes the experimental design 
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with different time points of sample collection. Initially, RNA was extracted at three 
days (day 0, day 2 and day 8) to trace the course of gene expression from initiation 
of differentiation to passage 1 (day 8) of NPCs. The quantification of the pluripotency 
marker OCT4 and NPC markers PAX6 as well as SOX1 with qPCR showed that the 
course of gene expression was similar among all iPSC clones (Figure 16B). While 
the expression of OCT4 clearly decreased over time, the expression of SOX1 and 
PAX6 increased to similar extends. In line with this, immunostainings for the NPC 
marker NESTIN and the proliferation marker Ki67 in passage 1 of NPCs indicated 
that cells were still proliferating and characterized by expression of NESTIN protein 
(Figure 16C). In addition, all cell lines showed similar cell morphologies in passage 1 





Figure 16: Differentiation of iPSC into passage 1 of NPCs. (A) Experimental design for differentiation of iPSC into NPCs. 
iPSC were thawed at passage 15 (P15). At P18, iPSC were counted prior to passaging. 48 h later, a monolayer protocol was 
applied and different analyses were performed at specific time points. (B) Time course of OCT4, SOX1 and PAX6 expression 
during differentiation. (n=3) (C) Immunofluorescence stainings for NESTIN and proliferation marker Ki67 at day 8 of 
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Since it has already been shown that the differentiation of stem cells, regulated by 
KMT2B, is linked to the cell cycle, I also investigated the distribution of cells in the 
cell cycle during first days of differentiation (day 0-2) with flow cytometry [166] (Figure 
S4). Figure 17A illustrates mean values (±SD) of cells either in G1, S or G2/M phase 
of the cell cycle from at least two independent experiments. These measurements 
revealed that the cell cycle distribution in iPSC was similar among all iPSC clones 
with most cells being either in G1 or G2/M phase. At day 1, the number of cells in 
G2/M phase increased in iPSC clones to more than 53 % and subsequently, 
decreased at day 2 in WT2, Pat1 and Pat2 to similar extends. However, only WT1 
showed still a higher number of cells in G2/M phase at day 2, which is in line with a 
deviating behavior of WT1 during differentiation that was observed. More specifically, 
WT1 had always lowest cell confluencies at day 1, even though same cell numbers 
were seeded and hence, appeared to proliferate more slowly during the next days 
(Figure S5, data not shown). 
In summary, the presented data show that patient-derived iPSC clones showed 
normal expression rates of important NPC markers during the first days of 
differentiation pointing towards a regular ability of these cells for the initial onset of 
differentiation. Even if, iPSC clone WT1 showed an aberrant cell cycle distribution at 
day 2, the comparison of iPSC clone WT2 with patient-derived iPSC clones does not 
reveal any obvious cell cycle differences during the first days of differentiation. 
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Figure 17: Investigating iPSC and differentiating cells. (A) Pie chart illustrating iPSC and differentiating cells, which were 
fixed, stained with PI and subsequently analyzed with cell cytometry. G1 phase (dark grey); S phase (middle grey); G2/M phase 
(light grey). Mean in percentage ± SD. iPSC: n=2; day 1: n=3; day 2: n=2. (B) Representative image of NPC morphology at P1. 
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4.2.9 CRISPR/Cas9-mediated Knock Out of kmt2ba and kmt2bb in zebrafish 
Since patient-derived iPSC did not show any obvious differences during early stages 
of differentiation into NPCs in vitro, I next aimed to investigate the effect of the 
identified c.5462insC mutation on tissue level in a homozygous KMT2B KO. For this, 
I intended to establish an in vivo KO model and aimed to prepare expression 
constructs, which can be used for subsequent rescue experiments. 
The zebrafish Danio rerio is a common model system for the investigation of 
microcephaly [68,69,209]. KMT2B has two predicted homologs in zebrafish, namely 
kmt2ba and kmt2bb, which have not been extensively investigated yet (Figure S6). 
Maternal RNA of both homologs is present already at early stages of embryogenesis 
pointing towards important functions during developmental [72]. In order to knock out 
both homologs of KMT2B, I aimed to use the CRISPR/Cas9 approach and initially 
established a positive control targeting the tyrosinase (tyr) gene in the lab of PD Dr. 
Roland Dosch [183]. A successful KO of tyr causes loss of pigmentation in injected 
embryos visible with the naked eye (Figure S7). This positive control was therefore a 
reliable and fast marker to confirm the functional quality of reagents and correct 
handling during all performed injections. 
In order to mimic the human c.5462insC mutation in zebrafish, I aligned the coding 
sequences of kmt2ba and kmt2bb with KMT2B and designed appropriate single-
guide RNA (sgRNA) sequences to target both homologs in close proximity to the 
identified human c.5462insC mutation. Cas9 RNA and sgRNAs targeting either  
 
Table 15: Position and protein effect of different mutations in human KMT2B and zebrafish homologs. 
gene exon cDNA position protein effect 
KMT2B 27 c.5462insC p.Leu1822Thrfs*12 
kmt2ba 28 c.5192_5199delGGACTCCT p.Thr1732Valfs*33 
kmt2bb 28 c.7020_7024delCGACC p.Asp2341Trpfs*40 
 
 
kmt2ba, kmt2bb or tyr were injected into one cell stages of wt hybrids (ABxTLF). 
Subsequently, injected F0 fish were genotyped and positive mosaic fish were 
crossed with ABxTLF (Figure S7C). The F1 generation was screened for 
heterozygous candidate fish with either insertions or deletions predicted to cause a 
premature truncation of kmt2ba or kmt2bb protein. Table 15 summarizes the position 
of mutations in kmt2ba and kmt2bb, which were finally selected. In order to increase 
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the number of heterozygous mutants (kmt2ba+/- and kmt2bb+/-), positive fish were 
crossed with ABxTLF for a second time. 
4.2.10 Detection of microcephaly in a kmt2bb knock out model 
In order to receive homozygous KO fish of each genotype, I crossed adult kmt2ba+/- 
fish with kmt2ba+/- fish and kmt2bb+/- fish with kmt2bb+/- fish. Subsequent Sanger 
sequencing confirmed the expected mendelian pattern of inheritance in the next 
generation (Figure 18A and Table 16). kmt2ba and kmt2bb KO embryos were both 
viable and showed no drastic phenotypic abnormalities within the first five days post 
fertilization (dpf). 
 
Table 16: Mendelian ratios of wt, heterozygous and homozygous kmt2ba as well as kmt2bb KO fish after crossing 
kmt2ba+/- with kmt2ba+/- and kmt2bb+/- with kmt2bb +/-. 
 kmt2ba+/- x kmt2ba+/-   kmt2bb+/- x kmt2bb+/- 
WT (+/+) 39 (24,8 %) 51 (21,3 %) 
heterozygous KO (+/-) 78 (49,7 %) 130 (54,4 %) 
homozygous KO (-/-) 40 (25,5 %) 58 (24,3 %) 
Total number 157 239 
 
 
Since the presented patient suffered from a syndrome characterized by features 
including a reduced head circumference and reduced body length (see 4.2.1), I 
initially only quantified the head area of fish between 1 dpf and 5 dpf (Figure 18B). 
No obvious differences were detectable by 5 dpf, neither for kmt2ba nor for kmt2bb 
(Figure 19). A closer look, however, revealed that for kmt2bb a trend towards a 
reduced head area was obvious at 5 dpf, even though the reduction was not 
significant yet (WT vs. KO p=0.06). Therefore, I decided to investigate the head area 
also at later developmental stages and subjected 14 as well as 21 dpf fish for 
measurements. Subsequent quantifications revealed that kmt2ba KO showed still no 
significant differences at any investigated time point (Figure 19). In contrast, 
homozygous kmt2bb KO larvae had significant reduced head areas at 14 as well as 
21 dpf, and furthermore, the reduction was progressive (mean relative head area 5 
dpf=0.90; mean relative head area 14 dpf=0.77; mean relative head area 21 
dpf=0.68) (Figure 19). Heterozygous kmt2bb KO fish showed only significant 
differences compared to wt fish at 14 but not at 21 dpf (14 dpf **p=0.0045, 21 dpf 
p=0.8564). In line with the phenotype of the patient, the total size of kmt2bb KO fish  
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Figure 18: CRISPR/Cas9-based KO in zebrafish. (A) Electropherogram depicting the position of PAM sequences and 
generated deletions in wild-type (+/+) and homozygous kmt2ba as well as kmt2bb KO (-/-) fish. (B) Complete overview of 
kmt2bb (+/+) and kmt2bb (-/-) fish from dorsal perspective at 14 dpf. Yellow line highlights area, which was measured in order to 
estimate head area of fish. Scale bars=2 mm. (C) Sagittal sections of kmt2bb (+/+) and kmt2bb (-/-) fish after Hematoxylin and 
eosin (HE) stain at 12 dpf. Forebrain (F); Midbrain (M); Hindbrain (H). scale bars= 100 µm. 
 
 
as well as the brain size were reduced, while the overall structure of the brain 
appeared normal (Figures 18B/C). 
In order to proof that loss of KMT2B underlies the observed syndromic microcephaly 
in kmt2bb KO fish, I cloned wt KMT2B into the pCS2+ expression vector, which can 
be used for subsequent rescue experiments. In addition, I prepared four KMT2B 
expression constructs with varying mutations, in order to characterize the relevance 
of different protein domains for the rescue of the underlying phenotype in zebrafish 
(Figures S8 and S9). Two expression constructs have missense mutations in the 
SET domain of KMT2B (p.Tyr2604Ala and p.Glu2618Lys). The p.Tyr2604Ala 
mutation abolishes the methyltransferase activity of KMT2B, whereas the
p.Glu2618Lys mutation is an unpublished mutation identified in a patient with
syndromic microcephaly (data not shown) [137]. Two additional KMT2B constructs 
express truncated forms of KMT2B including the p.Leu1822Thrfs*12 mutation, which 
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fish. Genotypes were subsequently determined via Sanger 
sequencing. kmt2bb 5 dpf (total n=40): WT vs. Het p=0.2088; WT vs. KO p=0.0600; Het vs. KO p=0.4417. kmt2bb 14 dpf (total 
n=49): WT vs. Het **p=0.0045; WT vs. KO ***p=0.0007; Het vs. KO *p=0.0262. kmt2bb 21 dpf (total n=56): WT vs. Het 
p=0.8564; WT vs. KO ***p=0.0009; Het vs. KO ***p<0.0001. (unpaired t-test) 
 
 
the FYRN domain. The second truncating expression construct carries a nonsense 
mutation (p.Phe1175*) leading to an early stop of KMT2B protein translation already 
after the CXXC motif (Figure S8A). These expression constructs together with the 
kmt2bb KO zebrafish model, which I generated within my PhD thesis, will enable us 
to firstly, characterize the pathogenic effect of each identified mutation in KMT2B and 
secondly, will enable us to investigate if the microcephaly development of our patient 
is exclusively dependent on the SET domain of KMT2B. 
Taken together, the presented data unravel different important novel findings. The 
data indicate that both KMT2B homologs have different functions in zebrafish 
embryos. In line with the phenotype of the patient, KO of kmt2bb causes 
microcephaly during early developmental stages. Since homozygous kmt2bb KO 
showed a more severe phenotype than heterozygous kmt2bb KO, the presented data 
indicate that the underlying pathomechanism is rather caused by haploinsufficiency 
than by a dominant negative effect.  
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4.2.11 Investigation of apoptosis in the kmt2bb-/- zebrafish model 
In order to investigate whether increased apoptosis underlies the reduced growth 
rate in kmt2bb KO, I investigated apoptosis with immunostainings for activated 
Caspase 3 in fixed embryos followed by Sanger sequencing. Since the trend for a 
reduced head area was already detectable in kmt2bb KO at 5 dpf (Figure 19), I 
expected to detect an increased activation of apoptosis, if present, already at earlier 
time points. Zebrafish embryos are transparent and are thus a nice model system to 
perform whole-mount immunostainings. However, the skin of older embryos and 
larvae impedes the antibody to enter the tissue and hence, requires intensive 
protocol establishment. Based on this, I performed initial whole-mount 
immunostainings at 32 hours post fertilization (32 hpf) [65]. These immunostainings 
revealed that kmt2bb KO embryos showed large areas of activated Caspase 3 at 32 
hpf compared to wt embryos, predominantly detectable at the head, caudal to the  
 
 
       
Figure 20: Investigation of apoptosis in kmt2bb
-/-





 embryos at 32 hpf using an antibody recognizing activated Caspase 3. Rectangle highlights area, which was 
applied for quantification in (B). Scale bars=100 µm. Cartoon: lateral perspective of zebrafish embryo at 30 hpf illustrating 
position of forebrain (blue), midbrain (red), midbrain-hindbrain-boundary (green) and hindbrain (orange). Cartoon was modified 
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eye. A comparison with published zebrafish data indicated that the described area 
was likely assigned to the forebrain and/or midbrain of zebrafish embryos (Figure 
20A) [210]. Quantification of the signal indicated that the activated Caspase 3 area 
was indeed significantly increased in kmt2bb KO embryos (***p<0.0001) (Figure 
20B).  
Taken together, the performed immunostainings for activated Caspase 3 point 
towards an increased activation of apoptosis in kmt2bb KO embryos at 32 hpf. Future 
experiments are necessary to document the course of apoptosis and associated 
molecular processes in more detail.  
4.2.12 Histological investigation of the Emx1-Crepos/+;Kmt2bfl/+ mouse model 
The homozygous KO of kmt2bb in zebrafish pointed towards an increased activation 
of apoptosis during embryonic development. Considering the importance of Kmt2b 
during early embryonic stages, I aimed to investigate early corticogenesis and 
associated progenitor cells in more detail. Since the complexity of the cerebral cortex 
is unique to mammals, I decided to change the model system and use the mouse 
model instead. The murine corticogenesis and associated pathological processes are 
already well characterized [1,211]. Since we aimed to investigate affected cells of the 
cerebral cortex before they induce apoptosis, I chose the heterozygous Kmt2b KO 
model for initial experiments. According to the mouse organogenesis cell atlas 
(MOCA), Kmt2b is expressed in NPCs and RGCs between E9.5 and E13.5 and 
hence, we decided to investigate embryos at E13.5 [212]. 
The previous described zebrafish data pointed towards an underlying 
haploinsufficiency rather than an underlying dominant negative effect (see 4.1.10.). 
Based on this, I used the following Cre/loxP system. A floxed Kmt2b line (Kmt2bfl/fl), 
with exon 2 flanked by loxP sites, was crossed with an Emx1-Cre line (Emx1-
Crepos/+), expressing Cre in early cortical progenitor cells from E9.5, thereby causing 
a conditional heterozygous Kmt2b KO in the cerebral cortex [213]. The pregnant 
female was sacrificed at E13.5 (early corticogenesis) and embryos were 
subsequently collected and genotyped (Figure 21A). Emx1-Crepos/+;Kmt2bfl/+ embryos 
(hereinafter referred to as “heterozygous Kmt2b cKO”) and Emx1-Cre+/+;Kmt2bfl/+ 
embryos (hereinafter referred to as “control”) were applied for subsequent 
experiments. qPCR analysis revealed that the expression of Kmt2b was significantly 
reduced in cortices of heterozygous Kmt2b cKO embryos by 45 % and this reduction
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Figure 21: Investigating heterozygous Kmt2b cKO. (A) Genotyping of Kmt2b embryos after crossing Emx1-Cre
pos/+
 mice with 
Kmt2b
fl/fl
 mice were all heterozygous for the floxed (fl) and wild-type (wt) Kmt2b allele and either positve or negative for the Cre 
allele. (B) qPCR confirming reduction of Kmt2b expression in cerebral cortices of heterozygous Kmt2b cKO embryos. 
**p=0.0033 (n=4; Mean ± SD; unpaired t-test). (C) WB confirming reduction of Kmt2b in cerebral cortices of heterozygous 
Kmt2b cKO embryos. α-Tubulin served as loading control (n=3). (D) Immunohistochemistry for neural stem cell (NSC) markers 




was verified via WB on protein level as well (Figure 21B/C). In collaboration with the 
lab of Dr. Tran Tuoc at the Institute of Neuroanatomy, Göttingen, I next performed 
immunohistochemistry (IHC) to investigate progenitor cells and generated neurons at 
E13.5. IHC for the neural stem cell (NSC) markers Sox2 as well as Pax6 and pan-
neuronal markers HuCD and NeuN, however, did not reveal any obvious differences 
in heterozygous Kmt2b cKO embryos (Figure 21D). In order to investigate progenitor 
cells in more detail, a double staining for Pax6 positive RGCs, of the VZ, and Tbr2 
positive IPCs, of the SVZ, was performed. However, also these immunostainings did 
not reveal any significant differences (Figure S10).  
B A C 
D 
 Results  
 
   70 
In summary, using the Cre/loxP system, I successfully generated a heterozygous 
cKO of Kmt2b in the murine cerebral cortex. Subsequent IHC at E13.5, however, did 
not reveal any significant structural differences in analyzed brain areas between 
control and heterozygous Kmt2b cKO embryos indicating that heterozygous Kmt2b 
cKO embryos had either a mild phenotype, which was not detectable with IHC, or 
that these embryos did not present with a phenotype during early corticogenesis. 
4.2.13 scRNAseq analysis in the heterozygous Kmt2b cKO model 
The presented IHC data did not reveal an obvious phenotype in heterozygous Kmt2b 
cKO embryos. Previous studies, however, already illustrated that the severity of the 
human phenotype can not always be recapitulated in murine KO models, even if the 
molecular pathomechanism is detectable [77]. I therefore aimed to investigate 
heterozygous Kmt2b cKO in more detail, with the main focus on gene expression, 
due to the known function of Kmt2b as methyltransferase. Considering the IHC 
results, I expected only mild differences and decided to investigate gene expression 
with a more sensitive NGS-based approach than RNAseq and applied scRNAseq.  
For this, I extracted forebrains at E13.5, pooled tissues of four embryos after 
genotyping and subjected samples to scRNAseq, which was performed in 
collaboration with the lab of PD Dr. Malte Spielmann, at the Max Planck Institute for 
Molecular Genetics, Berlin. Subsequently, 10,000 nuclei per sample were subjected 
to library preparation using the Chromium Single Cell 3ʹ Library & Gel Bead Kit v3 
(10x Genomics) (see 3.2.1.8.4). Sequencing resulted in approximately 7,700 and 
8,600 nuclei in control and heterozygous Kmt2b cKO samples, respectively, with an 
average of 1,300-1,500 unique molecular identifiers (UMI) per nuclei (hereinafter 
referred to as “cells”). Subsequently, scRNAseq data were analyzed using the R 
toolkit seurat [214,215]. It is important to consider for data analysis that the 
developing forebrain consists already of different brain regions at E13.5, including 
cerebral cortex, choroid plexus, and ganglionic eminences [76,216]. This indicates 
that besides progenitor cells of the cerebral cortex, which produce excitatory 
glutamatergic projection neurons, also progenitor cells of the ganglionic eminences 
can be found and these cells produce inhibitory GABAergic neurons [76].  
The performed analysis resulted in the identification of 14 cell clusters with most cells 
at E13.5 being characterized by progenitor-like characteristics, which is in line with 
E13.5 as an early time point of cortical neurogenesis (Control 68.4 % vs. KO 
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Figure 22: scRNAseq in heterozygous Kmt2b cKO embryos at E13.5. (A) Uniform manifold approximation and projection 
(UMAP) plot illustrating clustering of forebrain cells, pooled from four embryos of each genotype. Neural progenitor cell (NPC); 
neural epithelia cells (NEC); inhibitory neurons (IN); excitatory neurons (EN); endothelian cells (EC); motorneurons (MN); 
immunocells/macrophages (I/M); WNT-signaling (WNT); indistinct neuronal markers (NCT); not annotated (NA). (B) Quantitative 
comparison of the amount of each identified cell cluster in control and heterozygous Kmt2b cKO (KO) embryos. Number in 
boxes represent percentages of cells. 
 
 
66.8%) (Figure 22). Among these identified progenitor clusters, cells arranged in 
either three NEC clusters (Control 34.8 % vs. KO 32.9 %) or in two NPC clusters 
(Control 33.6 % vs. KO 33.9 %). NEC clusters 1 – 3 expressed RGC markers, which 
overlap with markers of the VZ [217-219]. NEC1 expressed Hes5, Ednrb and Sox2, 
while clusters NEC2 and NEC3 expressed Pax6. NEC1 and NEC3 expressed 
proliferation markers Ki67 and Top2a, whereas cells in NEC2 did not express these 
proliferation markers indicating that clusters NEC1 and NEC3 contained proliferating 
cells and NEC2 did not. A closer look at the proliferating NEC clusters NEC1 and 
NEC3 revealed that these clusters were slightly reduced in heterozygous Kmt2b cKO 
embryos compared to control animals (Control 24.5 % vs. KO 20.8 %) (Figure 22B). 
In contrast, NEC2, which did not express proliferation markers, was slightly increased 
in heterozygous Kmt2b cKO embryos (Control 10.3 % vs. KO 12.1 %). 
B A 
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Figure 23: Forebrain specific marker genes in heterozygous Kmt2b cKO embryos. UMAP plots illustrating cells expressing 
specific markers of different forebrain regions (Emx1, Dlx2, Isl1) in control and heterozygous Kmt2b cKO embryos (KO). 
 
 
The NPC cluster NPC1 expressed Pbx3 and Zfhx3 indicating that these cells likely 
represented precursors of inhibitory neurons, which are generated in ganglionic 
eminences of forebrains and migrate long distances towards cortical layers (Control 
17.9 % vs. KO 17.8 %) [220-222]. Accordingly, NPC1 clustered in close proximity to 
inhibitory neuronal clusters IN1 and IN3 and in addition, these cells expressed Isl1, a 
gene expressed in cells of ganglionic eminences (Figures 23) [223]. The NPC cluster 
NPC2 expressed Eomes (Tbr2), a marker of IPCs from the SVZ of the developing 
neocortex (Control 15.7 % vs. KO 16.0 %) [218,224]. In line with the important role of 
IPCs for neuron production in the developing neocortex, NPC2 clustered in close 
proximity to excitatory neurons (EN) (Figure 22A) [225].  
Most differentiated neuronal cells at E13.5 were inhibitory neurons (IN), which is in 
line with previous published forebrain data [226]. Three IN clusters were identified 
  
 Results  
 
   73 
    
Figure 24: Apoptosis-associated genes in heterozygous Kmt2b cKO embryos. UMAP plots illustrating cells expressing the 
apoptosis-associated genes Bax and Trp53 in control and heterozygous Kmt2b cKO (KO) embryos. 
 
 
(Control 16.8 % vs. KO 17.8 %) and in agreement these cells expressed the ventral 
telencephalon specific genes Isl1 and Dlx2 (Figure 23) [223]. Moreover, one EN 
cluster was identified (Control 3.8 % vs. KO 3.8 %). Emx1 is a marker for cells mainly 
derived from the cerebral cortex itself and hence, expression of Emx1 should be 
detected in RGCs, IPCs and ENs of developing cortices [227]. However, Emx1 gene 
expression was barely detectable in scRNAseq data, which can be likely attributed to 
the high number of dropout events of scRNAseq (Figure 23) [228,229].  
In addition, non-neuronal cell clusters were characterized by endothelian cells (EC) 
(Control 2.4 % vs. KO 3.1 %) and immune cells / macrophages (I/M) (Control 0.3 % 
vs. KO 0.3 %). Next to the EC cluster, one cluster expressed several WNT-signaling 
related genes (WNT-cluster) (Control 1.7 % vs. KO 1.5 %). The expression of Otx2, 
Igfbp2 and Igfbp5 indicated that cells of the WNT-cluster also had non-neuronal 
character and were possibly cells of choroid plexus [218].  
Since we intended to investigate molecular changes prior to the onset of apoptosis in 
the heterozygous Kmt2b cKO model, apoptosis-associated genes were investigated 
in more detail. Analyses of identified clusters did not reveal any significant 
differences in expression of genes associated with apoptosis indicating that 
apoptosis was not apparently activated at E13.5 (data not shown). Since Andreu-
Vieyra et al. confirmed increased expression of Trp53 and different apoptosis-
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associated genes like Bax in conditional Kmt2b KO oocytes, expression of these 
genes was investigated in more detail [133]. The performed analysis revealed that 
the number of Bax expressing cells was slightly increased in heterozygous Kmt2b 
cKO embryos albeit the difference was not obvious for Trp53 (Figure 24). 
In summary, the performed scRNAseq analysis resulted in the identification of 14 cell 
clusters in developing forebrains at E13.5, which were mainly characterized by 
progenitor-like characteristics. However, no significant differences between control 
and heterozygous Kmt2b cKO embryos were detectable. A slight shift in the ratio of 
proliferating vs. non-proliferating RGCs is interesting and points towards initial 
differences. However, since these experiments were performed at the end of my PhD 
thesis, future experiments are essential in order to characterize these differences in 
more detail. 
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5 Discussion 
5.1 Novel insights into the pathogenesis of syndomic microcephaly 
Patients with syndromic microcephaly are characterized by a reduced head 
circumference and additional varying clinical features. A study in 2014 estimated that 
beside microcephaly, affected patients frequently show abnormal brain morphologies 
(76 %), intellectual disability (65 %), epilepsy (43 %), ophtalmological malformations 
(30 %), facial dysmorphism (19 %), oropharynx (13 %), skeletal (13 %), kidney (13 
%), heart (14 %) and gastrointestinal (9 %) malformations [230]. In 29 % of 
investigated cases, a genetic cause was identified, while the cause remained 
unknown in 41 % indicating that a substantial number of microcephaly patients 
remain without a genetic diagnosis. 
In the course of my PhD thesis, I aimed to address this issue and firstly, expanded 
the mutation spectrum in known microcephaly-associated genes in two patients with 
syndromic microcephaly. Secondly, I identified a novel highly convincing candidate 
gene for microcephaly and discovered a low-level somatic mosaicism in one affected 
family member. Finally, I characterized a mutation in a novel microcephaly-
associated gene KMT2B and provide first experimental data for the underlying 
pathomechanism, thereby expanding our knowledge about microcephaly and giving 
novel insights into cellular processes beyond microcephaly. 
5.1.1 The power of NGS 
My PhD project is a practical example how state-of-the-art technologies can be 
applied in order to answer different scientific questions. Within the course of my PhD 
thesis, I applied four different NGS-based approaches, namely WES, deep amplicon 
sequencing, RNAseq and scRNAseq. Whereas the results of RNAseq and 
scRNAseq will be in focus later in the discussion, the WES and deep amplicon 
sequencing results will be discussed in the following. 
5.1.1.1 Identification of a low-level somatic mosaicism  
In 2010, WES was applied for the first time as gene identification and diagnostic tool 
in order to identify mutations in patients with Miller syndrome [151]. Since then, its 
usage has increased enormously and to date, WES is still the method of choice to 
identify mutations in monogenic diseases. The release of WES data from a large 
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healthy control group (60,706 individuals) in the ExAC Browser, allows insights into 
common and rare genetic variants and facilitates the discrimination between 
mutations and polymorphisms [231]. Even though WES covers not the whole 
genome, but only the coding exons and surrounding intronic regions, it is assumed 
that approximately 80 % of mutations are located within these regions [232]. The 
success rate of WES varies massively in published literature and ranges from 29 % 
up to 68 % [233-235].  
In the course of my PhD, I investigated in total five WES data of patients with 
syndromic forms of microcephaly and identified causal variants in three analyses.  
In the first WES analysis, I investigated a family characterized by varying severities of 
syndromic microcephaly and identified a frameshift mutation (c.848delA; 
p.Asn283Thrfs*7) in the DLG3 gene in index patient K3627 and his affected sister, 
but not in the affected mother (Figure 5). These data indicated that the variant did not 
co-segregate with the phenotype in the family, which usually would exclude DLG3 as 
candidate gene. However, since the c.848delA mutation was highly convincing (see 
4.1.1.2.), I applied DNA derived from different tissues of the mother to deep amplicon 
sequencing. The c.848delA mutation was detectable at varying low levels, thereby 
proving a low-level somatic mosaicism and emphasizing that DNA derived from 
different tissues should be investigated when mosaics are hypothesized. Even 
though cDNA position 848 was covered in WES data with 103 reads, the deep 
amplicon sequencing results illustrated why the c.848delA mutation was not called 
here. Considering a VAF of 0.4 % in blood derived DNA (Table 11), not one single 
read is estimated to be positive in 103 reads and instead, for one positive read, a 
minimum of 250 reads is required. The mean coverage in the WES data of the 
mother estimated 78 reads and hence, 250 reads exceeds the mean coverage of 
WES by far, indicating that WES is not a suitable approach to detect low-level 
mosaicisms.  
The presented analysis was the first investigation of low-level mosaicism using deep 
amplicon sequencing at the Institute of Human Genetics in Göttingen. However, the 
awareness about the relevance of mosaic mutations for genetic diseases increased 
enormously during the past years, since firstly, somatic mosaic mutations can 
manifest phenotypes in affected patients; secondly, mosaic mutations might occur 
more frequently than expected thereby reducing the number of misinterpreted de 
novo germline mutations; and finally, mosaic mutations might account for incomplete 
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penetrance and variable expressivity in some pedigrees [191,192,236-238]. Since 
mosaic mutations escape detection in routine diagnostics, deep amplicon sequencing 
was subsequently established in the laboratory diagnostic of the Institute of Human 
Genetics in Göttingen and is offered for genetic testing to date.  
5.1.1.2 Expanding the mutational spectrum of DDX11 
In the second WES analyses, I expanded the mutation spectrum of DDX11, a known 
gene associated with Warsaw breakage syndrome and only one dozen reported 
cases to date (Figure 6B) [193,195]. Warsaw breakage syndrome has an autosomal 
recessive trait of inheritance and affected patients are clinically very heterogeneous, 
but they share some common features including microcephaly, intrauterine growth 
retardation, and deafness [195]. DDX11 is a known DNA helicase important for the 
proper cohesion of sister chromatids during mitosis and thus, for maintaining 
genomic integrity [194]. The protein has an iron-sulfur domain (267 – 350 aa) and six 
helicase motifs distributed along the DDX11 protein. The first identified nonsense 
mutation of index patient K3923 is predicted to truncate DDX11 already N-terminally 
of the iron-sulfur domain (p.Gln148*). The second identified nonsense mutation of 
index patient K3923 is predicted to introduce a stop codon near the C-terminus of the 
protein (p.Arg879*) (DDX11 total length: 906 aa). Wu et al. investigated a previously 
reported p.Lys897del mutation in DDX11 in more detail, which is in close proximity to 
the identified p.Arg879* mutation [239]. The authors reported that the p.Lys897del 
mutation results in an impaired DNA binding and ATPase activity of DDX11. Based 
on these data, it can be hypothesized that the identified nonsense mutations in index 
patient K3923 result most likely in loss of protein function and genomic instability, 
which finally underlies the development of microcephaly.  
However, the present WES analysis was difficult since the performed investigation 
was hampered by DDX11L sequences. The DDX11L gene family evolved as a result 
of segmental duplication from DDX11 and 18 copies have been described yet [240]. 
These copies are distributed in sub-telomeric regions along the genome and show 
high sequence similarities especially with exons located towards the 3 prime end of 
the DDX11 gene (RefSeq NM_001257144: in total 27 exons). As a result, the 
c.2557C>T mutation in exon 26 of DDX11 was not called during the first round of 
WES analysis, even though the position was covered with more than 100 reads and 
instead, variant calling required less stringent filter criteria. In worst case, the non-
identified DDX11 mutation could have resulted in complete exclusion of DDX11 as 
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disease-associated gene. Figure 6B depicts the electropherogram after Sanger 
sequencing of exon 4 and 26 in DDX11. In line with the described sequence similarity 
between DDX11 and DDX11L, peak height, especially of the identified c.2557C>T 
mutation in exon 26, was not as expected 50 %, but instead, had only a small height 
indicating that PCR primers amplified not only DDX11, but also DDX11L. The 
reduced variant frequency might be misinterpreted as normal sequencing 
background if data are not treated with sufficient care and it is even worth speculating 
that DDX11L copies negatively influenced the number of reported DDX11 cases to 
date.  
5.1.1.3 Identification of novel FANCI mutations affecting splicing  
In the third WES analysis, I identified two novel mutations affecting splicing in the 
FANCI gene, which is associated with Fanconi anemia [196].  
The first identified mutation in FANCI (c.2890-2A>G) changed the highly conserved 
acceptor splice site in intron 26 from AG to GG (Figure 7B). It is estimated that 98,7 
% of intronic acceptor splice sites show a canonical AG and mutations affecting this 
position have been frequently reported in genetic diseases to date [241-243]. Based 
on this, I was convinced about the severe effect of the identified c.2890-2A>G 
mutation and did not verify its influence on FANCI pre-mRNA splicing. Wimmer et al. 
divided splice site mutations into five categories (Figure 25) [244]: Category (I) 
describes mutations that affect canonical splice sites in introns resulting in exon 
skipping. Category (II) describes intronic mutations that generate novel intronic splice 
sites resulting in insertion of cryptic exons. Category (III) describes exonic mutations 
that generate cryptic splice sites resulting in partial loss of exonic sequences. 
Category (IV) is similar to (I) and describes that, after loss of canonical splice sites, a 
cryptic splice site can be used instead resulting in either partial intronic retention or 
partial exon skipping. Finally, category (V) describes mutations that destroy exonic 
splice enhancers (ESE) and cause exon skipping. According to the categories of 
Wimmer et al., it is likely that the c.2890-2A>G mutation causes more than one 
aberrant splice product of FANCI pre-mRNA since it can be assigned to categories (I) 
and (IV), both characterized by skipping of exon 27.  
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Figure 25: Splicing categories of Wimmer et al. [244]. Five splicing categories (I-V) describe different mutations that result in 
divergent splicing products. Exon (ex); splice site (SS); pseudo exon (p.e.); intron (int); exonic splice enhancer (ESE). Cartoon 
modified after Abramowicz & Gos [245]. 
 
 
The second mutation was more difficult to interpret because at first glance it was only 
a missense mutation (c.2108A>G) in exon 21 (Figure 7B). Investigations of reverse 
transcribed cDNA, confirmed that the c.2108A>G mutation was the second mutation 
affecting splicing via generation of a cryptic splice site in exon 21 (Figure 7C). The 
c.2108A>G mutation can therefore be assigned to category (III) of splicing defects, 
and resulted in loss of 62 bp from exon 21 (p.Asp703Glyfs*2) [244].  
FANCI is an important protein involved in DNA damage response, a well known 
mechanism involved in the pathogenesis of microcephaly [54-56]. Smogorzewska et 
al. reported a putative nuclear localization signal (NLS) located between amino acid 
779 and 795 in FANCI [246]. Importantly, the putative NLS is located C-terminally to 
the predicted p.Asp703Glyfs*2 mutation and thus is lost in the truncated protein. This 
indicates that even if the identified p.Asp703Glyfs*2 protein was stable, it would most 
likely not be able to translocate into the nucleus in order to exert its physiological 
function. Moreover, FANCI possesses an armadillo (ARM) repeat close to the C-
terminus (985 aa – 1207 aa), which is important for DNA binding [246,247]. This 
repeat might therefore be impaired or lost in splicing products of the identified 
c.2890-2A>G mutation and based on these findings, it is likely that both identified 
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mutations result in loss of protein function and subsequently, in loss of genomic 
integrity, which underlies the microcephaly development.  
The FANCI investigation nicely illustrated the essential interplay between clinicians 
and scientists in order to find the underlying genetic cause. More than 50,000 
variants were called in the WES data of patient K3929 prior to the application of filter 
criteria (data not shown). In addition, even after application of filter criteria, 
heterozygous variants in several microcephaly-associated genes can possibly remain 
(Table S1). Considering a monogenic disease, finding the “one” causative mutation 
can be challenging and requires a combination of appropriately applied filter criteria, 
variant interpretation and assessment of putative phenotypic outcome. Patient K3929 
was only two years of age when he was clinically investigated and at that time, he did 
not show any abnormal blood count (see 4.2.3). Patients with Fanconi anemia are 
clinically very heterogeneous, however, hematological abnormalities are key 
hallmarks that develop during different time points of childhood [248]. A clinical 
update was therefore a mandatory step in order to decide about future investigations. 
The c.2108A>G mutation was back then only certainly known as missense mutation 
(p.Asp703Gly) and a new blood sample was necessary for the extraction of RNA and 
subsequent splicing analysis. Convincing data were therefore important in order to 
decide whether the family should be contacted again, since they suffered already 
enough after patient K3929 received two bone marrow transplantations accompanied 
by recurrent infections and hospitalization.  
 
In conclusion, using NGS-based WES, I successfully identified four novel mutations 
in the microcephaly-associated genes DDX11 and FANCI. Using a combination of 
WES and deep amplicon sequencing, I identified a novel mutation in the DLG3 gene 
and proved a low-level somatic mosaicism. Mutations in DLG3 have only been 
reported in patients with X-linked mental retardation to date, highlighting that DLG3 is 
a novel highly convincing candidate gene underlying microcephaly [188]. Therefore, 
my results end the long odyssey towards a diagnosis for these families and provide 
important information about the underlying genetic cause and open perspectives in 
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5.2 The pathomechanism underlying KMT2B-associated microcephaly 
The main part of my PhD project focused on the characterization of KMT2B, a novel 
gene associated with syndromic microcephaly. Prior to the start of my thesis, a de 
novo c.5462insC mutation (p.Leu1822Thrfs*12) was identified in a girl presenting 
with severe microcephaly, short stature, reduced body weight, and facial 
dysmorphism (see 4.2.1). During my PhD, I was able to characterize the c.5462insC 
mutation in more detail and provide first data pointing towards the underlying 
pathomechanism, which will be discussed in the following. 
5.2.1 The methyltransferase KMT2B and its importance for stem cells 
Even before KMT2B became associated with a human genetic disease in 2016, its 
role in human and murine stem cells was already intensively described (see 1.4.2.) 
[127,128,137,148,166,170,171]. These studies together revealed that Kmt2b is 
important for H3K4me3 at promoter and enhancer regions in stem cells and that loss 
of Kmt2b results in impaired differentiation of cells and increased apoptosis rates. At 
the beginning of my PhD thesis, I investigated patient-derived fibroblasts, however, I 
did not observe any obvious phenotype during culturing of cells (see 4.2.4). These 
data are in line with a depletion of Wdr5, an important cofactor of COMPASS(-like) 
complexes, that also causes defects in stem cells but not in fibroblasts [249]. Based 
on that, we were convinced that a similar in vitro model was crucial for the 
investigation of the underlying pathomechanism in the present microcephalic patient, 
with the c.5462insC mutation and decided to generate patient-derived iPSC (see 
4.2.5).  
Considering the function of KMT2B as an important methyltransferase in stem cells, 
we aimed to investigate gene expression differences in patient-derived iPSC and 
performed RNAseq. The number of DE genes differed in each single comparison, 
with the highest numbers of DE genes constantly in comparisons with iPSC clone 
Pat2 (Table 13). Interestingly, Hu et al. demonstrated that the number of DE genes in 
Kmt2b KO ESCs increased significantly when cells differentiated into primordial germ 
cells [137]. The number of DE genes was more than doubled in comparison to ESCs, 
six days after differentiation was initiated and more than tripled, nine days after 
differentiation was initiated. In line with this, the PCA plot from the present RNAseq 
experiment illustrated a high biological variance between iPSC clone Pat1 and Pat2 
(Figure S3). This variance was even higher than the variance between Pat1 and both 
wt-derived iPSC clones and prevented a paired data analysis. Considering these 
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results and the importance of Kmt2b for differentiation of stem cells, it can be 
hypothesized that iPSC clone Pat2 already initially started to differentiate whereas 
Pat1 did not.  
However since only two iPSC clones were investigated, we can not certainly rule out 
that the high biological variance has other causes and is a result of incomplete 
quality check after generation of iPSC. Karyotyping is the method of choice to check 
chromosomal integrity in iPSC, while the resolution ranges from 5 up to 10 
megabase (Mb) [250,251]. In contrast, we performed an Array-CGH analysis and 
received a resolution of 1 Mb in iPSC. Indeed, we identified CNVs in all applied iPSC, 
which were most likely related to reprogramming (Table S2). The size of these CNVs 
ranged from 2.7 up to 3.3 Mb indicating that these CNVs would have been most likely 
missed in studies using karyotyping. We decided to continue with iPSC clones, since 
no disease or pluripotency-associated genes were affected by these chromosomal 
aberrations, but of course, we can not exclude any relevance of these CNVs for 
iPSC. In addition, we can not rule out smaller CNVs and single nucleotide variants 
(SNVs) in iPSC clones due to the minimal resolution of 1 Mb. More than 1,000 SNVs 
can be detected in iPSC and from these, a handful can affect coding sequences 
[252]. SNVs can occur during different stages of iPSC culture. They can either be 
present already as low-level mosaics in donor cells, occur de novo during 
reprogramming, or occur during culture of iPSC [253,254]. Identifying these SNVs is 
only possible with NGS-based approaches including whole-genome sequencing 
(WGS), WES or deep amplicon sequencing, which were not applied here. Finally, we 
can not exclude that the high biological variance is connected to the reprogramming 
of fibroblasts to iPSC itself. The epigenome is reconstituted during the process of 
reprogramming and H3K4me is an important part of it [255,256]. Variations in the 
epigenome between iPSC lines have been associated with reprogramming, whereas 
these differences usually decrease with continuous passaging [255,257,258]. We did 
not investigate DNA methylations or histone modifications during the course of 
reprogramming or during culturing of iPSC in general. Hence, we can not rule out 
that the high biological variance between iPSC clone Pat1 and Pat2 is linked to 
aberrant epigenome reconstitution originated during reprogramming and can be both 
dependent or independent of KMT2B.  
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5.2.1.1 Linking WNT-signaling to the function of KMT2B during stem cell 
differentiation 
The subsequent RNAseq analysis in iPSC identified differential expression of several 
WNT-signaling-associated genes (see 4.2.7). A connection of WNT-signaling and 
KMT2B is highly interesting and indeed, different studies pointed already towards a 
direct regulation. Kerimoglu et al. performed RNAseq and H3K4me3 ChIPseq in 
hippocampus of adult Kmt2a and Kmt2b cKO mice [174]. RNAseq did not point 
towards altered expression of WNT-signaling-associated genes. However, ChIPseq 
uncovered that promoter regions of several WNT-signaling-associated genes, 
including Fzd2 and Fzd7, which were de-regulated in Pat1 derived iPSC, had 
reduced H3K4me3 in Kmt2b cKO mice (Table 4). An altered H3K4me3 at these 
genes was not observed in Kmt2a cKO mice, indicating that Kmt2b specifically 
generates H3K4me3 at WNT-signaling-associated genes. In addition, GST-pulldown 
assays revealed an interaction of β-Catenin and KMT2B pointing towards a putative 
role of β-Catenin in targeting KMT2B COMPASS-like complexes to WNT-regulated 
genes [259]. Furthermore, the WNT-signaling pathway has already been linked to the 
development of primary microcephaly as well. Mutations in the WDFY3 gene, for 
instance, have been identified in patients presenting with primary microcephaly and 
the pathogenesis was linked to a de-regulation of WNT-signaling (see 1.2.1) [63]. 
Based on these findings, we used the presented RNAseq data of my PhD thesis as 
an indicator to select the direction of further investigations. A putative de-regulation of 
WNT-signaling can have different outcomes. Either canonical or non-canonical WNT-
signaling pathways are affected (see 1.1.2). Non-canonical WNT-signaling has not 
been extensively investigated in stem cells yet, whereas canonical WNT-signaling 
has been widely described. The publications about the roles of canonical WNT-
signaling in ESCs are controversial. While some papers reported an importance of 
activated canonical WNT-signaling for self-renewal [260,261], others reported an 
importance of activated signaling for differentiation [201,202]. Giving the reported role 
of Kmt2b for differentiation of ESCs and its redundancy for self-renewal, we aimed to 
investigate differentiation of iPSC in a next step [170].  
All iPSC clones were differentiated into P1 of NPCs, accompanied by a normal 
course of OCT4, SOX1 and PAX6 gene expression (see 4.2.8). Lubitz et al. reported 
an impaired differentiation of homozygous Kmt2b KO ESCs, which was accompanied 
by a delayed reduction of Oct4 during embryoid body (EB) formation [170]. The data 
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from my PhD thesis did not uncover any delayed reduction of OCT4 in patient-
derived cells, which indicates that the underlying pathomechanism in our patient is 
either different, or that different approaches account for this discrepancy. Lubitz et al. 
investigated a homozygous Kmt2b KO in murine ESC, while we investigated a 
heterozygous depletion of KMT2B in human iPSC. This emphasizes that different in 
vitro systems characterized by different dosages of KMT2B were investigated and of 
course, these deviant conditions might account for the observed differences. In 
addition, Lubitz et al. used the EB formation assay and differentiated cells into 
mature neurons (β-Tubulin III positive). The EB formation assay is commonly used in 
vitro in order to investigate the differentiation ability of stem cells towards all three 
germ layers, thereby testing their pluripotency [262]. In my PhD thesis, pluripotency 
of iPSC was not investigated and since we hypothesized an early involvement of 
KMT2B in the microcephaly-associated pathomechanism, iPSC were differentiated 
into an early stage of NPC (see 4.2.8). It is therefore likely that an impaired 
differentiation of patient-derived cells becomes obvious during later stages of 
differentiation in vitro, for instance during differentiation into mature neurons, or 
during differentiation into organoid cultures [85].  
In order to investigate an involvement of WNT-signaling in more detail, different small 
molecules that either activate or inhibit WNT-signaling can be applied, to firstly, 
perform subsequent rescue experiments, or secondly, to enhance the molecular 
phenotype of differentiating patient-derived iPSC, also into organoid cultures 
[263,264]. 
In summary, the presented data of my PhD thesis point towards a de-regulation of 
WNT-signaling in patient-derived iPSC, while the significance for the underlying 
pathomechanism still has to be investigated. Even though patient-derived iPSC 
showed normal initiation of differentiation into early NPCs, characterization of mature 
NPCs, their differentiation into neurons and also differentiation of iPSC into the 
mesodermal and endodermal lineage should be in focus of future investigations, to 
fully characterize the differentiation potential of patient-derived cells. 
5.2.1.2 The role of apoptosis in patient-derived cells 
Beside WNT-signaling-associated genes, several apoptosis-associated genes were 
differentially expressed in Pat1 derived iPSC including down-regulation of the TRP53 
gene. p53 is an important regulator of different cellular processes like apoptosis and 
is well known as transcription factor to regulate the expression of several 
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downstream target genes [265]. In addition, p53 is important for the release of 
Cytochrome C from mitochondria during activation of apoptosis [208]. In line with 
this, no increased Cytochrome C release was obvious in patient-derived iPSC, 
pointing towards a physiological or even down-regulated disposition for apoptosis in 
these cells. However, these results contrast the published data of Kmt2b KO ESCs, 
which indeed stated an increased activation of apoptosis raising the question for the 
reason [170]. As already mentioned above, Lubitz et al. investigated a homozygous 
Kmt2b KO compared to the heterozygous KMT2B mutation of the presented iPSC 
model from my PhD thesis. The authors did not comment on ESCs with 
heterozygous Kmt2b KO indicating that either no or just marginal apoptotic 
phenotypes were detectable in these cells.  
Since the presented in vivo zebrafish data from my PhD thesis point towards an 
increased apoptosis rate in homozygous kmt2bb KO embryos (see 4.2.11), I still 
hypothesize that increased apoptosis is involved in the pathomechanism underlying 
the phenotype of our patient. Different scenarios are conceivable that explain why 
apoptosis was not detectable in the in vitro models yet. First of all, it is difficult to 
compare in vitro with in vivo data, since environments and conditions differ and can 
only be partially simulated in vitro. Cells have to scope with different cellular stresses 
like replication stress and DNA damage during cortical development and it has been 
shown that cells of the VZ and SVZ are very sensitive for the activation of apoptosis 
[57,266]. Hence, it is possible that stress induction in patient-derived iPSC can evoke 
obvious differences, which are hidden in stress-free conditions [267,268]. In addition, 
it has to be considered that only dermal fibroblasts and iPSC were investigated for 
apoptosis in my PhD thesis in vitro. During cortical development, the VZ and SVZ are 
characterized by a pool of different stem and progenitor cells including NECs, RGCs 
and IPCs (see 1.1.1). Apoptosis might become therefore obvious in other cell types 
like mature NPCs or during differentiation of NPCs into neurons in vitro. In line with 
this, Lubitz et al. reported also increased apoptosis rates during differentiation of 
homozygous Kmt2b KO ESCs into neurons (β-Tubulin III positive) [170]. In my PhD 
thesis, iPSC were differentiated into NPCs. For this protocol, single cell iPSC cultures 
were required and the Rho-associated protein kinase (ROCK) inhibitor Y-27632 was 
applied in order to increase cell survival (see 3.2.2.3). Y-27632 is commonly used in 
iPSC cultures and suppresses mitochondrial dependent apoptosis. However, Y-
27632 also affects the metabolism of treated cells [269-271]. Based on that, we can 
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not exclude that Y-27632 had any impacts on the cellular phenotype during iPSC 
differentiation.  
Taken together, even though increased apoptosis was not detectable in patient-
derived iPSC in vitro, apoptosis is still favored as involved cellular mechanism in the 
microcephaly-associated pathomechanism. Characterization of patient-derived 
mature NPCs and differentiation of these cells into neurons or organoid cultures in 
vitro might be required in order to uncover apoptosis in patient-derived cells.  
 
5.2.2 Haploinsufficiency vs. dominant negative effect 
Haploinsufficiency implies that a heterozygous mutation results in loss of protein 
function, while the amount of the remaining wt protein is not sufficient to fulfill its 
physiological functions. Dominant negative effect (DNE) has been first defined by 
Herskowitz in 1987 [272]. In contrast to haploinsufficiency, DNE implies that mutant 
and wt protein interact with each other, which impairs also the function of the wt 
protein and finally results in a more severe functional reduction than 
haploinsufficiency. KMT2B is cleaved by the endopeptidase Taspase 1 and 
subsequently, the N- and C-termini associate via its FYRN and FYRC domain (see 
1.4.2). The cleavage site for Taspase 1 is located C-terminally of the identified 
p.Leu1822Thrfs*12 mutation of our patient and hence, the p.Leu1822Thrfs*12 protein 
can not be cleaved anymore, while its FYRN domain is intact. As a result, the FYRN 
domain of mutant KMT2B could possibly interact with the FYRC domain of wt 
KMT2B, thereby impairing its physiological function and causing a more severe effect 
(Figure 3). Based on this, it was mandatory during my PhD thesis to investigate 
whether haploinsufficiency or DNE were the disease underlying effect in our patient.  
5.2.2.1 p.Leu1822Thrfs*12 KMT2B is not detectable in vitro 
One major part of my PhD thesis focused on the identification of the c.5462insC 
transcript and p.Leu1822Thrfs*12 KMT2B protein in patient-derived cells (see 4.2.6). 
Initially, I applied deep amplicon sequencing to confirm stability of the c.5462insC 
transcript. Usually, allele specific (q)PCRs are performed for these types of 
investigations via usage of complementary mismatches in primer/probe sequences, 
which enable proper allele discrimination [273-275]. The identified c.5462insC 
mutation, however, affected a cytosine stretch, offering only reduced sequence 
variation at the mutation site and complicating specificity of primer/probe design. 
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Deep amplicon sequencing, on the other hand, requires only a regular PCR product 
with primers flanking the mutation site, which underscores that deep amplicon 
sequencing was the method of choice for this investigation. 
In addition, I aimed to specifically identify the mutant protein with a sensitive 
approach. For this, I applied mass spectrometry and focused for direct identification 
of mutant KMT2B protein on the unique eleven amino acid sequence, derived from 
the frameshift (p.Leu1822Thrfs*12). Before I applied patient-derived cells for 
analysis, I aimed to establish the method with overexpressed ectopic mutant KMT2B. 
During establishment, we nicely identified several peptides of KMT2B, located N-
terminally of the mutation site, however, unfortunately, we did not detect the unique 
frameshift derived peptide (data not shown). Therefore, I could not use mass 
spectrometry for direct identification of mutant KMT2B protein in patient-derived cells. 
Instead, I assessed the total amount of KMT2B protein (wt and mutant KMT2B) in 
nuclear and cytosolic fractions and these results were in line with the reduced 
amount of KMT2B detected with WB analysis, which together favored an underlying 
haploinsufficiency as disease underlying effect (see 4.2.3).  
5.2.2.2 In vivo results favor haploinsufficiency as disease underlying effect 
In addition, I investigated a KO of the KMT2B homolog kmt2bb in zebrafish (see 
4.2.10). Homozygous kmt2bb larvae showed a more severe reduction of the head 
area than heterozygous kmt2bb KO larvae and hence, favored again an underlying 
haploinsufficiency as disease underlying effect.  
While homozygous kmt2bb KO embryos were characterized by a progressive form of 
microcephaly, heterozygous kmt2bb KO larvae showed a significant reduction at 14 
dpf, but not at 21 dpf. However, we have to take into consideration that the applied 
zebrafish lines (hybrid of ABxTLF) had a different genetic background, which might 
explain this inconsistency (PD Dr. Roland Dosch, Institute of Human Genetics 
Göttingen, personal communication). In line with this, high variations in head shape 
were observed during head measurements and these variations were independent of 
kmt2ba and kmt2bb genotypes (data not shown).  
 
In order to finally proof haploinsufficiency vs. DNE in vivo, I prepared wt and 
c.5462insC KMT2B expression constructs, which can be subsequently used for 
transcription of RNA (Figure S8A). Single injection of wt and c.5462insC KMT2B 
RNA and combined injection of wt and c.5462insC KMT2B RNA into zebrafish 
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embryos will finally proof whether the p.Leu1822Thrfs*12 protein exerts a DNE or not 
[276]. Since different Kmt2a KO studies reported varying lethal phenotypes, which 
were associated with varying length of Kmt2a protein, I also aimed to investigate a 
second, earlier truncated KMT2B protein [147,277,278]. The identified 
p.Leu1822Thrfs*12 mutation truncates KMT2B after the FYRN domain. For the 
second truncated KMT2B protein, I therefore introduced a stop codon in exon 10, 
predicted to result in KMT2B truncation already after the CXXC domain (p.Phe1175*) 
(Figure S8A). This mutant protein has its CXXC domain, which is important for 
recruitment to target sites, however, it lacks all C-terminal located domains including 
PHD1-4, BROMO and SET domain [137].  
In summary, my PhD thesis provides fundamental in vitro and in vivo data that favor 
haploinsufficiency over DNE as disease underlying effect. Overexpression of wt and 
p.Leu1822Thrfs*12 KMT2B in zebrafish will be essential to finally proof this.  
 
5.2.3  Early corticogenesis in the heterozygous Kmt2b cKO mouse 
5.2.3.1 The strength of scRNAseq over RNAseq 
The NGS-based approach scRNAseq was first introduced in 2009 [279]. Thereafter, 
the amount of published data increased vigorously and today, a bunch of scRNAseq 
data is available including data from specific brain regions and even from whole 
murine embryos [212,218,279,280]. scRNAseq has the advantage over RNAseq that 
transcripts from each cell are uniquely barcoded during library preparation. These 
transcripts can be subsequently assigned to single cells and these can be assigned 
again to different cell populations characterized by similar expression profiles [228]. 
In contrast, RNAseq investigates only a pool of cells and hence, data from small 
cellular populations might remain undetected indicating that scRNAseq is more 
sensitive in order to identify differences of small cellular populations [281]. Since the 
IHC results of my PhD thesis did not reveal an obvious phenotype in heterozygous 
Kmt2b cKO embryos, only a mild phenotype was hypothesized and hence, 
scRNAseq was the method of choice for subsequent gene expression analysis. 
5.2.3.2 scRNAseq - Identification of mild differences between proliferating and 
non-proliferating RGCs  
Roughly 80 % of all neurons in the cerebral cortex are ENs, which are generated in 
the proliferative zones (VZ and SVZ) of the developing neocortex itself and hence, 
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abnormalities here are typically investigated in studies focusing on microcephaly 
development [76,282]. The remaining number of neurons in the cerebral cortex are 
inhibitory and are not generated in the developing neocortex itself, but instead, 
mainly in the ganglionic eminences and these cells migrate towards the cortical 
layers while differentiating [76,283]. 
We applied forebrains of heterozygous Kmt2b cKO embryos to scRNAseq, since 
haploinsufficiency of Kmt2b in the cerebral cortex could possibly impact the 
surrounding tissue as well. Even though the performed analysis did not uncover any 
significant differences in heterozygous Kmt2b cKO embryos, subsequent in-depth 
analysis revealed that the ratio of proliferating vs. non-proliferating RGCs was slightly 
shifted between genotypes (see 4.2.13). Indeed, these differences were only mild 
and thus, they likely point towards the initial steps of the pathogenesis and are 
therefore discussed in the following.  
RGCs are considered as progenitors of most neurons in the developing neocortex 
[17,18,284,285]. They mainly undergo asymmetric cell divisions generating daughter 
cells that either remain as RGC, or differentiate towards IPC, neuron, or later also 
towards astrocytes [15-18,284,286]. This implies that RGCs play an important role in 
balancing the number of progenitors and hence, in regulating the number of 
generated neurons and finally cortical size. In line with this, disturbances in RGCs 
have been frequently reported underlying the development of microcephaly 
[287,288]. Premature differentiation of RGCs results in depletion of the progenitor 
pool and hence, in loss of neurons, which are subsequently formed during 
neurogenesis. Even though the scRNAseq data did not show any differences in the 
number of IPCs and ENs at E13.5, it is possible that these differences become 
apparent during later embryonic stages, which should be investigated in future 
experiments.  
Based on the scRNAseq data, we can not distinguish if the RGCs of clusters NEC1, 
NEC2 and NEC3 belong exclusively to the cerebral cortex or also to the ventral 
telencephalon. The identified NEC clusters represent most likely a mixture of RGCs 
from different telencephalic regions including progenitors from ganglionic eminences. 
An imbalance of RGCs from the cerebral cortex and ganglionic eminences indicates 
that the conditional Kmt2b KO affected both progenitor pools. Gorski et al. confirmed 
that the applied Emx1-Cre line expresses Cre not only in developing cortices, but 
also in parts of the ganglionic eminences [76]. Therefore, the expression data of 
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Gorski et al. strengthen the hypothesis that the observed imbalance in RGCs is not a 
coincidence, but rather specific for the conditional heterozygous Kmt2b cKO.  
5.2.3.3 Future perspectives - Detailed characterization of the mild phenotype 
during corticogenesis 
The causes for an imbalance between proliferating vs. non-proliferating RGCs can be 
diverse. It is conceivable that the regulation of proliferation vs. differentiation of RGCs 
itself is impaired, or that the cause can be found already earlier in NECs and that the 
transition of NECs into RGCs is affected [284,289].  
Considering the data of my PhD thesis that pointed towards a putative involvement of 
WNT-signaling, a disturbed balance of proliferation vs. differentiation in RGCs might 
be interesting, since this process is indeed regulated by WNT-signaling (see 1.1.2) 
[28,31]. A very mild phenotype in heterozygous Kmt2b cKO animals, on the other 
hand, might point towards a too late onset of Cre expression and hence, too late 
onset of the cKO, which favors earlier developmental stages as important time point. 
Emx1 is expressed from E9.5 while NECs start to transform to RGCs between E9.0 
and E10.0 indicating that earlier Cre expression, for instance under the promoter of 
Foxg1 (E8.0), could cause a more severe phenotype in heterozygous Kmt2b cKO 
embryos [13,77,290]. Since Kmt2b was already known to be important during early 
embryonic stages and in order to determine the exact time point of its involvement for 
cortical neurogenesis, I included exactly these two Cre lines in the appropriate animal 
application [171]. We decided to perform initial experiments with the Emx1-Cre line 
since this mouse line results in a more consistent phenotype compared to the Foxg1-
Cre line (Dr. Tran Tuoc, Institute of Neuroanatomy Göttingen, personal 
communication). However, based on the presented scRNAseq data, either an earlier 
initiated cKO of Kmt2b, or even a heterozygous germline KO of Kmt2b should be in 
focus of future experiments.  
Even though the scRNAseq data pointed towards an imbalance of proliferating vs. 
non-proliferating RGCs, no increased expression of apoptosis-associated genes was 
detected, which at first glance contrasts the increased apoptosis activation observed 
in homozygous kmt2bb KO zebrafish embryos (see 4.2.11). However, apoptosis can 
still be an important part of the pathomechanism and two scenarios are possible 
here. Firstly, it is conceivable that Kmt2b dosage determines apoptosis activation and 
therefore apoptosis was not initiated in heterozygous Kmt2b cKO embryos. Or 
secondly, it is conceivable that apoptosis is activated during later developmental time 
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points, namely in differentiating neurons indicating that regulation of proliferation and 
apoptosis are both involved in the underlying pathomechanism at different time 
points [287,291]. KMT2B has been already associated with apoptosis as well as with 
cell proliferation in previous studies (see 1.4.2). Furthermore, a later onset of 
apoptosis activation also matches the above discussed apoptosis results from iPSC 
(see 5.2.3), which together favor a later onset of apoptosis activation during 
corticogenesis.  
5.2.3.4 Analyzing heterozygous Kmt2b cKO embryos 
We decided to start with initial investigations in heterozygous Kmt2b cKO embryos 
mainly due to two reasons. Firstly, we aimed to investigate affected cells during early 
corticogenesis before they induce apoptosis and hence, a milder phenotype was 
intended. Secondly, several published data pointed towards a detectable phenotype 
already in heterozygous Kmt2b cKO animals and gave reason to start with initial 
investigations here, which will be discussed in the following. 
Even though Glaser et al. did not report a phenotype in heterozygous Kmt2b KO 
mice, it was conceivable that a mild form of microcephaly remained undetected in 
these mice and in line with this, Goldsworthy et al. reported in 2013 that 
heterozygous germline Kmt2b KO animals of Glaser et al. indeed had diabetes, 
which was not reported yet [146,175]. Additionally, Kerimoglu et al. investigated a 
conditional Kmt2b KO in excitatory neurons of adult mice forebrains (CamKII-
Cre;Kmt2bfl/fl) [173]. Even though the authors intended to generate a homozygous 
KO, roughly 30 % of Kmt2b protein was still detectable and these animals showed 
impaired memory formation. In addition, a heterozygous KO of the sister gene Kmt2a 
was reported with an obvious phenotype characterized by growth retardation, 
anemia, hypo-fertility and segment anomalies [147]. However, unlike us, Yu et al. 
investigated a heterozygous germline KO of Kmt2a and not a cKO, which most likely 
causes a more severe phenotypic manifestation. 
Moreover, similar cKO strategies using the same Emx1-Cre line of my PhD thesis 
resulted in heterozygous cKO embryos presenting with microcephaly. Mao et al. 
investigated a heterozygous cKO of Rbm8a (Emx1-Cre;Rbm8afl/+) between E11.5 
and E14.5 and observed severe cortical abnormalities from E12.5 [287]. In addition, it 
was previously shown that germline haploinsufficiency of Magoh (MagohMos2/+) 
caused severe cortical abnormalities starting from E12.5 [291]. McMahon et al. 
established a heterozygous cKO model for the Magoh gene (Emx1-Cre;Magohfl/+) 
 Discussion  
 
   92 
and confirmed microcephaly at E16.5 [292]. Since McMahon et al. did not comment 
on earlier time points, it is not known whether microcephaly was already detectable 
prior to E16.5 in Emx1-Cre;Magohfl/+ mice as well. Rbm8a and Magoh are both 
components of the exon junction complex (EJC) and hence, are involved in RNA 
splicing [293,294]. A direct connection of Kmt2b with these genes can not be made 
and in agreement, Kmt2b does not regulate expression of Magoh in murine ESCs 
[171]. However, instead, Kmt2b regulates expression of the duplicated Magoh gene 
Magohb in murine ESCs [171]. MAGOH and MAGOHB are both components of the 
EJC and involved in nonsense-mediated mRNA decay (NMD) [295]. The proteins 
show 98 % sequence identity and both genes are ubiquitously expressed in adult 
mice. Based on their data, Singh et al. hypothesized that these proteins are either 
involved during different developmental stages or that MAGOHB compensates the 
function of MAGOH during specific time points [295]. According to MOCA, not only 
Magoh but also Magohb is expressed in NPCs and RGCs between E9.5 and E13.5 
of murine developing brains [212]. In line with the observed imbalance in RGCs from 
my PhD thesis, heterozygous cKO of Rbm8a and Magoh resulted in premature 
depletion of progenitor cells and additionally, in increased neuronal apoptosis 
[287,291].  
In conclusion, initial murine experiments were performed in heterozygous Kmt2b cKO 
embryos at E13.5, which point towards an imbalance of proliferating vs. non-
proliferating RGCs. However, in order to receive a more detailed characterization of 
the pathomechanism, future experiments should investigate heterozygous as well as 
homozygous Kmt2b (c)KO animals at different time points.  
 
5.2.4 Characterization of KMT2B protein and RNA 
5.2.4.1 Putative SET domain independent functions of the KMT2B protein 
Several publications focus on SET domain dependent methyltransferase functions of 
KMT2B and investigate H3K4 methylation [127,137,173,174]. Of course, these 
publications consistently confirmed an essential involvement of KMT2B for these 
epigenetic modifications, however, growing published as well as unpublished data 
indicate that this is not “the whole story”, and that KMT2B has either SET domain 
independent functions or non-histone targets as well.  
Several KMTs have already been associated with non-histone targets and Set1, the 
yeast homolog of KMT2B, targets a non-histone protein as well [296-298]. Apart from 
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this, the SET domain is not the only enzymatic domain in KMT2B. KMT2B has 
different domains and motifs that are not completely characterized and leave 
possibilities for SET domain independent functions (see 1.4.2). In line with this, Wang 
et al. showed that PHD2 of KMT2B is characterized by an intrinsic E3 ubiquitin ligase 
activity, which can modify H3 and H4 in vitro, while its relevance for non-histone 
targets has not been investigated yet [161]. Importantly, the PHD2 finger is located 
N-terminally to the p.Leu1822Thrfs*12 KMT2B protein from our patient and is 
therefore intact, which further emphasizes why detection of the mutant protein was 
an important focus of my PhD thesis (see 4.2.6). However, since the results of my 
PhD thesis point towards a likely instability of the p.Leu1822Thrfs*12 protein, also 
modifications accomplished by PHD2 might be involved in the pathogenesis of the 
microcephaly development in our patient. 
Additional consent for SET independent functions comes from O'Donnell-Luria et al. 
who just recently discovered heterozygous mutations in KMT2E, in patients with 
neurodevelopmental diseases [299]. The phenotypic spectrum of investigated 
KMT2E patients varied tremendously, while microcephaly was reported in some 
affected patients. The KMT2E protein has a PHD finger and a SET domain. 
However, its SET domain has no intrinsic methyltransferase activity in vitro indicating 
that the protein has either different functions or that it requires additional regulations 
in order to become activated [300].  
Furthermore, studies focusing on KMT2A point towards SET independent functions 
as well and these studies are highly interesting since KMT2A and KMT2B evolved 
from the same ancestor gene and show several similarities in their protein structure 
(Figure 3). Ali et al. showed that the transactivation domain (TAD), but not the SET 
domain of KMT2A, is essential to regulate S phase progression of U2OS cells [169]. 
The TAD domain is located between amino acid position 2847 and 2855 of KMT2A. 
A sequence alignment revealed that KMT2B has a highly similar peptide sequence 
(2111aa - 2119aa), which has not been investigated yet. Importantly, this peptide is 
located C-terminally of the p.Leu1822Thrfs*12 KMT2B protein of our patient and 
therefore, certainly lost, which indicates that the peptide might be involved in the 
underlying pathomechanism as well.  
Finally, also murine in vivo data of Kmt2a point towards SET domain independent 
functions. Kmt2a has been targeted in different KO models, which were all embryonic 
lethal, while they showed varying phenotypes. The first study inserted a lacZ reporter 
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into exon 3 of Kmt2a [147]. Homozygous Kmt2a KO embryos died after E10.5. 
Heterozygous animals were viable and showed obvious phenotypes including growth 
retardation, anemia, hypo-fertility, and segment anomalies, which is in line with an 
important role of Kmt2a for Hox gene regulation. Deleting Kmt2a in exon 5 resulted in 
earlier embryonic lethality than deletions in exon 3 and these homozygous KOs died 
already around the two cell stage [277]. Heterozygous animals were alive and 
showed neurological and skeletal anomalies [277]. The difference between these KO 
models on Kmt2a protein level is that the first study truncated Kmt2a after AT hook 
motifs, whereas the second study truncated Kmt2a in the CXXC domain (Figure 3). 
Replacing exons 12-14 of Kmt2a and hence, truncating Kmt2a in PHD2, caused 
lethality between E11.5 and E14.5 in homozygous embryos, while heterozygous 
animals were alive with mild anemia [301]. In contrast, if only the SET domain was 
replaced, homozygous KO mice were even viable and showed only skeletal 
anomalies [278]. 
In my PhD thesis, as in most Kmt2b KO studies, KO of Kmt2b was achieved after 
removal of the second exon causing truncation of the protein early after the first AT 
hook motif [146]. Goldsworthy et al. introduced a different Kmt2b KO mouse, which 
has the full length Kmt2b protein characterized by reduced methyltransferase activity 
[175]. The authors achieved this with an N-ethyl-N-nitrosourea (ENU) mutagenesis 
and identified a missense mutation in the SET domain of Kmt2b (p.Met2628Lys). 
Interestingly, they reported a divergent lethal phenotype compared to Glaser et al. 
[146]. However, since the methyltransferase activity was not completely abolished 
and other random mutations can not certainly be excluded, the p.Met2628Lys Kmt2b 
KO mouse of Goldsworthy et al. can not be used to study SET domain independent 
functions of Kmt2b. 
In conclusion, in contrast to the described Kmt2a studies, no other Kmt2b KO 
models, either with varying length of Kmt2b proteins, or with a deleted SET domain, 
have been investigated to date. Since several data point towards SET domain 
independent functions of KMT2B, it is a mandatory step to investigate if the 
microcephaly development of our patient is truly SET domain dependent or even 
SET domain independent. 
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5.2.4.2 The zebrafish – Model to study SET domain dependency for 
microcephaly development  
Since the above discussed data favor also SET domain independent functions of 
KMT2B, a deeper characterization of encoded protein domains and target proteins is 
an essential step. During my PhD thesis, I aimed to address this characterization. For 
this, I established a kmt2bb KO model in zebrafish characterized by significant 
microcephaly development (see 4.2.11). In order to investigate if the phenotype 
development is dependent on the SET domain function, I prepared different 
expression constructs, which can be subsequently used during rescue experiments.  
The prepared KMT2B expression constructs harbor different mutations (Figure S8A). 
Beside wt and p.Leu1822Thrfs*12 KMT2B, two constructs are characterized by 
missense mutations. The first missense mutation was reported by Hu et al. in 2017 
[137]. The authors introduced this Kmt2b mutation (p.Tyr2602Ala, corresponding to 
p.Tyr2604Ala in human KMT2B) in murine ESCs and confirmed abolishment of the 
methyltransferase activity, whereas the protein was still recruited to target sites. 
Therefore, the p.Tyr2604Ala protein has its full protein length and can be used as 
negative control for the methyltransferase activity. As long as the pathomechanism is 
dependent on the SET domain, it should not be able to rescue the phenotype. The 
second missense mutation is an unpublished mutation of our collaborator Dr. Gaetan 
Lesca from the Hospices Civils de Lyon, Bron, France. To my knowledge, missense 
mutations in KMT2B have only been reported in patients with dystonia, but not in 
patients with microcephaly [154]. Dr. Lesca identified the c.7852G>A mutation in a 
patient with syndromic microcephaly (-2.5 SD) and no signs of dystonia by the age of 
six years, which is similar to the phenotype of our patient (unpublished data). The 
c.7852G>A mutation (p.Glu2618Lys) is therefore the first KMT2B missense mutation 
causing microcephaly. The p.Glu2618Lys mutation affects the highly conserved SET 
domain of KMT2B and is in close proximity to the p.Tyr2604Ala mutation of Hu et al. 
[137]. Both positions are highly conserved among KMT2 proteins and even down to 
the yeast homolog Set1 (Figure S9). In silico mutagenesis using the published SET 
domain crystal structure of KMT2D uncovered that both missense mutations face the 
substrate channel of the SET domain indicating that the p.Glu2618Lys mutation 
abolishes methyltransferase activity in KMT2B as well (Figure S8B) [124].  
In summary, during my PhD thesis, I established an in vivo kmt2bb KO model and 
prepared different expression constructs, which will be essential for subsequent 
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rescue experiments in order to proof whether microcephaly development is 
dependent or independent of the SET domain in KMT2B. 
5.2.4.3 A lncRNA transcribed from the KMT2B locus 
Beside the above discussed SET independent functions of the KMT2B protein, other 
functions might also be encoded in different KMT2B RNA sequences. It has already 
been reported that RNAs can be bi-functional, indicating that the same RNA 
transcript can either be translated into protein or perform regulatory functions as RNA 
[302,303]. Moreover, the awareness for different transcripts after alternative splicing 
including lncRNAs increased during the past years. These non coding RNAs have 
typically a length of > 200 bp and are already associated with the development of 
human diseases [304,305]. lncRNAs of 16,849 genes and 75,141 transcripts have 
been annotated in GENCODE to date, while roughly 40 % are brain specific 
[306,307]. lncRNAs have been shown to bind WDR5, an essential component of 
COMPASS-(like) complexes and are important for the regulation of gene expression 
including the HOXA gene [308,309]. In addition, lncRNAs are required for 
pluripotency in stem cells, during neuronal differentiation and seem to be involved in 
cortical development as well [310,311]. However, they have not been identified as 
cause underlying microcephaly in human patients to date. 
In my PhD thesis, I investigated expression of KMT2B in patient-derived fibroblasts 
and iPSC (Figure 12B). The expression of KMT2B was significantly reduced in 
fibroblasts, which is in agreement with the published reduction of KMT2B in 
fibroblasts of dystonia patients [176]. The significant down-regulation, however, was 
not consistent in iPSC clones. A closer look revealed that expression of KMT2B was 
increased in both patient-derived iPSC clones by approximately 20 % compared to 
patient-derived fibroblasts, but not consistently in wt-derived iPSC clones (Figure 
12B). In order to explain this difference, I looked for additional transcripts of KMT2B 
and indeed found one lncRNA (ENST00000606995.2) annotated in ENSEMBL [312]. 
This lncRNA is encoded in exon 3 of KMT2B and hence, not affected by the identified 
c.5462insC mutation of our patient (exon 27). Subsequent reverse transcription PCR 
(RT-PCR) confirmed that the lncRNA as well as the protein coding mRNA were 
detectable in investigated fibroblasts and iPSC (Figure S1). Even though the lncRNA 
was not specific for iPSC, its identification might be relevant for disease development 
allowing different conceivable scenarios.  
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Firstly, the identified lncRNA might influence pluripotency and differentiation of iPSC. 
Based on this, expression levels of the identified lncRNA should be quantified in 
iPSC and during differentiation as a next step. Sheik Mohamed et al. uncovered that 
expression of the lncRNA AK028326 was linked to mRNA expression of the 
pluripotency marker Oct4 and knock down of AK028326 resulted in reduced 
expression of Oct4 mRNA [313]. Even though no differences in OCT4 protein level 
was detectable in my PhD thesis, mRNA expression of OCT4 was increased in both 
patient-derived iPSC (Figure 11B/C). Hence, it will be interesting to investigate if a 
connection between the expression of the KMT2B lncRNA and OCT4 mRNA can be 
drawn in iPSC and during neuronal differentiation. In order to characterize the 
identified lncRNA in more detail, its ability for protein binding should be investigated 
as well. For this, a biotinylated RNA-pulldown experiment can be designed using the 
biotinylated KMT2B lncRNA as bait, which is followed by mass spectrometry in order 
to identify binding partners [314]. It will be interesting to see whether the KMT2B 
lncRNA binds COMPASS(-like) complexes or COMPASS independent proteins, 
thereby uncovering novel COMPASS independent functions of KMT2B. 
Secondly, the identification of the lncRNA enables the hypothesis that other unknown 
KMT2B lncRNAs are present as well. Since 39 % of lncRNAs have a Poly(A) signal, 
the RNAseq (iPSC) and scRNAseq data (murine forebrains) of my PhD thesis can be 
re-investigated for KMT2B lncRNAs, which are specifically expressed in iPSC and 
during early cortical development [307].  
In conclusion, even though the present thesis does not uncover SET domain 
independent functions of KMT2B, it provides first interesting hints that point towards 
this direction, which should be investigated in more detail during future experiments.  
 
5.2.5 Future perspectives – Investigating KMT2B-associated phenotypic 
variations in the zebrafish model 
At the beginning of my PhD thesis, KMT2B was not associated with any genetic 
disease. The patient of the present thesis was characterized by syndromic 
microcephaly, but showed no characteristics of the neurological movement disorder 
dystonia. Hence, the focus of the present thesis was not pointed towards dystonia 
development and instead, exclusively towards microcephaly development. End of 
2016, mutations in KMT2B were published in patients with dystonia for the first time 
and only 21 % of affected patients were presenting with microcephaly [148,154,176]. 
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In one reported family, microcephaly showed incomplete penetrance, while the 
dystonia phenotype was variable expressed [176]. The reported mean age of onset 
for dystonia estimated 4.1 years and 6.4 years for predicted protein truncation 
mutations and missense mutations, respectively [176]. Our patient is currently aged 
10 years and shows no signs of any movement disorder (see 4.2.1). Still, it can not 
be excluded that our patient develops dystonia during later developmental stages. 
However, considering her age, it is unlikely and awaits an explanation. 
Zech et al. hypothesized that the dosage of KMT2B is crucial for development of 
dystonia [148]. Based on the data of my PhD thesis, it can be agreed that 
haploinsufficiency and dosage of KMT2B is likely the cause for microcephaly 
development as well. However, the underlying pathomechanism might be even more 
complex and the established zebrafish models could help to shed light into this 
discrepancy.  
KMT2B has two homologs in zebrafish, namely kmt2ba and kmt2bb which have been 
both targeted with CRISPR/Cas9 while only KO of kmt2bb resulted in microcephalic 
larvae (see 4.2.10). Based on published literature, it is conceivable that the human 
phenotype is spread over these homologs and that dystonia becomes obvious only in 
kmt2ba KO fish [68]. The kmt2ba KO larvae showed no obvious phenotype by 21 
dpf, also no signs of aberrant muscular contractions. In order to investigate also later 
developmental stages in more detail, I set up new crosses with heterozygous kmt2ba 
and kmt2bb KOs at the end of my PhD project. This progeny can be subsequently 
used for genotyping and intensive characterization. Adult homozygous kmt2ba and 
kmt2bb KO fish should be investigated e.g. for viability, fertility, and swimming 
behaviors because dystonia characteristics might of course manifest during later 
developmental stages as well. The zebrafish has already been used to investigate 
the pathogenesis of dystonia-associated genes. The described zebrafish phenotype 
varies in published literature, while some publications report swimming and 
locomotion defects in animals, others do not observe any obvious movement 
abnormalities [315-318]. 
In the course of my PhD project, I also knocked down kmt2ba and kmt2bb with 
morpholinos in zebrafish larvae. For this, I injected morpholinos into one cell stage 
embryos that blocked translation of kmt2ba and kmt2bb mRNA [319]. The results of 
these injections were not included in the present thesis, since injected control 
morpholinos also induced a slight phenotype and hence, observations should be 
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interpreted very carefully (data not shown). During these injections, only injections of 
morpholinos targeting kmt2ba resulted in curved embryos characterized by reduced 
movements. Thus, these observations might point towards a dystonia related 
phenotype and await further investigation. 
But how is it possible that the dystonia phenotype becomes obvious after morpholino 
injection, but not in homozygous kmt2ba KO embryos of the CRISPR/Cas9 
experiments? The difference might be found in a putative maternal effect of kmt2ba, 
which was targeted with morpholinos, but not in the CRISPR/Cas9 experiment. 
kmt2ba RNA is detectable at high levels in zebrafish embryos already very early at 
0.75 hpf and decreases around 4 hpf, which is the opposite course of the kmt2bb 
RNA level within the first four hpf [72]. However, this RNA is not expressed by the 
embryo itself and instead, is inherited from the mother [320]. The embryo starts to 
express own genes around 3.5 hpf [321]. As a result, maternal inherited RNAs and 
proteins affect earliest embryonic stages and many are degraded with progressive 
development when own zygotic genes are expressed [322]. Translation blocking 
morpholinos target these maternal inherited RNAs [323]. However, in the present 
thesis, only heterozygous kmt2ba KO fish were crossed among each other, 
underscoring that the heterozygous adult female fish inherited kmt2ba RNA to the 
embryos and hence, maternal effects were not investigated. In order to investigate 
maternal effects of kmt2ba in future experiments, homozygous female kmt2ba KO 
fish have to be used for crossings and could possibly result in detection of dystonia 
phenotypes in the next generation.  
Assuming that kmt2ba and kmt2bb result in different phenotypes in zebrafish, the 
next question that immediately arises is the reason for this difference. At the 
beginning of my PhD thesis, I hypothesized that KO of kmt2bb is the preferred 
candidate for microcephaly development. This hypothesis based on a sequence 
alignment of human KMT2B with kmt2ba and kmt2bb. Even though the SET and post 
SET domains of KMT2B are highly conserved in kmt2ba and kmt2bb, kmt2bb has the 
conserved Taspase 1 cleavage site while kmt2ba has not (Figure S6). KMT2B is 
known to be cleaved by Taspase 1 while the FYRN and FYRC domain associate 
afterwards and hence, kmt2bb can be cleaved by Taspase 1 but kmt2ba remains 
likely un-cleaved. Even though the importance of protein cleavage is still not known, 
Hsieh et al. showed that knock down of Taspase1 results in reduced expression of 
HOX genes, thereby pointing towards a connection of protein cleavage and 
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regulation of target genes [115,164]. Taspase 1 mediated cleavage is only restricted 
to KMT2A and KMT2B indicating that cleavage per se is not important for SET 
domain activity, since KMT2C, KMT2D, KMT2F and KMT2G perform H3K4 
methylations without cleavage [163,164]. Kmt2b was shown to be mainly detectable 
in its cleaved form in murine ESCs [127]. However, the ratio of cleaved vs. un-
cleaved protein might be tissue specific, since the un-cleaved form is clearly 
detectable [146]. In line with this, in my PhD thesis, WB using a N-terminal binding 
KMT2B antibody detected two protein bands in primary dermal fibroblasts (Figures 
12). Furthermore, using mass spectrometry, peptides located C-terminally of the 
Taspase 1 cleavage site were identified in wt-derived iPSC, indicating that un-
cleaved KMT2B is detectable in iPSC as well (data not shown). Considering all these 
data and a likely dosage effect of KMT2B for disease development, it can be 
hypothesized that the varying phenotypes in KMT2B patients might not simply be 
dosage dependent, but might be even more complex. The ratio of cleaved vs. un-
cleaved KMT2B protein might be important to determine the phenotypic outcome. 
Cleaved and un-cleaved proteins could possibly have different target sites and 
hence, explain different phenotypes.  
In summary, combining the data and observations of my PhD thesis as well as 
published literature, it is conceivable that cleavage of KMT2B is involved in 
phenotypic differences of affected patients. Detailed characterization of target sites 
and the importance of protein cleavage for target site recruitment should be in focus 
of future experiments in order to answer this question.  
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6 Conclusion  
During my PhD thesis, I identified four novel mutations in DDX11 and FANCI, two 
known microcephaly-associated genes, thereby expanding the mutation spectrum 
underlying microcephaly development. In addition, I identified a mutation in the novel 
and highly convincing microcephaly-associated candidate gene DLG3, which should 
be investigated during future analyses thereby promoting our knowledge about the 
diverse molecular processes underlying microcephaly manifestations. Moreover, the 
identification of DLG3 was associated with application of the NGS-based approach 
deep amplicon sequencing, which I introduced at the Institute of Human Genetics in 
Göttingen.  
Furthermore, I characterized a mutation in the novel microcephaly-associated gene 
KMT2B. My results provide important novel directions for future experiments in order 
to decipher the KMT2B protein and its functions during brain development in more 
detail. Since mutations in KMT2B are not only associated with microcephaly 
development, but also with cancer and dystonia, the presented data can be applied 
to processes and therapeutic opportunities beyond microcephaly as well. A putative 
link between WNT-signaling and KMT2B offers novel opportunities for drug 
development in order to fight cancer. In addition, the data of my thesis support that 
the established zebrafish model is a promising in vivo approach to identify small 
molecules for drug development in order to ameliorate dystonia features in patients 
with KMT2B mutations.  
 
 Supplementary  
 




Figure S1: Verification of KMT2B lncRNA. (A) Two different PCRs were performed using primers either specific for the 
lncRNA (left) or for the lncRNA as well as the mRNA (right). Subsequent Sanger sequencing confirmed presence of a lncRNA 
beside the mRNA in exon 3 of KMT2B in fibroblasts as well as in iPSC. (B) Cartoon illustrating the binding sites of primers used 
for PCRs. Primer pair 1 (fwd1 + rev) amplified specifically the lncRNA since the binding site of the fwd1 primer is split in the 
mRNA sequence due to retention of a 433 bp fragment. In contrast, primer pair 2 (fwd2 + rev) amplified both RNAs since the 





Figure S2: Expression of APC2 and CTNNB1 is not consistently de-regulated in patient-derived iPSC. APC2: WT1 vs. 
Pat1 ***p<0.0001; WT1 vs. Pat2 p=0.6062; WT2 vs. Pat1 ***p=0.0001; WT2 vs. Pat2 p=0.3234. CTNNB1: WT1 vs. Pat1 
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Figure S3: PCA plot illustrating variance of iPSC samples applied for RNAseq. Two biological replicates were applied of 




Figure S4: Cell cycle distribution during iPSC differentiation. iPSC and differentiating cells (day 1 and day 2) were fixed, 
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Figure S5: Representative morphology of differentiating cells at day 1. At the start of differentiation (day 0), iPSC colonies 
were broken down to single cells and 1.5 x10
6 
iPSC were transferred to new matrigel coated 6-well plates per iPSC clone. Cells 
attached at varying degrees. Scale bars=100 µm. 
 
 
    
Figure S6: The zebrafish homologs kmt2ba and kmt2bb. Alignment of KMT2B protein sequence with kmt2ba and kmt2bb. 
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Figure S7: CRISPR/Cas9-based strategy in zebrafish. (A) The established CRISPR/Cas9 positive control targeted the gene 
tyrosinase (tyr) and caused loss of pigmentation after successful KO visible with the naked eye. (B) Sanger sequencing 
confirmed that the tyr gene was successfully targeted with injected CRISPR and Cas9 RNAs. (C) Experimental strategy in order 





Figure S8: Expression constructs for subsequent zebrafish experiments. (A) cDNA and protein position of all prepared 
KMT2B mutations. In-silicu mutagenesis of the p.Tyr2604Ala and p.Glu2618Lys mutations in published SET domain of KMT2D 
[124]. Left: wild-type KMT2D. Middle: p.Tyr2604Ala in KMT2B corresponds to p.Tyr5426Ala in KMT2D. Right: p.Glu2618Lys in 
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Figure S9: Protein alignment of different KMT2s. Protein alignment of all KMT2s with homologs of Drosophila melanogaster 









Figure S10: Immunohistochemistry for RGC marker Pax6 as well as IPC marker Tbr2 in control and heterozygous 
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Table S1: Heterozygous and hemizygous variants 





1 DDX59 c.919G>A p.Val307Ile  
1 TARBP1 c.1691C>T p.Ser564Phe  
1 CASZ1 c.2464G>A p.Gly822Ser  
1 DLGAP3 c.37C>T p.Arg13Cys  
2 LONRF2 c.112G>A p.Asp38Asn  
2 ZNF638 c.784A>T p.Met262Leu  
2 ESPNL c.1687G>A p.Val563Ile  
5 GIN1 c.200A>G p.Glu67Gly  
6 BYSL c.109C>T p.Arg37Trp  
6 LRP11 c.122C>T p.Pro41Leu  
8 PPP1R16A c.494C>T p.Ala165Val 
 
 












 1. FANC genes show recessive trait 
of inheritance - no second variant 
identified 
2. phenotypic exclusion of gene 
10 ANK3 c.2239T>G p.Tyr747Asp  
10 ARHGAP22 c.1388C>T p.Pro463Leu  
11 HPS5 c.2414T>C p.Leu805Ser  
11 INSC c.1313G>A p.Arg438Gln  
11 APOA4 c.1147C>A p.Gln383Lys  
11 ART5 c.800G>C p.Arg267Pro  
12 ANO6 c.2734C>T p.Leu912Phe  
12 ABCD2 c.2007A>C p.Lys669Asn   
12 M6PR c.321C>G p.Asn107Lys  








14 PTGDR c.1055C>T p.Ser352Phe  
15 IL16 c.1375G>A p.Glu459Lys  
15 IGDCC4 c.1471C>T p.Arg491Trp 
 
 





16 ITGAX c.2105G>A p.Arg702Gln  
16 TIGD7 c.386T>G p.Phe129Cys  
17 DNAH9 c.5372C>T p.Ala1791Val  










1. similar variant in ExAC with high 
allele frequency 
2. microtubule-associated genes 
have recessive trait of inheritance - 
no second variant identified 








20 TMC2 c.933+1G>C   
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Table S2: Array CGH-analysis of dermal fibroblasts and iPSC. 
 WT 
Fibro 
WT1 WT2 Patient 
Fibro 





Size: ca. 2.7 Mb 
No 
 
























Size: ca. 2.8 Mb 
No Yes Yes No (Yes) (Yes) (Yes) 






Table S3: Gene set enrichment analysis with topGO applying DE genes shared by all four comparisons. Table 
summarizes enriched GO pathways of the GO categories „molecular function“ and „biological process“. 
Molecular Function Biological Process 
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Table S4: Gene set enrichment analysis with top GO applying DE genes shared by all four comparisons and by three 
out of four comparisons. Table summarizes candidate GO pathways of the GO term „Molecular Function“ and 
„Biological Process“. 
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Table S5: Top 30 of KEGG pathway enrichment analysis of comparison “WT2 vs Pat1”. GeneRatio: number of DE 
genes in pathway / total number of DE genes. BgRatio: Total number of genes in pathway / Total number of genes in all 
pathways 
KEGG pathway GeneRatio BgRatio pvalue FDR 
Glycine, serine and threonine 
metabolism 
19/1172 32/5765 1,42608E-06 0,000449215 
Hepatocellular carcinoma 52/1172 146/5765 1,0152E-05 0,001344327 
Protein digestion and absorption 27/1172 60/5765 1,28031E-05 0,001344327 
Phospholipase D signaling pathway 44/1172 122/5765 3,40901E-05 0,002657796 
Relaxin signaling pathway 41/1172 112/5765 4,21872E-05 0,002657796 
Platinum drug resistance 26/1172 64/5765 0,000153822 0,008075652 
Glutathione metabolism 19/1172 42/5765 0,00022633 0,010184868 
Chronic myeloid leukemia 28/1172 74/5765 0,000362274 0,014264555 
ECM-receptor interaction 26/1172 69/5765 0,000626426 0,019876261 
Proteoglycans in cancer 52/1172 168/5765 0,000630992 0,019876261 
Cell adhesion molecules (CAMs) 35/1172 103/5765 0,00076822 0,021999017 
Arginine and proline metabolism 18/1172 43/5765 0,001030224 0,027043375 
Estrogen signaling pathway 33/1172 98/5765 0,001281501 0,031051754 
Focal adhesion 52/1172 174/5765 0,001531168 0,034451275 
Autoimmune thyroid disease 10/1172 19/5765 0,001767658 0,035847816 
Glutamatergic synapse 32/1172 96/5765 0,001820841 0,035847816 
Toxoplasmosis 31/1172 93/5765 0,002131331 0,037638696 
Asthma 7/1172 11/5765 0,002150783 0,037638696 
Viral myocarditis 17/1172 43/5765 0,0029495 0,047569184 
Colorectal cancer 28/1172 84/5765 0,003423518 0,047569184 
Endometrial cancer 21/1172 58/5765 0,003571521 0,047569184 
Leishmaniasis 19/1172 51/5765 0,003794222 0,047569184 
Chagas disease (American 
trypanosomiasis) 
26/1172 77/5765 0,003864673 0,047569184 
Amyotrophic lateral sclerosis  17/1172 44/5765 0,003914007 0,047569184 
Apoptosis 36/1172 116/5765 0,003915571 0,047569184 
Gastric cancer 37/1172 120/5765 0,003926345 0,047569184 
Graft-versus-host disease 9/1172 18/5765 0,004706704 0,054720355 
Long-term depression 19/1172 52/5765 0,004864032 0,054720355 
Wnt signaling pathway 40/1172 134/5765 0,005219128 0,056690531 
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Table S6: Applied synthetic oligonucleotides of PhD thesis. 






























KMT2B_1951_F CAGTTTACCCCAAGCGAAG  
KMT2Bcl_F1_rev                   CACCATCCGTTCTGTGCC  
KMT2Bcl_F2_fwd              GGCACAGAACGGATGGTG  
KMT2Bcl_F2_rev               GCAACAGCGTCTTCACTATC  
KMT2Bcl_F3_fwd              GATAGTGAAGACGCTGTTGC  
KMT2Bcl_F3_rev               AGAACATCTGTGTCCAGTGG  
KMT2Bcl_F4_fwd CCA CTG GAC ACA GAT GTT CT  
KMT2Bcl_F4_BamHI_
GFP_N1_rev   
GGT GGC GAC CGG TGG ATC CCG 
GTT AAG GAA CCG ACG GCA G  
 
KMT2Bcl_Seq_841_F CGTGGAGGACAGTCAAGC  
KMT2B_Seq_945_fwd GAT GGG ACA ATT GTC CTT GG  
KMT2B_Seq_1025_rev    CTGTCCAGATCCAACTCTTC  
KMT2B_Seq_1154_fwd CTGTAGCTGAGGAGATGATG  
KMT2B_Seq_1987_fwd     GAATCGGTGCTTACTCCTC  
KMT2B_Seq_2056_rev    AGGCTCAGCTGGAGAGTC  
KMT2B_Seq_4044_fwd  CGACTATGAGAGCAAGATGAT  
KMT2B_Seq_4156_rev     TCCGCAGGTGTACAGCAC  
KMT2B_Seq_6522_fwd    GTT AAG CCT TGG CCC TGC  
KMT2B_Seq_6642_rev     CAAAGGTGGCTGCTTCACT  
KMT2B_Seq_7364_fwd     CCT TTA GTG GAA TGA GTG GG  
KMT2B_Seq_7567_rev     GAGGCCAGGAAGTTGAACAT  
KMT2Bcl_Seq_4987_re CCGGGCACACATGAAGTG  
KMT2Bcl_1987_rev GAGGAGTAAGCACCGATTC  
KMT2Bcl_6522_rev          GCAGGGCCAAGGCTTAAC  
KMT2Bcl_fr.2.2-3_fwd GTGTCAACTGCCTAGACAAG  
KMT2Bcl_fr.2.2-3_rev GGTCGCTGTTTGACGCAG  
KMT2Bcl_fr.3-4.1_fwd GAGCACAGTGGATGCTCG  
KMT2Bcl_fr.3-4.1_rev CGGGATGGCGAGTAGTTG  
KMT2Bcl_F2_rev               GCAACAGCGTCTTCACTATC  
KMT2Bseq1511-F GAGGCCCTCCGGAAGAC  
KMT2Bseq4261-R CACCACCTTGGAGCTCAG  
KMT2Bseq7909-F GAT GTA GTG GAC GCC ACG  
KMT2Bseq4504-F GAATCTGCGTTCGGCTG  
KMT2Bseq4881-F GAATGTGCATGCTGCTGTG  
KMT2Bseq336-F GAG CAG TGA CGG GGA ATC  
KMT2B_K3027_7C_F GTG AGG ACC CCC CCA CTG  
KMT2B_K3027_7C_R CAGTGGGGGGGTCCTCAC  
KMT2B_Y-A_2604_F CAT CGA GGC CTC TGG CAT  
KMT2B_Y-A_2604_R ATGCCAGAGGCCTCGATG  
KMT2B_2618_3_F GGA AGA AGT TCT ACG ATG GG  




Oct4_Fwd CAGTGCCCGAAACCCACAC qPCR [324] 
Oct4_Rev GGAGACCCAGCAGCCTCAAA  
Sox2_Fwd TACCTCTTCCTCCCACTCCA qPCR 
Sox2_Rev GGTAGTGCTGGGACATGTGA  
Nanog_Fwd CAGAAGGCCTCAGCACCTAC qPCR 
Nanog_Rev ATTGTTCCAGGTCTGGTTGC  
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COL1A1_Fwd gggattccctggacctaaag qPCR [198] 
COL1A1_Rev ggaacacctcgctctcca   
DLG3_Ex6_fwd TAATTCTTTCTGTGGCCAGG Verification of 
variant 
 
DLG3_Ex6_rev ctacagtgccaccactgagc  
PAX6qPCR-F GTGTCTACCAACCAATTCCACAAC qPCR [325] 
PAX6qPCR-R CCCAACATGGAGCCAGATG 
Sox1qPCR-F GCAAGATGGCCCAGGAGAA qPCR 
Sox1qPCR-R CCTCGGACATGACCTTCCA  
GAPDH_qPCR_F CCATGTTCGTCATGGGTGTGAAC   
GAPDH_qPCR_R CGGCCATCACGCCACAGTTT   
kmt2ba-ex28-F CACACAATTGTGCACAGTCC Genotyping 
zebrafish 
 
kmt2ba-ex28-R GAGACAGATGAGCACAAGAC  
DDX11ex26-F tcgccgtgggaatgtgc Verification of 
variant 
 
DDx11ex26-R GAGATGCCACAGTGGATGC   
DDX11ex4-F CAGCATGGTTCAATGGCTGC Verification of 
variant 
 
DDX11ex4-R TCTGGACAGGGGTAGTGGAG  
kmt2bb_ex28_new-F GAAGCCCTTGAATTGGGGTT Genotyping 
zebrafish 
 
kmt2bb_ex28_new-R TGAACAACGTTCAAATCGGTATC  
CRISPR-F 
AGC ACC GAC TCG GTG CCA CTT T
TT CAA GTTGAT AAC GGA CTA GC
C TTA TTT TAA CTT GCT ATTTCT A
GC TCT AAA AC 
CRISPR/Cas9  
WIF1-qPCR-F AAGGTTGGCATGGAAGACAC qPCR [326] 
WIF1-qPCR-R TTAAGTGAAGGCGTGTGCTG 
APC2-qPCR-F GAGGAACTGGACCGGGAAC qPCR  
APC2-qPCR-R TCGAGAACTGCGTCTCCAC  
FZD2-qPCR-F GCCCTCATGAACAAGTTCGGT qPCR  
FZD2-qPCR-R GAGCTCCGTCCTCGGAGTG  
NPTX1-qPCR-F GAGACGCTCAGCCAACTCG qPCR  
NPTX1-qPCR-R GGAATTGAGGCGGCTGTACT  
CTNNB1-qPCR-F GGTGGACCCCAAGCTTTAGT qPCR  























FANCI_ex21-22_F AATTTGTAACGCCAATGAATC Verification of 
variant 
 
FANCI_ex21-22_R GCGCTCTCTAGTGGAAAGAAC  





Srg3_TO666 TGT CAT CCA TGA GGA GTG GTC Genotyping 
mouse 
Kindly provided 
by Dr. Tran 
Tuoc 
Srg3_TO667 GGT AGC TCA CAA ATG CCT GT 
Emx1_Cre_To89  ATG CTT CTG TCC GTT TGC CG Genotyping 





by Prof. Andre 
Fischer Kmt2b_geno_R ggacaggagtcacatctgctagg 
qKmt2b_4 for GGAGGAAGAGAGCAGTGACG qPCR [174] 
qKmt2b_4 rev TCATCTGAATGAAAACCCTGAA 
HUWE1_ex33_F GCCAATTATTTTGTTGCTGG Verification of  
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HUWE1_ex33_R AGGAAATCTAAACTGTCTCCTGG variant  
KMT2B_lncRNA_5P_F GTGGCCCCCAAAAGCACC Investigation of 
lncRNA 
 
KMT2B_lncRNA_F ATGCCTGTGCCCCTGAGC  
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